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Abstract
An evaluation of the effect of an angiotensin-converting
enzyme inhibitor on the growth rate of small abdominal
aortic aneurysms: a randomised placebo-controlled
trial (AARDVARK)
Gaia Kiru,1* Colin Bicknell,2 Emanuela Falaschetti,1 Janet Powell2
and Neil Poulter1 on behalf of the AARDVARK collaborators
1Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK
2Department of Surgery and Cancer, Imperial College London, London, UK
*Corresponding author g.kiru@imperial.ac.uk
Background: Although data are inconsistent, angiotensin-converting enzyme inhibitors (ACE-Is) have been
associated with a reduced incidence of abdominal aortic aneurysm (AAA) rupture in analysis of
administrative databases.
Objectives: (1) To investigate whether or not the ACE-I perindopril (Coversyl arginine, Servier) reduces small
AAA growth rate and (2) to evaluate blood pressure (BP)-independent effects of perindopril on small AAA
growth and to compare the repeatability of measurement of internal and external aneurysm diameters.
Design: A three-arm, multicentre, single-blind, randomised placebo-controlled trial.
Setting: Fourteen hospitals in England.
Participants: Men or women aged ≥ 55 years with an AAA of 3.0–5.4 cm in diameter by internal or
external measurement according to ultrasonography and who met the trial eligibility criteria.
Interventions: Patients were randomised to receive 10mg of perindopril arginine daily, 5 mg of the
calcium channel blocker amlodipine daily or placebo daily.
Main outcome measures: The primary outcome was AAA diameter growth using external measurements
in the longitudinal plane, which in-trial studies suggested was the preferred measure. Secondary outcome
measures included AAA rupture, AAA repair, modelling of the time taken for the AAA to reach the
threshold for intervention (5.5 cm) or referral for surgery, tolerance of study medication (measured by
compliance, adverse events and quality of life) and a comparison of the repeatability of measures of
internal and external AAA diameter. Patients were followed up every 3–6 months over 2 years.
Results: In total, 227 patients were recruited and randomised into the three groups, which were generally
well matched at baseline. Multilevel modelling was used to determine the maximum likelihood estimates
for AAA diameter growth. No significant differences in the estimates of annual growth were apparent
[1.68 (standard error 0.02) mm, 1.77 (0.02) mm and 1.81 (0.02) mm in the placebo, perindopril and
amlodipine groups, respectively]. Similarly, no significant differences in the slopes of modelled growth over
time were apparent between perindopril and placebo (p= 0.78) or between perindopril and amlodipine
(p= 0.89). The results were essentially unaffected by adjustment for potential confounders. Compliance,
measured by pill counts, was good throughout (> 80% at all visit time points). There were no significant
in-trial safety concerns. Six patients withdrew because of adverse events attributed to the study
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medications (n= 2 perindopril, n= 4 amlodipine). No patients ruptured their AAA and 27 underwent
elective surgery during the trial (n= 9 placebo, n= 10 perindopril, n= 8 amlodipine).
Conclusions: We were unable to demonstrate a significant impact of perindopril compared with placebo
or amlodipine on small AAA growth over a 2-year period. Furthermore, there were no differences in the
times to reach a diameter of 5.5 cm or undergo surgery among the three groups. Perindopril and
amlodipine were well tolerated by this population. External AAA measurements were found to be more
repeatable than internal measurements. The observed AAA growth measurement variability was greater
than that expected pre trial. This, combined with slower than expected mean growth rates, resulted in our
having limited power to detect small differences between growth rates and hence this adds uncertainty to
the interpretation of the results. Several further analyses are planned including a multivariate analysis of
determinants of AAA growth, an evaluation of the possible differential effect of perindopril on fast AAA
growth and an investigation into the roles of central BP and BP variability on AAA growth.
Trial registration: Current Controlled Trials ISRCTN51383267.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 59.
See the NIHR Journals Library website for further project information. The NIHR Biomedical Research
Centre based at Imperial College NHS Trust supported the trial. Servier provided perindopril at no charge.
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Plain English summary
An abdominal aortic aneurysm (AAA) is a swelling of the main blood vessel (the aorta) in the body.Large AAAs may burst, and this is usually fatal.
When an AAA is small (< 5.5 cm across), changes in size can be monitored safely using ultrasound
scanning. Larger aneurysms need surgery before they burst. No drug treatments are currently available that
slow AAA growth, avoid surgery or stop them from bursting.
Some studies have suggested that drugs called angiotensin-converting enzyme inhibitors (ACE-Is), which
are usually used to treat high blood pressure, may reduce the risk of AAAs bursting. This trial investigated
whether or not an ACE-I called perindopril reduced the growth of small AAAs.
A group of 227 patients with small AAAs from 14 hospitals in England took part in the trial. Patients were
randomly allocated to receive perindopril or another drug used to treat blood pressure called amlodipine or
a placebo (dummy) pill. To see whether perindopril slowed AAA growth more than blood pressure
lowering with an ordinary tablet (amlodipine) or placebo, each patient had their AAA measured every
3–6 months for 2 years.
At the end of the trial we found that, on average, perindopril was about the same as amlodipine and
placebo in terms of affecting AAA growth. However, the AAAs in the trial grew more slowly than
expected and the accuracy of ultrasound scanning was less than expected, both of which may have
reduced our ability to detect small differences between groups if they were present.
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Scientific summary
Background
An abdominal aortic aneurysm (AAA) is a ballooning of the infrarenal aorta to either 1.5 times its normal
anteroposterior (AP) diameter or an absolute value of ≥ 3 cm. Small AAAs can be defined as those
between 3.0 cm and 5.4 cm in diameter. These small AAAs have a low risk of rupture, and operation to
repair small AAAs is fatal in approximately 2–3% of patients. Small AAAs are generally managed by
optimising cardiovascular health and placing the patient on a surveillance programme to measure the AAA
diameter at regular intervals. Once AAAs reach 5.5 cm (or if initially detected at a larger size) they are
often repaired as the risk of rupture rises exponentially above this size. If rupture does occur, one-third of
patients die without reaching hospital and repair is performed in fewer than half of those reaching hospital
alive, of whom 30–35% die within 30 days, leading to an overall mortality rate from rupture of ≥ 80%.
Although recent reports have suggested that the incidence of aneurysms appears to be in decline, AAA
remains a significant health risk in the older population, with around 4000 deaths each year in England
and Wales attributed to AAA rupture.
Except when they rupture, most small AAAs are asymptomatic and so, until recently, they were detected as
an incidental finding on clinical examination or various types of imaging performed for other purposes.
However, in the UK, the NHS Abdominal Aortic Aneurysm Screening Programme was introduced in 2009
and so many more small AAAs are now being detected early. The programme has been very successful and
screened its millionth man in autumn 2015. There is an opportunity to reduce the number of patients
needing AAA repair if we can slow or prevent AAA growth in this growing cohort of patients.
Although data on the effects of angiotensin-converting enzyme inhibitors (ACE-Is) in this context are not
consistent, ACE-Is have been associated with a reduced incidence of AAA rupture in analysis of
administrative databases. Previous trials of other drugs that may slow AAA growth have been hindered by
poor patient compliance. Therefore, this pilot trial was undertaken to assess whether or not an ACE-I could
potentially slow AAA growth and be well tolerated in doing so. We are unaware of other completed
randomised controlled trials designed to examine the efficacy of ACE-Is or angiotensin receptor blockers
(ARBs) in limiting or inhibiting AAA progression, although two trials of the impact of ARBs on the growth
rate of AAAs are in progress.
Objectives
Primary
l To investigate in a three-arm, randomised, placebo-controlled pilot trial the hypothesis that the ACE-I
perindopril (Coversyl arginine, Servier) reduces the growth rate of small AAAs.
Secondary
l To evaluate any blood pressure (BP)-independent effects of perindopril on the growth rate of
small AAAs.
l To determine differences in AAA rupture rate and/or time taken to reach an AAA diameter of 5.5 cm
and/or referral for surgical intervention among the three randomised groups.
l To evaluate how well perindopril is tolerated as measured by compliance, adverse events (AEs) and
quality of life.
l To compare the repeatability of ultrasound measurements of internal and external small AAA diameters.
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Pending the results of this pilot trial, our objective was to conduct a larger definitive trial to investigate
whether an ACE-I can reduce the rate of AAA-related mortality, rupture or surgery.
Methods
This randomised, single-blind (so classified because trial medications were not identical, but neither
the investigators nor the trial participants at each site were aware of their treatment allocations),
placebo-controlled study was performed at 14 sites in England. Participants were randomised to receive
perindopril (10mg of arginine salt daily), placebo (primary comparison) or amlodipine (5 mg daily)
(secondary comparison). The perindopril and amlodipine doses used were estimated to have similar effects
on BP reduction and hence a secondary comparison assessed whether or not any benefits of perindopril
were independent of a reduction in BP.
Men and women aged at least 55 years with an AAA of 3.0–5.4 cm in AP diameter (internal or external)
and a systolic BP (SBP) of < 150mmHg were invited to participate in the study. Patients who were already
required to take either an ACE-I or a calcium channel blocker (CCB) (with the exception of 5mg of
amlodipine) or an ARB were excluded. Those with known renal artery stenosis (> 50%), a serum creatinine
level of > 180 µmol/l, any clinically significant medical condition that, in the opinion of the investigator,
might interfere with the study results and/or reduce life expectancy to < 2 years, or a known allergy or
sensitivity to perindopril or amlodipine were also excluded.
Suitable subjects with SBP < 150mmHg who wished to participate in the trial were given either 5 mg of
amlodipine daily (if not already on a CCB) or 1.5mg of slow-release indapamide daily and were
asked to return for screening at 6 weeks. At this point they could be included in the trial if their SBP
was < 150mmHg.
Eligible subjects were randomised to the three groups using a 1 : 1 : 1 ratio and were stratified by centre
and into one of two ranges of baseline aneurysm size: 3.00–4.50 cm and 4.51–5.40 cm.
Patients were followed up every 3–6 months over 2 years. At each visit, three BP recordings were taken in
the sitting position using a validated semiautomated device after at least 10 minutes’ rest. The mean of the
second and third readings was used in the analyses. Smoking was not permitted during the 30 minutes
before BP measurement.
Ultrasound AAA diameter measurements were taken at each visit. For all patients the maximum internal
and external AP AAA diameters were measured from ultrasound images of the AAA in the transverse and
longitudinal planes. A scanning protocol was provided to all participating sites in an attempt to optimise
the consistency and accuracy of the ultrasound measurements made across the 11 scanning sites that
serviced the 14 collaborating hospitals.
Quality assurance (QA) scanning events were organised to ensure consistency between observers and
between measurements by the same observers (inter- and intraobserver variability). The specific aims of the
QA events were to ensure the reliability of the results in terms of inter- and intra-observer variability and
evaluate, which was the most accurate and repeatable AAA measurement. In addition, the quality of the
ultrasound images and the ultrasound measurement data were assessed centrally to ensure a reliable
standard of ultrasound scanning across the 11 scanning sites and to highlight any errors. Representative
ultrasound images from all sites were assessed for quality by a single experienced vascular scientist.
Blood tests for concentrations of creatinine and electrolytes were carried out at screening and 3, 12 and
24 months (in keeping with best recommended practice for the management of hypertension with ACE-Is).
SCIENTIFIC SUMMARY
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Patient compliance with trial investigational medicinal products was assessed using pill counts and
potential side effects of drug treatments were monitored.
Based on the inclusion of 225 patients with a baseline AAA diameter of ≤ 5.4 cm and an estimated AAA
growth rate (data from the UK Small Aneurysm Trial) of 2.6 mm per year, the trial had 90% power at the
5% level to detect a 38% reduction in growth rate associated with randomisation to the ACE-I group
compared with the placebo group. The detectable reduction in growth rates with 80% and 70% power
were 31% and 28%, respectively. On the assumption that the effects on aneurysm progression are
specific to ACE-I rather than to lowering of BP, the trial was powered to detect a smaller difference in
growth rate (< 20%) by comparing the ACE-I group with the other two groups. These calculations allowed
for a 10% attrition rate, defined as withdrawal of subjects who did not have more than baseline
measurements of their AAA diameter, thereby preventing the possibility of any direct measurement of
AAA growth over time.
It was anticipated that the AAA growth rate in those randomised to amlodipine would allow evaluation
of the extent to which any potential ACE-I effect on AAA growth rate compared with placebo was
attributable to a reduction in BP.
Patients were to be censored at the time of death, referral for AAA repair or AAA rupture should they
occur, or in the absence of these events, at the end of the trial.
The primary outcome measure was growth in AAA diameter using external measurements in the
longitudinal plane, estimated using multilevel modelling. Secondary outcome measures included AAA
rupture, AAA repair, modelling of the time taken for the AAA to reach the threshold for intervention
(5.5 cm) or referral for surgery, tolerance of study medication (measured by compliance, AEs and quality of
life) and a comparison of the repeatability of measures of internal and external AAA diameter.
Results
Between September 2011 and April 2013, 227 patients were randomised (n= 75 perindopril, n= 73
amlodipine, n= 79 placebo). Because of the large number of patients who were ineligible (mainly because
they were already taking an ACE-I), a recruitment extension of 6 months and the addition of nine extra
research sites was required.
The recruitment target was met by April 2013. Trial follow-up was completed in April 2015, with 70% of
patients completing all trial visits and an attrition rate of 6%. Groups were well matched at baseline for
standard demographic parameters.
Based on the QA scanning events, the measurement of maximum aortic diameter in the longitudinal plane
was more repeatable than the measurement of the diameter in the transverse plane. For the maximum
aortic diameter measured in the longitudinal plane, the intraobserver repeatability was similar for internal
and external measurements, but interobserver variability was better for external measurements. Therefore,
as most sites used more than one observer, external measurements in the longitudinal plane were selected
for monitoring AAA growth. Further support for this decision arose from comparisons of measurement
variability [standard deviations (SDs) between internal and external measures shown at most time points in
the trial].
Mean differences (SD) in SBP from baseline to 24 months in the perindopril, amlodipine and placebo
groups were –5.0 (16.3) mmHg, –2.8 (11.7) mmHg and +2.5 (16.5) mmHg, respectively.
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Compliance measured by pill counts was good throughout the trial (> 80% at all visit time points). There
were no significant safety concerns associated with any of the three allocated trial drugs. Six patients
withdrew because of AEs attributed to the study medications (n= 2 perindopril, n= 4 amlodipine). No
patients ruptured their AAA and 27 patients underwent elective surgery during the trial period (n= 9
placebo, n= 10 perindopril, n= 8 amlodipine).
Multilevel modelling was used to determine the maximum likelihood estimates for AAA diameter growth.
There were no significant differences in the estimated annual diameter growth rate among the three
randomised groups [1.68 (standard error 0.02) mm, 1.77 (0.02) mm and 1.81 (0.02) mm in the placebo,
perindopril and amlodipine groups, respectively]. Similarly, the differences in the slope of modelled growth
over time were not significant between perindopril and placebo (p= 0.78) or between perindopril and
amlodipine (p= 0.89). The difference in the slope of modelled growth between the perindopril group and
the placebo and amlodipine groups combined was also not significant (p= 0.92). These results were
essentially unchanged after adjustment for potential confounders including smoking, diabetes and statin
use. Similarly, there were no differences between the groups in time to AAA referral for repair and/or time
to reach an AAA diameter of 5.5 cm.
Conclusions
This study is, to our knowledge, unique in having evaluated the effect of an ACE-I on the growth rate of
small AAAs in a randomised placebo-controlled trial. The ACE-I perindopril was well tolerated in this trial,
with good compliance rates, and there were similar numbers of AEs in all three groups.
However, we were unable to demonstrate any significant impact of perindopril compared with placebo or
the CCB amlodipine on the growth rate of small AAAs over a 2-year period. The growth rates observed in
the trial were slower than expected, which may reflect specific characteristics of the included population
(e.g. SBP had to be < 150mmHg at baseline). With the observed growth rate of 1.7 mm per year,
190 patients per group would have been needed to detect a 1mm per year reduction in growth with a
power of 90%. The sample evaluated (n= 227) generated 51% power to detect a 1-mm difference in
growth (between two groups) and 85% power to detect a difference of 1.5mm (close to the annual
growth rate observed). However, the estimated difference in annual growth between the perindopril and
placebo groups was 0.08mm with 95% confidence interval of –0.50mm to 0.65mm. This statistically
excludes a likely reduction of 1mm per year with perindopril administration.
A significant BP reduction was apparent in both the perindopril group and the amlodipine group. The
doses of perindopril and amlodipine chosen for the trial were expected to cause similar BP reductions but
this was not realised. At 3 months BP reduction with perindopril was significantly greater than that with
amlodipine (p= 0.002). With similar withdrawal rates observed in all three treatment groups and no
differences in relation to compliance, the reasons for the difference in BP reduction between the
perindopril group and the amlodipine group remain unclear.
According to the QA repeatability studies, measurements in the longitudinal plane were more repeatable
than transverse measurements. However, overall, the measurement variability in the trial as reflected by
SDs was greater than anticipated, adding uncertainty to the interpretation of the results.
Implications for health care
Despite some earlier evidence which suggests that the rupture rates of AAAs may be lower in patients
taking ACE-Is, this trial found no evidence that patients with small AAAs should be prescribed an ACE-I to
slow AAA growth. The QA studies undertaken as well as the comparison of various aspects of the
variability of internal and external measurements provide support for the use of external rather than
internal AAA diameter measurements taken in the longitudinal plane.
SCIENTIFIC SUMMARY
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The following research recommendations are made as a consequence of the conduct and findings of
the trial:
l Further work relating to the data already collected in the trial:
¢ A multivariate analysis of determinants of AAA growth in the trial.
¢ Potential differences were observed between the three treatment groups in relation to the
numbers of patients whose AAA grew at a fast rate during the trial (as defined by a growth rate of
> 5mm per year). However, formal analyses are still required.
¢ An evaluation of the incremental predictive power of baseline and changing central BP and BP
variability on AAA growth rates.
l Further work potentially arising from the trial:
¢ An evaluation of currently available data regarding AAA growth rates in those with SBP
< 150mmHg and ≥ 150mmHg to investigate whether growth rates could be critically affected by
this systolic threshold or other systolic and diastolic thresholds.
¢ An evaluation of whether the BP-lowering effect of perindopril and amlodipine is affected by the
presence or absence of an AAA.
¢ The strong protective effect of type 2 diabetes on the development of AAAs observed in large
observational databases merits further investigation.
¢ A large measurement variability study to optimise training and standardisation.
¢ A trial to evaluate the impact of ACE-Is on the rupture of larger AAAs.
Trial registration
This trial is registered as ISRCTN51383267.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (NIHR). The NIHR Biomedical Research Centre based at Imperial College NHS
Trust supported the trial. Servier provided perindopril at no charge.
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Chapter 1 Background and rationale
Introduction
An abdominal aortic aneurysm (AAA) is a ballooning of the infrarenal aorta to either 1.5 times its normal
anteroposterior (AP) diameter or to an absolute value of ≥ 3 cm.1 Small AAAs can be defined as those
between 3.0 cm and 5.4 cm in diameter. These small AAAs have a low risk of rupture, whereas the
operation to repair them is fatal in approximately 2–3% of patients.2 Small AAAs are generally managed
by optimising cardiovascular health and placing the patient on a surveillance programme to measure the
AAA diameter at regular intervals. Once AAAs reach 5.5 cm (or if initially detected at a larger size), they
are often repaired as the risk of rupture rises exponentially above this size. If rupture does occur, the
results of emergency aneurysm repair are not good, with only about 40% of patients surviving. Without
repair few survive, so that overall the survival of AAA rupture is probably < 20%. Although recent reports
have suggested that the incidence of aneurysms appears to be in decline,3,4 AAA remains a significant
health risk in the older population, with around 4000 deaths each year in England and Wales attributed to
AAA rupture.5
Except when they rupture, most AAAs are usually asymptomatic and so, until recently, they were detected
as an incidental finding on clinical examination or ultrasonography, abdominal computerised tomography
(CT) or magnetic resonance imaging performed for other purposes. However, in the UK, the NHS
Abdominal Aortic Aneurysm Screening Programme (NAAASP) was introduced in 2009 and so many more
small AAAs are now being detected early. The programme has been very successful and screened its
millionth man in autumn 2015. There is an opportunity to reduce the number of patients needing AAA
repair if AAA growth can be slowed or prevented in this growing cohort of patients.
Although data on the effects of angiotensin-converting enzyme inhibitors (ACE-Is) in this context are not
consistent, ACE-Is have been associated with a reduced incidence of AAA rupture in analysis of
administrative databases.6 Previous trials of some other drugs to slow AAA growth have been hindered by
poor patient compliance.7 Therefore, this pilot trial was undertaken to assess whether or not ACE-Is could
potentially slow AAA growth and are well tolerated in doing so. We are unaware of any other completed
randomised controlled trials (RCTs) designed to examine the efficacy of ACE-Is or angiotensin receptor
blockers (ARBs) in limiting or inhibiting AAA progression, although two trials of the impact of ARBs on the
growth of AAAs are in progress.
Risk factors
A wide variety of risk factors have been attributed to the formation and progression of AAAs. The single
most important risk factor for AAAs has consistently been found to be smoking,8–10 although other risk
factors including male sex, age, high blood pressure (BP) [particularly raised diastolic BP (DBP)] and family
history of AAA are frequently linked with the aetiology of AAA.11 Low prevalence rates have been
observed among African12 and Asian13 men compared with Caucasian men. Several studies have also
found a strong coexistence of localised and generalised atherosclerosis and AAA,14,15 an underlying
disturbed connective tissue metabolism16 and an increased risk for AAA with increasing
alcohol consumption.17
There are many genetic syndromes that are associated with aortic aneurysmal disease affecting patients
often at a very early age, including Marfan syndrome, Ehlers–Danlos syndrome, Loeys–Dietz syndrome and
familial thoracic aortic aneurysms and dissections.18
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The NHS Abdominal Aortic Aneurysm Screening Programme
Phased implementation of the NAAASP began in July 2009. It was introduced after data from a number of
studies and existing local screening programmes in England showed a reduction in aneurysm-related
mortality when men aged ≥ 65 years were offered ultrasound screening.
The Multicentre Aneurysm Screening Study (MASS) was designed to assess whether or not AAA screening
would be beneficial.19 This study enrolled men aged 65–74 years who were randomised to receive
screening or not. Extended follow-up of patients confirmed that screening resulted in a reduction in
all-cause mortality. Over 13 years there were 224 AAA-related deaths out of the 33,883 participants in
the invited group and 381 AAA-related deaths out of the 33,887 participants in the control group, a 42%
relative reduction.20
In 2005 this evidence was assessed by the UK National Screening Committee, which concluded that
ultrasound screening should be offered to men in their 65th year, with men aged ≥ 65 years being able to
self-refer within the NHS.5
The initial outcomes from the NAAASP in England identified a lower prevalence of AAA than reported in
the MASS (1.4% vs. 4.7%). However, in the MASS, men aged 65–74 years were included, whereas the
NAAASP invites men in their 65th year only for screening.
Between 2009 and 31 March 2014 the NAAASP had scanned > 700,000 men and referred > 1000 men
with a large AAA for surgery. In the period 2013–14, 491 of the screened men had an elective AAA
repair and four of these men died (an elective repair mortality rate of 0.8%). In addition, seven of the
10 screened men who suffered aneurysmal rupture died (a rupture mortality rate of 70%).21
Because of the NAAASP a greater number of patients with a small AAA are being detected and, if there
were effective treatments to slow AAA growth, this could provide an opportunity to intervene before the
AAAs expand significantly and rupture. Also, the NAAASP potentially provides a useful pool of patients for
research purposes, not only for logistical reasons but also because this group of patients (who were
previously unaware of their AAA) may be receiving less clinical/medical intervention than patients who are
already receiving monitoring for their AAA. They are therefore of particular interest for interventional studies.
Current guidelines for the management of small abdominal
aortic aneurysms
Given the variability in aneurysm expansion rates,22 the optimal interval between surveillance scans remains
uncertain. Meta-analysis of small AAA growth rates has demonstrated that the screening interval should
be dependent on diameter and that long intervals between screening may be safe for the majority of
patients.23 However, guidelines must balance the need to reduce the cost of surveillance programmes
and the need to ensure safety, as well as increasing the face-to-face time for direct cardiovascular risk
factor education.
The UK guidelines recommend that rescreening intervals should shorten as the aneurysm enlarges and
these guidelines are expected to be updated in 2017.24 Usual clinical practice in the UK, and for those
patients in the NAAASP, involves follow-up surveillance imaging at 12-monthly intervals for patients with
an AAA of 3.0–4.4 cm in diameter and at 3-monthly intervals for those patients with an AAA diameter
between 4.5 cm and 5.4 cm.
BACKGROUND AND RATIONALE
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Abdominal aortic aneurysm treatment
In both the USA and the UK, elective surgery by either open or endovascular repair is undertaken to
prevent AAA rupture and this is generally recommended for patients with an AAA of ≥ 5.5 cm in diameter,
for symptomatic aneurysms or for aneurysms that have increased by > 0.5 cm in the past 6months. The
UK Small Aneurysm Trial (UKSAT) demonstrated that the overall mortality of patients with an aneurysm of
< 5.5 cm in diameter who received surveillance was similar to that in patients who received early open
surgery.22 Furthermore, surveillance was the more cost-effective option. Subsequent studies that have
randomised patients to surveillance or endovascular treatment of AAAs have corroborated this finding.25,26
There has been an increasing trend in the proportion of repairs performed as endovascular aneurysm
repair (EVAR) procedures, increasing from 54% in 2009 to 66% in 2013.27
Studies indicate that without surgery the 5-year survival rate for patients with an aneurysm of diameter
> 5 cm is about 20%.28 Surgery to replace the aneurysmal segment or endovascular placement of a
covered stent graft excluding the aneurysm is recommended if the risk of aneurysm rupture is high enough
to justify the risk of surgery. The rate of rupture of an aneurysm rises exponentially after it reaches 5.5 cm
in size, justifying the need for repair in most patients as aneurysm rupture is associated with a high
mortality rate. Approximately half of the patients with a ruptured AAA fail to reach hospital and, of those
patients who undergo emergency surgery, there is a 35–40% mortality rate at 30 days.29
Open surgical repair carries a significant risk of perioperative morbidity and mortality. The 2014 National
Vascular Registry report stated that, over the 5 years between 2009 and 2013, in-hospital mortality for
open repairs was 3.6%.27 The less-invasive EVAR technique has significantly lowered perioperative
morbidity and mortality rates27 but not all patients are anatomically suitable for EVAR and there is still
debate regarding the long-term benefits of EVAR. Several trials, including the EVAR,30 DREAM (Dutch
Randomized Endovascular Aneurysm Repair)31 and OVER (Open Versus Endovascular Repair)32 trials, have
found that the advantage of EVAR over open repair is lost during mid-term follow-up, with survival rates
beyond 2 years being similar in both groups.
Given the risks involved with AAA repair, strategies to reduce the need for surgery are needed. Currently,
there are no clear recommendations on pharmacological treatment approaches to prevent aneurysm
progression or reduce the risk of rupture.33
Growth rates of small abdominal aortic aneurysms
The growth rate of AAAs is highly variable both between patients and in the same patient over time.
Average growth rates increase as the aneurysm enlarges. The average growth rate for a 3.5-cm aneurysm
is estimated at 1.90mm per year, whereas that for a 4.5-cm aneurysm is 3.52mm/year. Therefore, given
an exponentially increasing aneurysm diameter, it would take an average of 6.2 years for a 3.5-cm
aneurysm to grow to 5.5 cm, whereas a 4.5-cm aneurysm would grow to 5.5 cm in 2.3 years.34 These
growth rates highlight the need for very accurate measurements of AAA to be obtained in a trial setting.
In the UKSAT, AAA growth was most strongly associated with diameter at baseline22 and smoking was
associated with an incrementally increased growth rate of 0.4 mm per year. Multivariate analysis of other
potential risk factors demonstrated that the presence of peripheral arterial disease (adversely) or diabetes
(beneficially) influenced AAA growth.
The risk factor profile for aneurysm growth has been reproduced in other studies, with AAA growth being
increased in smokers8,35 and decreased in patients with diabetes.36
Average baseline diameters and growth rates reported in the Western Australia screening study,37 MASS,19
Propranolol Aneurysm Trial,7 UKSAT22 and Second Manifestation of ARTerial disease study38 are shown
in Table 1.
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Rupture rates of small abdominal aortic aneurysms
Aneurysm size is one of the strongest predictors of the risk of rupture, with risk increasing considerably
for aneurysm diameters of > 5.5 cm. The UKSAT reported the risk of rupture for AAAs up to 5.5 cm in
diameter to be < 1 per 100 person-years in men and 3 per 100 person-years in women.39
Similarly, the 5-year overall cumulative rupture rate of incidentally diagnosed AAAs in population-based
samples is 25–40% for aneurysms of > 5.0 cm diameter and 1–7% for aneurysms of 4.0–5.0 cm
in diameter.40,41
Rupture rates have been found to be doubled in current smokers compared with ex-smokers or
non-smokers (p= 0.001) and to increase with mean arterial pressure (per 10mmHg) (p= 0.001).42
Blood pressure and abdominal aortic aneurysms
Raised BP was the leading risk factor contributing to the overall global burden of disease in 2010.43 The
recent decrease in case fatality rates associated with acute cardiovascular events in high-income countries
has been associated with a rise in the numbers of patients living with cardiovascular disease and the wider
use of preventative drugs in the context of primary and secondary prevention.
An association between hypertension and the incidence of AAA is frequently cited.12,44 The CALIBER
(CArdiovascular research using LInked Bespoke studies and Electronic health Records) study used linked
electronic health records to assemble a cohort of > 1 million patients aged ≥ 30 years and initially free
from cardiovascular disease, one-fifth of whom received BP-lowering treatments.36
Of all cardiovascular diseases, AAA had the strongest association with DBP [hazard ratio (HR) per 10mmHg
1.45, 95% confidence interval (CI) 1.34 to 1.56] and mean arterial pressure (HR 1.61, 95% CI 1.48 to
1.75) and the weakest association with systolic BP (SBP) (HR 1.08, 95% CI 1.00 to 1.17). Furthermore, it
was the only cardiovascular outcome for which the association with higher pulse pressure was reversed
(HR 0.91, 95% CI 0.86 to 0.98).36
However, mean baseline BP levels reported in several large AAA surveillance studies7,19,22,37 (Table 2) are all
above what is currently considered as controlled (< 140/90mmHg45) and the AAA growth rates observed
in these studies (see Table 1) may at least in part be related to these higher BPs.
Despite the relatively strong association between hypertension and the prevalence of AAA, the association
between increased BP and the rate of AAA growth or incidence of rupture is not clear and the evidence
supporting increased growth as a result of hypertension is lacking.
TABLE 1 Average baseline diameters and growth rates from the Western Australia Screening study, MASS,
Propranolol Aneurysm Trial, UKSAT and SMART study
Study Mean baseline AAA diameter (cm) Mean AAA growth rate (mm per year)
Western Australia screening study37 3.4 1.6
MASS19 3.5 2.6
Propranolol Aneurysm Trial7 3.8 2.4
SMART study38 3.9 2.5
UKSAT22 4.3 2.6
SMART, Second Manifestation of ARTerial disease.
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Non-pharmacological treatments to reduce the growth and
rupture rate of abdominal aortic aneurysms
There is clear observational evidence that smoking increases the likelihood of developing an AAA.11,12,46
For example, in the large (n= 114,567) Aneurysm Detection and Management (ADAM) screening study,
a history of ever smoking was associated with an odds ratio of 2.97 (95% CI 2.65 to 3.32) for 3.0- to
3.9-cm AAAs and 5.07 (95% CI 4.13 to 6.21) for ≥ 4-cm AAAs.46 In addition, a recent prospective
population-based study of 92,728 men in Oxfordshire found that men aged 65–74 years who were
current smokers had a 3% 10-year risk of acute AAA, highlighting the need for screening campaigns to
reach this high-risk group.47
Furthermore, several studies8,15,17 and meta-analyses48 have found higher growth rates in current smokers
than in past smokers.
Consequently, the standard non-pharmacological treatment for AAA is smoking cessation. However, it has
been suggested that smoking cessation may lose some of its importance once significant aortic dilatation
has occurred.35
Pharmacological treatments to reduce the growth and rupture
rate of abdominal aortic aneurysms
There remains a significant need to find medical therapies that could reduce the growth and rupture rates
of small and medium-sized AAAs.
As well as interest in the development of new AAA-specific treatments, there has also been interest in
assessing the impact of treatments already in use for other indications. Early evidence often arises from
animal studies but a small number of RCTs in humans have been carried out to assess the efficacy of some
of the currently available drugs.
Beta-blockers
Evidence that the use of beta-blockers might reduce the growth of AAAs first arose from animal
studies.49,50 However, a placebo-controlled RCT including 548 patients failed to find an association
between beta-blocker use and a significant reduction in AAA expansion.7 Compliance with the medication
was a problem, with 117 of 276 (42%) randomised to propranolol and 73 of 272 (27%) allocated to
placebo stopping the drugs because of side effects. Furthermore, the increase in AAA diameter was similar
in both the propranolol group and the placebo group (2.2 and 2.6 mm per year, respectively; p= 0.11)
based on an intention-to-treat (ITT) analysis. Patients receiving propranolol also reported a significantly
worse quality of life, leading the authors to conclude that the drug did not affect the growth rate of small
AAAs and patients with AAAs do not tolerate propranolol well. Similarly, no protective association was
observed for beta-blockers in a large observational study of patients with an AAA.6
TABLE 2 Mean baseline BPs reported in the Western Australia Screening study, MASS, Propranolol Aneurysm Trial
and UKSAT
Study Mean baseline BP (mmHg)
Western Australia screening study37 157/91
MASS19 155/83
Propranolol Aneurysm Trial7 143/81
UKSAT22 157/86
DOI: 10.3310/hta20590 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 59
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kiru et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
5
Statins
The evidence supporting the use of statins for the reduction of growth and rupture rates in AAA is
inconsistent. The UK Heart Protection Study (UKHPS) compared simvastatin with placebo for the reduction
of cardiovascular events over a mean of 5 years in 20,536 patients with vascular disease or at high risk of
vascular disease at baseline.51 This included 6748 patients with peripheral artery disease. The study
reported that the requirement for AAA repair was unaffected (1.2% in both groups). The Tromsø study
related statin prescription to the development of AAAs in 4345 subjects who were scanned over 7 years.44
The use of statins was associated with an increased risk of developing an AAA.
Contrary to the UKHPS51 and Tromsø study,44 a systematic review in 2008 found that statin use was
associated with reduced growth rates of AAAs.52 This included two cohort studies that both showed
reduced growth rates in patients taking statins.53,54 Evidence suggesting that statins may be of benefit was
also presented in a population-based combined case–control and follow-up study, which found that statin
use was associated with a reduced risk of ruptured AAA and lower case fatality following ruptured AAA.55
Despite inconsistent evidence, current guidelines recommend statin therapy in patients diagnosed with an
AAA because of their high cardiovascular risk.1
Doxycycline
Doxycycline was investigated as a treatment for AAA as a result of the theory that chlamydia or related
infections might be involved in AAA formation and growth.56 However, clear evidence for the role of
infection in the progression of AAAs is limited with small antibiotic trials showing no difference in
expansion rate.57
More recent studies have investigated the effects of doxycycline as an inhibitor of matrix metalloproteinases.
Matrix metalloproteinases are thought to play a role in the destruction of elastin and collagen in the aortic
wall, leading to degeneration, and several matrix metalloproteinases have been detected in AAAs,
importantly in greater proportions at the site of rupture.58–60 Doxycycline has been found to inhibit aneurysm
development and progression in numerous animal models.61–63 A small randomised pilot trial (n= 32) in
patients with small AAAs found that the AAA expansion rate in the doxycycline group was significantly
lower than that in the placebo group during both the 6- to 12-month period and the 12- to 18-month
period.64 However, a recent larger randomised trial (n= 286) found that 18 months of doxycycline therapy
did not reduce aneurysm growth or influence the need for AAA repair or time to repair.55 Nevertheless, the
results of this trial are being challenged in a new American trial, the Non-Invasive Treatment of Abdominal
Aortic Aneurysm Clinical Trial (NTA3CT), using transverse aorta CT measurements of AAA growth
(NCT01756833). Trials incorporating other protease inhibitors are also expected in the near future.
The role of the renin–angiotensin system
The renin–angiotensin system (RAS) is a peptidergic hormone system that has been recognised to be highly
involved in disturbances of the cardiovascular system. RAS blockade by ACE-Is and ARBs has been found
to not only decrease arterial pressure but also prevent or reverse endothelial dysfunction and aspects of
the atherosclerotic process, which results in a reduction in cardiovascular mortality and morbidity.65,66
In experimental studies both angiotensinogen and angiotensin type 1 receptors have been found to be
upregulated by approximately twofold in the walls of AAAs compared with the walls of atherosclerotic
aortas, although the expression of angiotensin type 2 receptors was similar.67 In hypercholesterolaemic
mice, angiotensin II infusion induces medial dissection of the aorta proximal to aortic branch points, with
subsequent formation of suprarenal aortic aneurysms, which can be prevented with the use of ACE-Is.68
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Furthermore, in a recent study, perindopril (Coversyl arginine, Servier) inhibited aortic degeneration and
AAA formation in the experimental AAA model induced by elastase and calcium chloride.69
Angiotensin-converting enzyme inhibition
In line with the animal studies that have suggested a potential role of the RAS system in AAA formation
and growth, an observational case–control study on a group of > 15,000 patients with AAAs found that
patients who received an ACE-I before admission were 20% less likely to present with a ruptured
aneurysm.6 These results remained after adjustments were made for demographic characteristics,
comorbidities, contraindications to ACE-Is, measures of health-care use and aneurysm screening.
The group noted that the reduction in risk of aortic rupture was distinct from antihypertensive and other
medications, suggesting that the mechanism may not be related to a BP-lowering effect. Calcium
channel blockers (CCBs) and beta-blockers, for example, were not associated with any reduction in risk.6
This large-scale study demonstrated an impressive reduction in AAA rupture but there were several
potential confounders in this study, not least the compliance with ACE-Is in smokers.
In addition, a recent cohort study of 21,791 patients with AAA identified from Danish registries suggested
that treatment with ACE-Is or ARBs was associated with a decreased risk of all-cause death and death
from AAA in patients who had not yet undergone surgery for AAA.70 However, there was no reduction in
the need for surgery for AAA.
When considering growth rate modulation by agents acting on the RAS, the evidence is certainly
conflicting. The Chichester small AAA surveillance study suggested an association between ARB
prescription and reduced AAA progression.71 However, in contrast, a report from the UK Small Aneurysm
Study group reported a small but significant association between ACE-I prescription and increased AAA
expansion.72 This significant difference remained after adjustment for known confounders such as
smoking, diabetes, BP and peripheral atherosclerosis.
In summary, currently there is no clear or consistent evidence that medication designed to inhibit the RAS
limits AAA progression or leads to a decrease in the risk of rupture.
Designing the trial
To date we are unaware (based on a recent literature review) of any other completed RCTs designed to
examine the efficacy of ACE-I or ARBs in limiting or inhibiting AAA progression. This report describes the
AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) trial, which was
commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA)
programme to address this need.
Objectives
Primary
l To investigate AAAs in a three-arm randomised placebo-controlled pilot trial the hypothesis that the
ACE-I perindopril reduces the growth rate of small AAAs.
DOI: 10.3310/hta20590 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 59
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kiru et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
7
Secondary
l To evaluate any BP-independent effects of perindopril on the growth rate of small AAAs.
l To determine differences in AAA rupture rate and/or time taken to reach an AAA diameter of 5.5 cm
and/or referral for surgical intervention among the three randomised groups.
l To evaluate how well perindopril is tolerated as measured by compliance, adverse events (AEs) and
quality of life.
l To compare the repeatability of ultrasound measurements of internal and external small
AAA diameters.
Later, pending the results of this pilot trial, our objective was to work with local and national aneurysm
screening programmes to conduct a larger, more definitive RCT to investigate the hypothesis that the use
of an ACE-I reduces the rate of AAA-related mortality, rupture or elective surgery.
BACKGROUND AND RATIONALE
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Chapter 2 Methods
Final study design
This randomised, single-blind, placebo-controlled study took place at 14 investigational sites in England.
The trial consisted of three parallel randomised arms, with patients receiving 10mg of perindopril daily
(arginine salt), placebo daily (primary comparison) or 5mg of amlodipine daily (secondary comparison).
The perindopril and amlodipine doses used were estimated to have similar effects on BP reduction73–75 and
hence the secondary comparison was included to assess whether or not any benefits of perindopril were
independent of BP reduction.
Trial participants
The following factors were taken into consideration when deciding on the inclusion and exclusion criteria
for the trial:
1. Abdominal aortic aneurysm size. Patients with an AAA of ≥ 5.5 cm diameter would be considered for
surgical intervention as per the current clinical guidelines. Therefore, patients with an AAA of ≤ 5.4 cm
diameter were included to minimise the rate of patient withdrawal from the study.
2. Sex. Although a lower prevalence of AAAs has been found in women, there is no evidence to suggest
that the trial medications would have a different mechanism of action between the sexes. Therefore,
both men and women were included.
3. Age. Assuming potentially differential benefits of ACE-Is for patients with AAAs related to genetic
syndromes, a lower age limit (initially 60 years and then amended to 55 years) was set to more
effectively screen out this group.
4. Ethnicity. Although a higher prevalence of AAAs has been found in Caucasian men than in black and
Asian men, there is no evidence to suggest that the trial medications would have a different mechanism
of action between races, specifically on AAA growth. Therefore, patients from all ethnicities
were included.
5. Blood pressure. Regarding the treatment of hypertension, the 2011 National Institute for Health and
Care Excellence (NICE) guidelines45 state:
l aim for a target clinic BP of < 140/90mmHg in people aged < 80 years with treated hypertension
l aim for a target clinic BP of < 150/90mmHg in people aged ≥ 80 years with treated hypertension.
However, the Quality and Outcomes Framework target for general practitioners (GPs) is a SBP of
< 150mmHg in people aged < 80 years. It seemed reasonable, therefore, to set an inclusion criterion of a
SBP of < 150mmHg in line with this Quality and Outcomes Framework target. Otherwise, eligible patients
who had a SBP of ≥ 150mmHg could be subsequently recruited into the trial but only after suitable BP
medication had been supplied and the SBP was controlled to < 150mmHg (see Planned drug interventions).
1. Medical history. Patients with any medical conditions that would interfere with their participation in the
trial or who would be at an increased risk of adverse effects by taking the study medications were
excluded from the trial.
2. Concomitant medications. Patients already receiving an ACE-I, a CCB or an ARB could not participate in
the trial. The only exception was patients receiving 5mg of amlodipine because the maximum dosage
of amlodipine is 10mg, thereby allowing the in-trial allocation to a further 5mg.
The final inclusion and exclusion criteria are listed in the following sections. Only patients who met these
criteria were considered for inclusion in the trial.
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Inclusion criteria
l Willing and able to give written informed consent.
l Men or women aged at least 55 years.
l With an AAA of 3.0–5.4 cm in diameter by internal or external measurement according
to ultrasonography.
l Systolic BP of < 150mmHg.
Exclusion criteria
l Patients who are already required to take an ACE-I, an ARB or a CCB (with the exception of 5mg
of amlodipine).
l Those with known renal artery stenosis (> 50%) or with a serum creatinine level of > 180 µmol/l.
l Those unable to give informed consent.
l Those too frail to travel for 3-monthly surveillance visits.
l Any clinically significant medical condition that, in the opinion of the investigator, would interfere with
the study results and/or reduce life expectancy to < 2 years.
l Participation in another trial of an investigational product or device within the previous 30 days.
l Known allergy or sensitivity to perindopril or amlodipine.
l Unable or unwilling to comply with the requirements of the study, in the opinion of the investigator.
Recruiting centres
Participants were recruited from 14 centres across England (Figure 1). Initially, patients were recruited from
five centres:
l Imperial College Healthcare NHS Trust (St Mary’s Hospital)
l Imperial College Healthcare NHS Trust (Charing Cross Hospital)
l Guy’s and St Thomas’ NHS Foundation Trust (St Thomas’ Hospital)
l Royal Free London NHS Foundation Trust (Royal Free Hospital)
l University Hospitals Coventry and Warwickshire NHS Trust (University Hospital Coventry).
The original arrangement was for there to be only two sonographers in the study, one to perform all of
the scans on patients at the London sites with the same mobile ultrasound scanner and one to perform all
of the scans on patients from University Hospital Coventry on the same model of ultrasound scanner
located in Coventry. This was principally to reduce intersonographer variability.
However, before the first patient was recruited into the study it was decided that patients in London
should be screened and recruited at their local research site but that all visits and measurements from
baseline onwards would take place at a central hub, the International Centre for Circulatory Health (ICCH),
Imperial College London. The advantages of this were that:
1. Patients would have complete flexibility in the days/times of their study visits.
2. In the case of cancellations or missed appointments, patients could be rebooked without restriction,
making it less likely for them to fall out of their protocol-defined visit window.
3. Experts in hypertension and antihypertensive medications and their side effects are based on site at
ICCH and were available to see at short notice patients who had experienced any AEs.
4. The issue of being able to identify available clinic space to conduct the patient visits at each of the
research sites was overcome.
5. In the case that the sonographer was unable to conduct patient visits (because of sickness, annual
leave, etc.), the back-up sonographer (who was based at ICCH) was available to conduct visits at short
notice with minimal disruption to her other duties.
METHODS
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Nine further sites were later added to enhance recruitment:
1. Hull and East Yorkshire Hospitals NHS Trust (Hull Royal Infirmary)
2. Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (Royal Bournemouth Hospital)
3. Colchester Hospital University NHS Foundation Trust (Colchester General Hospital)
4. Newcastle upon Tyne Hospitals NHS Foundation Trust (Freeman Hospital)
5. City Hospitals Sunderland NHS Foundation Trust (Sunderland Royal Hospital)
6. York Teaching Hospitals NHS Foundation Trust (York Hospital)
7. Norfolk and Norwich University Hospitals NHS Foundation Trust (Norfolk and Norwich
University Hospital)
8. Central Manchester University Hospitals NHS Foundation Trust (Manchester Royal Infirmary)
9. Sheffield Teaching Hospitals NHS Foundation Trust (Northern General Hospital).
Patient identification centres
Several patient identification centres (PICs) were also added to the study to further enhance recruitment
(see Figure 1). The PICs identified potential participants for the trial at their sites and referred them to the
associated research site for recruitment into the trial. The following PICs were approved for the study:
l West Middlesex University Hospital NHS Trust (West Middlesex University Hospital)
l King’s College Hospital NHS Foundation Trust (King’s College Hospital)
l Maidstone and Tunbridge Wells NHS Trust (Tunbridge Wells Hospital)
l South London Healthcare NHS Trust (Queen Elizabeth Hospital, Woolwich)
l Lewisham and Greenwich NHS Trust (Lewisham Hospital)
l Dartford and Gravesham NHS Trust (Dartford Hospital).
Recruitment
The clinical registries and the NAAASP databases (when relevant) at the study sites were used to identify
patients with an AAA. Permission to recruit NAAASP patients was obtained from the NAAASP research
committee. All patients were then prescreened against the inclusion and exclusion criteria. Sites were
asked to capture the patient initials for each identified patient and to record the reasons for ineligibility or
for non-participation to help inform study progress. These patients were entered onto the Consolidated
Standards of Reporting Trials (CONSORT) flow chart. Eligible patients were then subsequently invited to
consider entry into the trial.
It was the investigators’ responsibility to obtain written informed consent from patients after adequate
explanation of the aims, methods, anticipated benefits and potential hazards of the study, and before any
study procedures commenced. Potential participants were given a copy of the patient information sheet
(PIS) and informed consent form (ICF) (see Appendix 1). The original copy of the signed and dated ICF was
retained by the site.
Patients were given at least 24 hours to read the PIS and consider their participation.
Study correspondence for health professionals
Throughout the study, steps were taken to ensure that the relevant clinical personnel were kept updated
on patients’ involvement and progress in the trial. The following documents were created, approved by the
ethics committee and utilised in the study:
1. General practitioner letter A. The purpose of this letter was to inform the patient’s GP about his or her
involvement in the study, including a brief description of the trial and its requirements, with contact
information for the trial administration and clinical staff.
METHODS
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2. General practitioner letter B. The purpose of this letter was to inform the patient’s GP of the following
clinical issues that might require their attention (the relevant statement could be ticked):
i. the patient’s SBP in clinic was found to be > 150mmHg and the patient has been commenced/or
may require commencement on 1.5 mg of slow-release indapamide to potentially be suitable for the
study (see Planned drug interventions)
ii. the patient was not found to be taking statin medication and he or she may wish to perform a lipid
profile if not already carried out and consider initiating statin therapy
iii. the creatinine level was found to be > 180 µmol/l.
3. General practitioner letter C. The purpose of this letter was to inform the patient’s GP that, pending
BP assessment, the patient might need an alternative antihypertensive medication to maintain
normotension. The letter referred to the 2011 NICE guidelines45 and invited the GP to contact the chief
investigator for advice if required.
4. End-of-study letter. This was sent to the patient (with a copy sent to the GP and the relevant referring
consultant, if applicable) to say thank you for participating in the study and to inform the patient of the
medication that he or she was receiving during the trial.
In addition, for patients who had their follow-up visits at ICCH (St Mary’s Hospital), a study results letter
was sent to their referring consultant after each visit.
Study documents for patients
All patients were provided with an appointment diary at the start of the study as a method of reducing the
number of those missing or forgetting their appointments.
The appointment diary recorded the times and dates of the visits, and space was also available for patients
to record any side effects experienced between visits and to record any changes to their concomitant
medication or study medication.
Patients were provided with an emergency contact card at the start of the study and were asked to keep
this on them at all times. The contact card gave some brief information about the study, including the study
name and a list of the potential medications that patients might be receiving as part of the trial. It also
provided a 24-hour telephone number for the local site pharmacy who held the unblinding information.
Planned drug interventions
The primary comparison was the effect on AAA growth of the ACE-I compared with placebo; one-third
of randomised patients received 10mg of perindopril arginine daily and one-third received placebo daily.
To evaluate the BP-independent effects of the ACE-I, one-third of patients were randomised to a CCB
(5mg of amlodipine daily). It was estimated that, at these doses and in this population, the two drugs
would produce similar average BP-lowering effects of approximately 6/4 mmHg. This protocol also allowed
both drugs to be compared with placebo to evaluate any BP-lowering impact on AAA growth.
If the SBP of potential trial recruits was > 150mmHg at screening, sites were asked to arrange for these
patients to receive 1.5 mg of slow-release indapamide daily (either prescribed locally or through their GP)
or, if this was not appropriate, 5 mg of amlodipine for a 6-week period. Such patients then had their BP
measurements repeated after 6 weeks and if their SBP had fallen to < 150mmHg they were eligible to
proceed to randomisation.
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The most common side effect of ACE-Is is cough, which affects about 15% of those treated.76 However,
exclusion of those with a pretrial history of ACE-I intolerance was enforced to reduce the incidence of this
problem. During the trial, this side effect was monitored, particularly as we anticipated (based on past
research) that the majority of patients in the trial would be smokers or ex-smokers who tend to tolerate
ACE-Is less well. When in-trial cough was persistent and intolerable, patients stopped medication for
2 weeks and if the cough resolved they were changed to the ARB losartan (100mg per day). If the cough
continued (and hence was deemed to be unrelated to the trial medication), perindopril was restarted.
For all patients recruited into the trial who were not currently receiving a statin, sites were advised to
request that the their GP prescribe a drug in this class as per current guidelines.
Visit schedule
The study visit schedule for the AARDVARK trial is shown in Table 3.
Each patient had a maximum of 10 planned study visits. The visit schedule and interventions were as follows:
1. screening – informed consent, collection of demographic information, past medical history and current
medical therapies, review of most recent AAA ultrasound measurement, BP, blood for measurement
of creatinine and electrolytes
2. baseline – review of informed consent, review of demographic information, review and checking of
past medical history, review and checking of current medical therapies, ultrasound of AAA as per
study protocol, BP readings in triplicate, review of screening blood test results, collection of urine and
blood for the biomarker study (in a subset of patients), confirmation of patient eligibility,
randomisation and dispensing of study medication
3. 3 months – review and check medical history, review and check current medical therapies, collect
details of any AEs, ultrasound of AAA as per study protocol, BP readings in triplicate, collection of
blood for measurement of creatinine and electrolytes, dispensing of study medication and pill count
4. 6 months – review and check medical history, review and check current medical therapies, collect
details of any AEs, ultrasound of AAA as per study protocol, BP readings in triplicate, dispensing of
study medication and pill count
5. 9 months – review and check medical history, review and check current medical therapies, collect
details of any AEs, ultrasound of AAA as per study protocol, BP readings in triplicate, dispensing of
study medication and pill count
6. 12 months – review and check medical history, review and check current medical therapies, collect
details of any AEs, ultrasound of AAA as per study protocol, BP readings in triplicate, collection of
blood for measurement of creatinine and electrolytes, dispensing of study medication and pill count
7. 15 months – review and check medical history, review and check current medical therapies, collect
details of any AEs, ultrasound of AAA as per study protocol, BP readings in triplicate, dispensing of
study medication and pill count
8. 18 months – review and check medical history, review and check current medical therapies, collect
details of any AEs, ultrasound of AAA as per study protocol, BP readings in triplicate, dispensing of
study medication and pill count
9. 21 months – review and check medical history, review and check current medical therapies, collect
details of any AEs, ultrasound of AAA as per study protocol, BP readings in triplicate, dispensing of
study medication and pill count
10. 24 months – review and check medical history, review and check current medical therapies,
ultrasound of AAA as per study protocol, BP readings in triplicate, collection of urine and blood for
biomarker study (in a subset of patients), collection of European Quality of Life-5 Dimensions (EQ-5D)
questionnaire, health resource use questionnaire and pill count.
METHODS
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Blood pressure protocol
At each visit three BP recordings were taken in the sitting position using a validated semiautomated device
after at least 10 minutes rest. The mean of the second and third readings was used in analyses. Smoking
was not permitted in the 30 minutes before BP measurement. Omron 705CP-II machines (OMRON
Healthcare, Milton Keynes, UK) were distributed for collection of BP measurements at all except five sites,
where BP Plus devices (USCOM, Sydney, NSW, Australia) were used. The purchase of six BP Plus devices
was funded by the Foundation for Circulatory Health, Imperial College London. These machines were
distributed to the five sites (one machine was kept as a backup) where we expected the highest
recruitment levels (St Mary’s Hospital, Royal Bournemouth Hospital, Hull Royal Infirmary, Norfolk and
Norwich University Hospital and York Hospital). At these sites both peripheral and central BP recordings
were collected from the baseline visit onwards for all patients. At ICCH, 20 patients were already
participating in the trial prior to the BP Plus machine arriving; these patients had all of their BP
measurements taken using an OMRON machine.
Clinical laboratory samples
Angiotensin-converting enzyme inhibitors commonly cause mild increases in serum creatinine as part of the
desired result of reducing intraglomerular pressure. This slight rise in serum creatinine is to be expected
and is acceptable after starting ACE-Is.77 Blood tests for measurement of creatinine and electrolytes were
therefore carried out at screening and 3, 12 and 24 months (in keeping with best recommended practice
for the management of hypertension with ACE-Is) and results were reviewed regularly by the study team
and the Data Safety Monitoring Committee (DSMC). If the serum creatinine level rose > 30% above
baseline or progressively increased over time, investigators were advised to discontinue the study
medication. Lesser increases in serum creatinine were monitored as required more frequent blood tests.
Quality of life
The EQ-5D is a standardised measure of health status developed by the EuroQol group78 to provide a
simple, generic measure of health for clinical and economic appraisal. It is applicable to a wide range of
health conditions and treatments, and provides a simple descriptive profile and a single index value for
health status that can be used in the clinical and economic evaluation of health care.
The EQ-5D consists of two pages: a descriptive system and a visual analogue scale. The descriptive system
has five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has
three levels of severity (no problems, some problems, extreme problems) in the three-level version and five
levels of severity (no problems, slight problems, moderate problems, severe problems and extreme problems)
in the five-level version. The three-level version was utilised for the AARDVARK trial (see Appendix 2).
The visual analogue scale used to value EQ-5D health states is presented as a 20-cm vertical line calibrated
from zero (‘worst imaginable health state’) to 100 (‘best imaginable health state’). It asks respondents to
‘mark an ✗ on the scale to indicate how your health is today’.
This questionnaire was administered after 12 and 24 months of follow-up to allow quality of life to be
compared among the three randomised groups during treatment as part of the safety analyses.
METHODS
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Health resource use questionnaire
The health resource use questionnaire (see Appendix 3) was created specifically for this study to evaluate
the associated costs and burden of AAA patients to the NHS if there was a significant effect of ACE-Is on
aneurysm growth.
The questionnaire collects information relating to patients’ health service use (e.g. visits to their doctor,
nurse or GP) for reasons related to their aneurysm, use of social services, the amount of help they receive
from their family and carers and service use for reasons not related to their aneurysm.
This questionnaire was administered after 12 and 24 months of follow-up.
Data collection
Data were collected by the study team onto paper case report forms (CRFs) (see Appendix 4) and were
then entered onto corresponding electronic forms on the InForm™ ITM (Integrated Trial Management)
system (Oracle Corporation UK Ltd, Reading, UK). This is a web-based data entry system that builds an
Oracle database for each individual clinical trial. Bespoke web-based electronic CRFs with built-in validation
rules were designed to identify data entry errors in real time and provide a full audit trail of data entry and
changes. All persons entering data were trained prior to start-up and given personal login details with
access to forms restricted according to site and role. The electronic CRFs were designed in accordance with
the requirements of the trial protocol and complied with regulatory requirements. An automated audit trail
was recorded when (and by which user) records were created, updated or deleted. Error reports were
generated when data clarification was required and data queries were resolved by research nurses at
trial sites.
Trial reporting
The trial team was required to submit annual reports on trial progress, data completion rates and safety
and protocol compliance to the Medicines and Healthcare products Regulatory Agency (MHRA) and the
Research Ethics Committee (REC). Reports were also prepared for all trial-oversight committees.
In addition, monthly key figures and 6-monthly reports were prepared for the funding body (the NIHR HTA
programme). Monitoring meetings to discuss trial progress were also held with the NIHR at its request.
Trial monitoring
The data collected for the study were monitored on a regular basis to ensure that the integrity of the data
and the rights and well-being of participants were protected. Monitoring was completed at a central level
and a site level to check for any data errors, deviations or protocol non-compliance.
Validation checks were built into the InForm system, which enabled validation reports to be generated.
Any missing values, values out of range or spurious values within the data set were flagged. Queries were
sent to sites and followed up for resolution prior to data lock.
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All sites were visited prior to opening to recruitment, within 2 weeks of randomising their first patient and
then as required to achieve the following:
l Source data verification of 100% of ICFs signed since previous visit to ensure correct completion.
l Drug accountability for 100% of patients.
l Verification that all serious adverse events (SAEs) had been reported correctly.
l Source data verification of at least 50% of subjects randomised (a list of random patient numbers was
provided by the statistician in advance) should have been performed by the end of the study for
the following:
¢ Eligibility – the data on the screening worksheets should have been checked against the inclusion/
exclusion checklist and the subjects’ medical notes; for scanning sites, this eligibility should also
have been entered correctly on InForm.
¢ Existence – verification that subjects’ name and date of birth on the study worksheets and ICFs
match the details in the medical notes.
¢ Aneurysm measurements – by comparison of data on InForm against the study worksheets to
ensure that the measurements had been entered correctly.
¢ EQ-5D – by comparison of data on InForm against the hard copy of the questionnaire completed
by the patient.
¢ Health resource use questionnaire – by comparison of data on InForm against the hard copy of the
questionnaire completed by the patient.
¢ AEs and SAEs – by comparison of data on InForm against worksheets and medical notes.
¢ Blood pressure – by comparison of data on InForm against the data recorded on the study
worksheets. For BP measurements recorded using an OMRON machine with a printer, a printout of
the results should have been attached to the worksheets. If a BP Plus machine was used, the
measurements entered on InForm should have been checked against the study worksheets and,
if available, against the electronic BP Plus database.
Randomisation
Randomisation was performed using a 1 : 1 : 1 ratio stratified by centre and by baseline size of aneurysm
stratified into two size ranges: 3.0–4.5 cm and 4.51–5.40 cm. The randomisation code was generated by
an independent statistician using randomly permutated blocks of varying sizes using SAS computer
software (SAS Institute, Cary, NC, USA).
Any subjects successfully screened for the study and found to be eligible to proceed in the study were then
randomised via the InForm system by a trained member of the research team after appropriate consent.
Patients were allocated a unique study number for use in all future data collection.
Investigational medicinal products
Perindopril, amlodipine and placebo were produced in accordance with good manufacturing practice79 and
packaged and labelled by the Royal Free Hospital Pharmacy Manufacturing Unit. Overencapsulation of the
tablets for this pilot study proved too costly; therefore, the amlodipine, perindopril and placebo tablets
were not identical. The three investigational medicinal products (IMPs) were randomly allocated to either
bottle A, bottle B or bottle C by a statistician and this information was provided to the Royal Free
Manufacturing Unit to allow the IMPs to be deblistered and packed into the corresponding bottles.
Perindopril arginine (10mg) was provided by Servier at no cost. All products were checked by a qualified
person at the Royal Free Manufacturing Unit prior to release.
METHODS
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The Royal Free Manufacturing Unit held a manufacturer’s authorisation for IMPs (called the Manufacturing
and Importation Authorisation at the time of this study). Blinded treatment kits were labelled as per
European Commission Good Manufacturing Practice Guidelines, Annex 1379 to enable the treatment to be
identified and the batch source of the materials traced.
The IMPs were supplied to the participating sites on a demand basis with minimal wastage of materials.
Bottle accountability logs were maintained by all parties to allow full reconciliation of IMPs, including
assignment to patients.
Although the study was classed as single blind because the tablets were not identical, the following
measures were taken to avoid site staff becoming aware of treatment allocation:
l At no point during the study were the site staff informed of the contents of bottles A, B and C.
l Bottles A, B and C were the same colour and opaque so that the tablets could not be seen by
participating staff.
l Sites were advised that returned tablets should be counted only by the pharmacy staff. This was to
avoid any members of the research team identifying any of the tablets by their appearance.
Consequently, for all practical purposes the trial might reasonably be considered double blind.
Slow-release indapamide (1.5 mg) or amlodipine (5 mg) for use in the treatment of BP in those with a SBP
> 150mmHg following the initial screening visit was supplied by the site pharmacy or patients’ GPs in
blister packs (not blinded). Losartan (100mg) (an ARB) for use in patients who developed a cough during
the trial was supplied by the site pharmacy or patients’ GP in blister packs (not blinded).
Study drug administration and compliance
Either a 3- or a 6-month supply of study drug was dispensed at each visit (depending on the timing of the
next visit). For the initial 2 weeks following randomisation, patients were asked to take half doses of the
IMP dispensed (i.e. 5 mg of perindopril, 2.5 mg of amlodipine and half of the placebo tablet). This is in
line with standard clinical practice for the initiation of perindopril and hence was applied to all three
randomised groups. All patients were provided with pill cutters at their randomisation visit for this purpose.
After 2 weeks they were instructed to take the full dose. Patients were instructed to take their tablets at
the same time each morning.
Patient compliance with the trial IMPs and potential side effects of drug treatment were monitored closely.
When an in-trial cough was persistent and intolerable, patients stopped medication for 2 weeks and if the
cough resolved they were changed to losartan (100mg per day). If the cough continued (and hence was
deemed to be unrelated to the trial medication), the study treatment was restarted. All patients who were
switched to an ARB continued in the trial and were followed up on an ITT basis.
To encourage continued involvement in the trial, retention techniques (follow-up telephone calls, study
keyrings and Christmas cards) were used.
Compliance with study medication was evaluated using pill counts. Compliance (expressed as a
percentage) was calculated as the ratio of tablets taken (based on pill counts of tablets returned) divided
by the number of tablets that should have been consumed based on the dates that they were dispensed
and returned.
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Unblinding procedures
In the event of a medical emergency it may have been considered important for a clinician to be aware of
which treatment a patient had been using. It may have therefore been necessary for the trial code to be
broken and the treatment allocation to be revealed.
All sites were advised to provide a number on the patients’ emergency contact card to call for the
pharmacist or pharmacist-on-call (out of hours).
It was planned that all unblinding requests be discussed with the chief investigator of the trial, principal
investigator (PI) of the site or delegate during working hours.
The pharmacy department held an out-of-hours contact number for the PI (or delegate) so that
authorisation to unblind could be given. If the PI or delegate could not be contacted out of hours, the
pharmacists were permitted to break the code.
The pharmacists were advised to record the name, post, address and contact number of the person
requesting the unblinding, as well as the patient’s identification number, name and reason for unblinding.
Adverse event management
The following AEs were collected as part of the study:
l SAEs
l a single diagnosis or symptom that led to discontinuation of the trial drug
l AEs thought to be secondary to trial medication.
For each AE the following was recorded:
l start and end date and severity
l the likely causal relationship between the IMP and the AE in the opinion of the PI or delegate was
indicated as possible, probable or definite.
In addition, sites were requested to report any other AEs that impacted on patients’ participation in the
trial or that they felt should be reviewed by the medical monitors. AEs were followed up according to local
practice until they had stabilised or resolved.
Serious adverse events were defined as any untoward medical occurrence or effect that:
l resulted in death
l was life-threatening, that is, an event in which the subject was at risk of death at the time of the
event; it did not refer to an event that hypothetically might have caused death if it were more severe
l required hospitalisation or prolongation of an existing hospitalisation
l resulted in persistent or significant disability or incapacity
l resulted in a congenital abnormality or birth defect.
Medical judgement was exercised in deciding whether or not an AE/adverse reaction was serious in other
situations. Important AEs/adverse reactions that were not immediately life-threatening or that did not
result in death or hospitalisation but which may have jeopardised the health of a subject or may have
required intervention to prevent one of the other outcomes listed in the definition above were also
considered serious.
Any planned/elective hospitalisations that were scheduled prior to signing the informed consent but which
took place during participation in the study, as well as elective AAA repair, did not require reporting
as SAEs.
METHODS
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Reporting of protocol violations and deviations
Sites were requested to report all deviations from the study protocol. The site research staff were
responsible for ensuring that procedures were undertaken and treatment given in accordance with the
protocol. Any suspected protocol violation or deviation was reported on a protocol deviation form and also
recorded on the InForm system. The AARDVARK management team was responsible for reviewing all
protocol deviations and informing the sponsor as appropriate. Participants continued to participate in the
trial except if they had been randomised in error or if they requested to be totally withdrawn from the
study. Fully consented patients enrolled on the trial were followed up and analysed as per ITT analysis.
Subject confidentiality
All study staff were responsible for ensuring that participant confidentiality was maintained at all times.
On the study worksheets or any other documents submitted to the sponsor, subjects were identified by a
subject ID number and initials only.
The chief investigator and PIs were permitted direct access to subjects’ records and source documents only
for the purposes of monitoring, auditing or inspection by the sponsor, authorised representatives of the
sponsor, regulatory authorities and REC.
Retention of trial documents
This trial was coordinated by the Imperial Clinical Trials Unit (ICTU), which has well-established protocols
for the protection of data and facilities for the retention of documents in place. Data will be stored for a
minimum of 10 years (or according to changes in regulatory requirements) following completion of this
trial. Data generated by this work will be processed in accordance with the Data Protection Act 1998.80
The ICTU adheres to the Imperial College Code of Practice, drawn up in association with the College’s
data protection policy, relating to the collection, holding and disclosure of data relating to individuals.
The principal applicant and co-applicants act as custodians of the data and are responsible for its
security. The chief investigator or delegate will ensure the continued storage of the documents, even if
they leave the clinic/practice or retire before the end of the required storage period. Delegation will be
documented in writing. The PI at each site is responsible for the archiving of all of the essential trial
documents, including the Investigator Site File, in accordance with regulatory requirements.
The chief investigator and PIs were expected to retain a comprehensive and centralised filing system of all
study-related documentation that was suitable for inspection by the sponsor and representatives of
regulatory authorities.
Primary efficacy variables
The primary outcome measure was the growth of AAA external diameter (measured in the longitudinal
plane) as per the results of the intra-/inter-variability studies (see Chapter 3).
In the absence of any convincing evidence regarding the best method of measuring AAAs, it was decided
to inspect the within-trial assessments of measurement repeatability and base the primary outcome on
the modality (internal or external) with the greatest within-trial repeatability for the AP diameter in the
longitudinal plane.
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Secondary efficacy variables
Secondary outcome measures included:
l time taken for the aneurysm to reach the threshold for intervention (diameter of 5.5 cm)
l aneurysm rupture
l aneurysm repair/referral for repair
l repeatability of internal and external aneurysm diameters
l quality of life (EQ-5D) and a health resource use questionnaire (12 and 24 months)
l intolerance of ACE-Is
l drug compliance
l reduction in BP.
Safety variables
Safety was assessed during the trial by:
l assessment of AEs and SAEs
l monitoring changes in serum creatinine levels.
Statistical methods
Sample size
Based on the inclusion of 225 patients with a baseline AAA diameter of ≤ 5.4 cm and an estimated growth
rate (based on UKSAT) of 2.6mm per year,22 the trial was powered to 90% at the 5% level to detect a
38% reduction in growth rate associated with the ACE-I compared with placebo. The detectable reduction
in growth rates with 80% and 70% power were 31% and 28%, respectively. On the assumption that the
effects on aneurysm progression are specific to ACE-Is rather than other antihypertensive drugs, the trial
was powered to detect a smaller difference in growth rate (< 20%) by comparing the ACE-I group with
the other two groups. These calculations allowed for 10% attrition (see Attrition).
The placebo-corrected AAA growth rate in the amlodipine group could be used for evaluation of the
extent to which any ACE-I effect on AAA growth was attributable to BP reduction. The events of aneurysm
repair, aneurysm rupture and death were to be documented and patients censored at these time points or
in the absence of these events at the end of the study.
Attrition
Over a 2-year follow-up period, a total attrition rate of 10% was included in the power calculations for the
trial. Participants were included in the attrition rate if data from fewer than two study visits were available
for analysis and hence they could not contribute data to the measurement of AAA growth rate.
Outcome measures
The primary outcome measure was growth rate of AAA diameter measured using outer-to-outer (OTO)
measurements in the longitudinal plane, estimated using multilevel modelling. Secondary outcome
measures included AAA rupture, AAA repair/or referral for repair, time taken for the AAA diameter to reach
the threshold for intervention (5.5 cm), tolerance of study medication (measured by compliance, AEs and
quality of life) and a comparison of the repeatability of measures of internal and external AAA diameter.
Baseline demographics
Baseline demographic variables (including age, sex, ethnicity, smoking, alcohol, height and weight) and
other relevant clinical baseline characteristics (including other coexisting medical conditions, use of statins,
pulse pressure, BP, AAA diameter and serum creatinine level) are summarised for each treatment group.
METHODS
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Summaries of continuous variables are presented as means and standard deviations (SDs) if normally
distributed and as medians and interquartile ranges for skewed data, whereas categorical variables are
presented as frequencies and percentages as planned a priori in the statistical analysis plan.
Primary efficacy analysis
The AAA diameter growth from baseline to month 24 was analysed using linear mixed models (multilevel
modelling) in which repeated measurements were nested within subjects. The growth rate was estimated
from the individual specific trajectories of AAA diameter over time and the multilevel model has the
advantage of using all of the available measurements and of taking into account both between- and
within-individual variability over time. The model, described in detail below, gives an estimate of the
average growth rate and the difference in growth rate between treatment groups. To check for non-
linearity in AAA diameter growth with time, quadratic and cubic models were also fitted. We fitted the
following random-intercept model (under the standard assumptions):
y ij = β1 + β2timei j + ς1 j + εi j, (1)
where yij is the diameter for each subject j at occasion i, timeij is the corresponding time point, the
parameters β1 and β2 are the fixed effect, with β1 representing the mean diameter at baseline and β2 the
mean difference in diameter for a unit increase in time, ς1j is the random intercept, that is, the deviation of
the individual-specific intercept from the population intercept and ϵij is the residual error. Although 3- or
6-monthly measurements were used to fit the model, the results are presented with 1 year as the unit of
time (as annual growth rates are most commonly reported in the literature).
We then specified a random-coefficient model adding a random slope ς2j of time to allow patients to differ
in their rate of diameter growth:
y ij = β1 + β2timei j + ς1 j + ς2 j timei j + εi j, (2)
where ς2j represents the deviation of the individual-specific slope from the population slope.
The model assumption is that the random intercept and slope components had a joint normal distribution,
with a zero mean, a constant SD across individual-specific intercepts, a constant SD across individual-
specific slopes and a correlation between the random intercepts and random slopes. The residual error was
assumed to be normally distributed with a zero mean and constant SD.
To investigate the difference in growth rate between treatment groups we added two dummy variables for
the groups and their interaction with time to the fixed part. The primary comparison was perindopril
compared with placebo (B vs. A):
y ij = β1 + β2timei j + β3groupBj + β4groupC j + β5timei j × groupBj + β6timei j × groupC j + ς1 j
+ ς2 j timei j + εi j, (3)
where β1 and β2 are the mean intercept and slope for group A, β3 is the parameter representing the
difference in estimated mean diameter at baseline in group B compared with group A and β5 is the
parameter representing the difference in the estimated change in diameter over time for group B
compared with group A (same interpretation for β4 and β6 for group C compared with group A). A further
assumption of this model was that the variation between individual intercepts and slopes and the variation
of the residual errors did not differ between groups.
We also checked for a potential site effect adding the site in the model as a random effect. In the
sensitivity analysis we examined the site effect as a fixed term.
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Secondary efficacy analysis
All secondary end points were summarised in the form of frequency distributions and descriptive statistics
at each visit. Differences within groups were tested using paired t-tests and differences at different time
points between groups were analysed using linear regression adjusted for baseline. Log-transformation
was used for non-normally distributed variables.
The survival secondary end point (time taken to reach 5.5 cm or referred to surgery) was analysed using
Kaplan–Meier plots for descriptive analysis and the log-rank test was used to assess differences
between treatments.
The repeatability of measurement of internal and external aneurysm diameters was analysed using
Bland–Altman methodology. Using repeated measurements taken on the same patient on the same day by
different sonographers the repeatability coefficient for each sonographer was reported for intrasonographer
variability and the 95% limits of agreement for each sonographer compared with the most experienced
vascular scientist were reported for intersonographer variability.
General methodology
Histograms and box plots were used to assess the distributional assumptions and check for possible outliers.
All treatment evaluations were performed under the ITT principle unless otherwise specified. All statistical
tests were two-tailed at the 5% significance level.
All of the available AAA diameter measurements were included in the analysis (also from patients who
underwent AAA repair, who were withdrawn or who were lost to follow-up). An advantage of using
multilevel modelling for the analysis of repeated measurements is that all available information can be
used and it gives robust estimation with incomplete data under the assumption of ‘missing at random’.
Therefore, no extra missing data imputation was performed.
Nevertheless, before starting the data analysis, the level, pattern and likely causes of the missing data in
the baseline variables and outcomes were investigated. Some intermittent missing data were anticipated as
patients and sites were given the option of undertaking 6-monthly visits (and we can assume that this
intermittent missingness is missing at random).
Interim analysis
A preliminary analysis was undertaken in February 2015 and approval for this analysis was given by the
DSMC, Trial Steering Committee (TSC), NIHR HTA programme and Trial Management Group (TMG). The
main purpose of this analysis was to undertake a practice run of the final analysis to identify any early
potential problems and to give thought to a large-scale trial if warranted.
The results of this preliminary analysis were presented to the study writing committee. The writing
committee was also unblinded at this stage to help direct and support the writing of the final report.
Subsequent to being unblinded, members of the writing committee had no further involvement in data
collection for the trial.
Research governance and management
This IMP trial was conducted in accordance with Medical Research Council (MRC) Guidelines for Good
Clinical Practice81 and the Medicines for Human Use (Clinical Trials) Regulations 2004.82 Imperial College
London acted as the trial sponsor. A clinical trial authorisation was applied for and received from the MHRA.
A site agreement between Imperial College London and the participating sites outlined the responsibilities
of all parties and was signed prior to commencement of recruitment at the participating sites.
METHODS
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Three committees were established to govern the conduct of the trial: the TSC, the independent DSMC
and the TMG. These committees functioned in accordance with ICTU standard operating procedures.
Trial Steering Committee
The TSC consisted of three independent members [two vascular surgeons (one as chairperson) and a
patient representative] and two members of the trial team (chief investigator and trial manager).
The responsibilities of the TSC were to approve the main study protocol and any amendments, monitor
and supervise the trial with regard to its interim and overall objectives, review relevant information from
other sources, consider the recommendations of the DSMC and resolve problems brought by the trial
co-ordinating centres. The TSC, therefore, provided overall supervision for the trial on behalf of the HTA
programme and Imperial College London (sponsor) to ensure that the trial was conducted to the
rigorous standards set out in the MRC Guidelines for Good Clinical Practice.81 Meetings were held by
teleconference at regular intervals determined by need and not less than once a year.
Data Safety Monitoring Committee
The DSMC consisted of an independent statistician (chairperson), a vascular surgeon, an expert in
hypertension and the trial statistician. In addition, two members of the trial team (the chief investigator
and trial manager) attended the open sessions of the DSMC meetings.
The DSMC was responsible for reviewing the progress of the trial and accruing data and providing advice
on the conduct of the trial to the TMG and TSC. The DSMC was required to inform the chairperson of the
TMG if, in its view:
l there were concerns about the safety of one or more of the treatment arms
l the results showed a benefit of one treatment arm over another that was so large, and precise, that it
was likely to convince a broad range of clinicians to change practice
l it was evident that if the trial continued it would fail to show a clear benefit for any treatment arm
l accrual of patients was so low that it was unlikely that a sufficient number of patients would be
recruited to provide meaningful results.
It also had a specific role in reviewing the trial’s progress with the aim of:
l monitoring evidence for treatment harm (e.g. toxicity data, SAEs, deaths)
l suggesting additional data analyses, for example of main outcome measures, but only when this was
relevant to the trial continuing or stopping early
l deciding whether or not to recommend that the trial continued to recruit participants or if recruitment
should be terminated either for everyone or for some treatment groups and/or some
participant subgroups
l monitoring planned sample size assumptions and recommend amendments if appropriate
l monitoring recruitment figures and losses to follow-up
l advising on major protocol modifications suggested by investigators or sponsors such as changing the
main end points
l assessing data quality, including completeness
l monitoring compliance with the protocol by participants and investigators
l monitoring the continuing appropriateness of patient information
l assessing the impact and relevance of external evidence.
DOI: 10.3310/hta20590 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 59
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kiru et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
25
Trial Management Group
The TMG consisted of the chief investigator, co-applicants, PIs, trial manager, monitors, project
administrators, statisticians, research nurses and patient representative. This group was responsible for the
day-to-day management of the trial. The group met on a monthly basis during the recruitment period of
the trial and on an ad hoc basis during the follow-up and close-out period.
Patient and public involvement
Several patients with small AAAs were consulted to seek their opinions about the design and running of
the trial. All of these patients reported that they would feel reassured by the increased surveillance of their
AAA. In addition, a close relative of one patient approached emphasised the painful and stressful nature of
the surgery that his relative had undergone and how he wished that there had been an alternative to that
surgery. Therefore, anything that could be done to slow the growth of the AAA, to prevent or delay the
need for distressing major surgery, was seen as positive.
A patient representative was present on the TMG and was involved in the design of the trial as well as
review of protocol amendments and changes to the patient literature.
Protocol changes
All changes to the trial protocol and study conduct were reviewed by the sponsor and submitted to the
REC and MHRA for approval as appropriate.
A summary of the amendments made prior to participant recruitment, during recruitment and after
recruitment are provided in Tables 4–6, respectively.
TABLE 4 Amendments made prior to participant recruitment
Amendment number Documents amendment relates to Date of approval
1 l The new SPC from Sandoz Ltd
l The amendments application form
l A copy of the amended EudraCT application form
11 May 2011
2 l Protocol version 3
l Summary of changes from protocol version 2 to version 3
l PIS version 5
l Contact card version 3
l New appointment diary version 1
5 August 2011
EudraCT, European Union Drug Regulating Authorities Clinical Trials; SPC, Summary of Product Characteristics.
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TABLE 6 Amendments made post participant recruitment
Amendment number Documents amendment relates to Date of approval
7 l GP letter C
l End-of-study letter
14 November 2014
TABLE 5 Amendments made during participant recruitment
Amendment number Documents amendment relates to Date of approval
3 l Protocol version 4 (clean and tracked)
l Summary of changes from protocol version 3 to version 4
l PIS and ICF version 6
l Patient invitation letter version 1
l Trial poster version 1
30 January 2012
4 l Protocol version 5 (clean and tracked)
l Summary of changes from protocol version 4 to version 5
l PIS and ICF version 7 (clean and tracked for biomarker and
non-biomarker sites)
l GP letters A and B version 2
4 May 2012
5 l Protocol version 6 (clean and tracked)
l Summary of changes from protocol version 5 to version 6
l PIS and ICF version 8 (clean and tracked for biomarker and
non-biomarker sites)
l GP letter A version 3
l Patient invitation letter version 2
17 July 2012
6 l Protocol version 7 (clean and tracked)
l Summary of changes from protocol version 5 to version 7
l PIS and ICF version 9 (clean and tracked for biomarker and
non-biomarker sites)
l Patient invitation letter B version 1
4 September 2013
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Chapter 3 Ultrasound measurements and
quality assurance
Obtaining abdominal aortic aneurysm measurements
Accurate initial and repeat measurements of AAAs are essential to correctly ascertain growth rates in a trial
setting and also to direct clinical management. Ultrasonography is a widely used, non-invasive and
effective method for screening and obtaining measurements of AAA diameter. Static images are produced
by freezing the image obtained using ultrasound and then accurate measurements can be taken
using callipers.
Ultrasonography has been found to be accurate when used to assess AAA diameters by trained observers
when compared with CT, and 95% of the differences between the two measurements can be expected to
be < 3.5mm.83 Similar accuracy was obtained for trained screeners in the UKSAT22 and other aneurysm
screening19 and observation84 studies.
In a clinical setting, ultrasound studies of AAAs are most often undertaken by vascular scientists and
sonographers who have been trained extensively to undertake such studies. However, staff with no or
limited previous experience of ultrasonography can be trained rapidly to identify the presence of AAAs
reliably.85–87 This model of training is used extensively in the NAAASP.
The visualisation of the abdominal aorta may be dependent on the sonographer’s experience and the
extent of the patient’s bowel gas and body mass index. However, in a study by Hoffman et al.,88 despite
the level of difficulty reported, the accuracy of aortic measurements by the novices was independent of
obesity and central adiposity.
Other common difficulties when scanning include ‘eccentric’ aneurysms and tortuous aortas, as well as the
incorrect identification of other structures that appear tubular in cross-section (e.g. the inferior vena cava,
the superior mesenteric artery and the gall bladder). The accurate selection of the boundaries of the aorta
is also clearly important.89 It is important that these factors are addressed and that quality improvement
strategies are appropriately implemented in trials using ultrasound measurements.
When using ultrasound it is generally accepted that AP abdominal aortic diameters are recorded as
standard because of their superior repeatability compared with transverse diameters.90 However, the most
reliable method of measuring AAA diameter remains debatable. The two main methods are measuring the
internal diameters [i.e. inner anterior wall to the inner posterior wall (inner to inner or ITI) or intima to
intima] or measuring the external diameters [i.e. from the outer anterior to the outer posterior wall (OTO)
or adventitia to adventitia] (Figure 2). Some studies also use leading edge to leading edge measurements.
Screening technicians employed by NAAASP are trained to correctly identify and take ITI measurements of
AAAs by undertaking a 3-month accredited training programme. For trained screening technicians, the ITI
method has been found to have better reliability and reproducibility than OTO measurement.91 Conversely,
when comparing the reliability and reproducibility of measurements taken by vascular scientists, it has
been suggested that the OTO method is superior, with the ITI method underestimating the aortic size92
and having greater variability because of difficulty identifying the internal wall because of thrombus93 (see
Figure 2), that is, aneurysm growth rates measured using internal diameters have greater noise or scatter
than growth rates measured using external diameters.42
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The purpose of the trial quality assurance (QA) process was to:
1. ensure that there was adequate completeness of data collection by all sites
2. ensure the use of a standard protocol in the ultrasound scans carried out across 11 scanning sites by
different sonographers on different ultrasound scanning systems
3. ensure the reliability of the results in terms of inter- and intra-observer variability
4. evaluate the reliability of AP AAA measurements taken using internal and external methods in both
transverse and longitudinal planes to determine which provided the most repeatable measurements.
Abdominal aortic aneurysm measurement terminology
To ensure accurate comparison with both past and present research it is important to define the
terminology used in this report.
Planes
In this study, AP measurements of the AAAs were taken on a transverse plane (referred to as transverse
measurements within this report) and on a longitudinal plane (referred to as longitudinal measurements
within this report). Figure 3 shows the transverse and longitudinal body planes.
Direction of the ultrasound probe
Figure 4 shows the direction of the probe required to obtain an AP diameter in a longitudinal plane.
An example of an image that would be obtained in this view in shown in Figure 5.
FIGURE 2 An image of an AAA in the transverse plane showing internal and external AP measurements.
The crosses (×) indicate the position of the inner anterior and inner posterior wall and the pluses (+) indicate the
position of the outer anterior and outer posterior wall. The asterisk indicates the inner border of an area of
thrombus on the posterior wall and it is important that the posterior inner wall calliper is not placed on the inner
border of the thrombus.
ULTRASOUND MEASUREMENTS AND QUALITY ASSURANCE
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Transverse plane Longitudinal plane
FIGURE 3 Transverse and longitudinal body planes.
FIGURE 4 Direction of probe required for an image in the longitudinal plane. Reproduced with permission
from Fpnotebook.com.
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Figure 6 shows the direction of the probe required to obtain an AP diameter in a transverse plane.
An example of an image that would be obtained in this view is shown in Figure 7.
An example of a lateral wall to lateral wall diameter taken in a transverse plane is shown in Figure 8.
Lateral wall to lateral wall diameters were not collected in this trial. This is because tortuosity of the aorta is
common in aneurysmal disease as the aorta grows in length as well as width and these diameters can be
considerably inaccurate.
FIGURE 5 Example of an AP diameter taken in the longitudinal plane.
FIGURE 6 Direction of probe required for an image in the transverse plane. Reproduced with permission
from Fpnotebook.com.
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FIGURE 7 Example of an AP diameter taken in the transverse plane.
FIGURE 8 Example of an AAA image in the transverse plane with the measurements taken from lateral wall to
lateral wall.
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Ultrasound scanning protocol
At the time of this study there still remained debate over the best method of obtaining AAA
measurements, as highlighted earlier. Therefore, four measurements in total – both maximum AP internal
and external measurements in the transverse and longitudinal planes – were recorded on all patients, to
enable a reliable comparison and to inform future practice.
The study was initially designed to have just two dedicated scanning staff between five sites (four in
London and one in Coventry) to enhance the accuracy and repeatability of measurements. After 6 months
it became clear that fewer patients than anticipated were eligible for the trial at these sites and therefore
we were required to expand the study to recruit at 14 sites to meet the recruitment target, with scanning
taking place at 11 sites (patients from all four London recruiting sites were scanned at ICCH, St Mary’s
Hospital; see Figure 1).
This required more rigorous scanning and quality control protocols to be implemented to ensure maximum
accuracy in the measurement of AAAs at all sites. A scanning protocol was provided to all participating
sites to ensure the highest possible standard and accuracy in the ultrasound scans carried out across the
11 scanning sites. The final version of the scanning protocol is provided in Box 1.
BOX 1 Ultrasound scanning protocol
l At each site it is requested that a single fully trained sonographer, vascular scientist or ultrasound screening
technician performs all scans when possible.
l When alternative arrangements for the sonographers are made at some sites (e.g. vacation, illness),
sonographers should follow identical protocols and should ensure that there is internal consistency in
recorded measurements from the site.
l The same ultrasound system and probes should be used for each subject on each occasion.
l The patient should be brought into the room and allowed to rest on the couch in the semi-recumbent
position for a period of 5 minutes for acclimatisation (while details are entered onto the duplex system).
l Once scanning is to be performed, the patient should be laid flat on the examination couch with abdomen
exposed from xiphisternum to pubic symphysis.
l The room should be appropriately lit to facilitate accurate scanning in a standard fashion (i.e. similar on
all occasions).
l Review previous image to determine the point from which to begin measurement.
l Perform an initial scan, checking for compressibility, pulsation and anterior branches, to enable the aorta to
be correctly identified.
l The aorta should then be scanned in both longitudinal and transverse planes from the renal arteries to the
bifurcation of the iliac arteries.
l The point of maximum dilatation in both transverse and longitudinal planes should be identified.
l Image optimisation should be achieved using gain/depth etc. control to produce an image with the clearest
wall appearance.
l All images must be taken with the highest quality and accuracy.
l Following maximum point identification, the longitudinal image should be frozen on screen.
l Four images in total must be saved.
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Longitudinal measurement
l Measurements are now taken using the calipers from the anterior side of the aorta to the posterior side.
The measurements taken should be at 90° to the wall.
l An ITI measurement should be made by placing the calipers on the inside of the aortic wall, taking care not
to misidentify plaque or thrombus as in the inner wall.
l This image should be saved after labelling the scan image with LS (for longitudinal view), ITI and the time
of the scan within the study (baseline, 3 months, 6 months, etc.) and adding the sonographer’s initials.
l An OTO measurement should be made by placing the calipers on the outer walls, taking care not to
misidentify the surface of the spine or other structures as the posterior wall.
l This image should be saved after labelling the scan image with LS, OTO and the time of the scan within the
study (baseline, 3 months, 6 months, etc.) and adding the sonographer’s initials.
Transverse measurements
l The ultrasound probe should be pivoted 90° at the same point (of maximum size) on the aorta. This image
in the transverse plane should be frozen.
l An ITI measurement should be made by placing the calipers on the inside of the aortic wall, taking care not
to misidentify plaque or thrombus as in the inner wall.
l This image should be saved after labelling the scan image with TS (for transverse view), ITI and the time of
the scan within the study (baseline, 3 months, 6 months, etc.) and adding the sonographer’s initials.
l Check the results that have been obtained. If the ITI and OTO measurements in TS and LS are not similar
then the patient should be rescanned and checked – if there is a reason for disagreement such as tortuosity
of the vessel, make a comment on the record.
l Problematic measurements: if you are experiencing difficulty defining and measuring the aorta and its
aneurysm, please consult a more senior sonographer for assistance and make a note on the ‘Relevant
comments’ section of the scanning log.
Storage of images
Images, with measurements and labelled as described in the scanning protocol, will be stored on the hard drive
of the scanner and subsequently downloaded onto the Picture Archiving and Communication System or other
storage devices at the co-ordinating centre. All sites will be required to download all images onto a CD to be
sent to the co-ordinating centre for QA purposes.
BOX 1 Ultrasound scanning protocol (continued)
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Longitudinal anteroposterior inner-to-inner measurements
Thrombus
Thrombus
Lumen
Outer wall
Surname: MM (patient study initial)
Forename: 12 (study number)
Date: 25/08/2013
LS ITI
3-month visit
Sonographer CG (Imperial)
Spine
Inner wall
Outer wall
Inner wall
(a)
Longitudinal anteroposterior outer-to-outer measurements
Surname: MM (patient study initial)
Forename: 12 (study number)
Date: 25/08/2013
LS OTO
3-month visit
Sonographer CG (Imperial)
Spine
(b)
Thrombus
Thrombus
Lumen
Outer wall
Inner wall
Outer wall
Inner wall
BOX 1 Ultrasound scanning protocol (continued)
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Transverse anteroposterior inner-to-inner measurements
Thrombus
Lumen Surname: MM (patient study initial)
Forename: 12 (study number)
Date: 25/08/2013
TS ITI
3-month visit
Sonographer CG (Imperial)
Spine
(c)
Outer wall
Inner wall
Transverse anteroposterior outer-to-outer measurements
Surname: MM (patient study initial)
Forename: 12 (study number)
Date: 25/08/2013
TS OTO
3-month visit
Sonographer CG (Imperial)
Spine
(d)
Outer wall
Inner wall
Thrombus
Lumen
BOX 1 Ultrasound scanning protocol (continued)
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Performance in data collection
Recording of the four AAA measurements was required for each patient at each visit. A key performance
indicator for sites was that of completeness of data recording for all four required measurements.
The completeness of data collection at each visit was between 94% and 100%. Table 7 describes the
percentages of patients who attended who had all four required measurements recorded at the end of
the study visit.
TABLE 7 Numbers and percentages of patients with required AAA measurements collected at each visit
Measurement Placebo Perindopril Amlodipine Total
Randomisation (n) 79 73 72 224
External diameter longitudinal 79 (100) 71 (97) 71 (99) 221 (99)
Internal diameter longitudinal 78 (99) 71 (97) 68 (94) 217 (97)
External diameter transverse 79 (100) 73 (100) 72 (100) 224 (100)
Internal diameter transverse 78 (99) 71 (97) 69 (96) 218 (97)
3-month visit (n) 76 68 67 211
External diameter longitudinal 74 (97) 65 (96) 65 (97) 204 (97)
Internal diameter longitudinal 74 (97) 65 (96) 65 (97) 204 (97)
External diameter transverse 74 (97) 65 (96) 65 (97) 204 (97)
Internal diameter transverse 74 (97) 65 (96) 65 (97) 204 (97)
6-month visit (n) 69 62 62 193
External diameter longitudinal 66 (96) 61 (98) 60 (97) 187 (97)
Internal diameter longitudinal 66 (96) 61 (98) 60 (97) 187 (97)
External diameter transverse 67 (97) 61 (98) 60 (97) 188 (97)
Internal diameter transverse 68 (99) 61 (98) 60 (97) 189 (98)
9-month visit (n) 64 57 57 178
External diameter longitudinal 63 (98) 56 (98) 54 (95) 173 (97)
Internal diameter longitudinal 63 (98) 56 (98) 54 (95) 173 (97)
External diameter transverse 62 (97) 56 (98) 54 (95) 172 (97)
Internal diameter transverse 62 (97) 56 (98) 54 (95) 172 (97)
12-month visit (n) 71 61 54 186
External diameter longitudinal 68 (96) 60 (98) 51 (94) 179 (96)
Internal diameter longitudinal 69 (97) 60 (98) 51 (94) 180 (97)
External diameter transverse 68 (96) 60 (98) 52 (96) 180 (97)
Internal diameter transverse 69 (97) 60 (98) 52 (96) 181 (97)
15-month visit (n) 60 49 47 156
External diameter longitudinal 57 (95) 47 (96) 44 (94) 148 (95)
Internal diameter longitudinal 57 (95) 47 (96) 44 (94) 148 (95)
External diameter transverse 57 (95) 47 (96) 44 (94) 148 (95)
Internal diameter transverse 57 (95) 47 (96) 44 (94) 148 (95)
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Quality assurance events
Inter- and intraobserver QA scanning events were organised to ensure consistency between sonographers,
screening technicians and others responsible for aortic measurements and between measurements by the
same observers. Specific aims of the QA events were:
1. to ensure the reliability of the results in terms of inter- and intra-observer variability.
2. to evaluate which was the most accurate and repeatable of AP AAA measurements taken using ITI and
OTO methods in both transverse and longitudinal planes.
Three QA days were arranged, one each in York, Hull and London. A total of 19 observers scanned
patients over the course of the trial (Table 8). Of these, 12 (63%) attended the QA days. At least one
observer from each of the 11 scanning sites attended one of the QA events. The numbers of observers
attending and scanning centre locations are documented in Table 8. Six volunteers were scanned on
8 July 2013, five volunteers were scanned on 13 September 2013 and five volunteers were scanned on
8 November 2013.
At each event the following took place:
l review of the scanning requirements as documented in the protocol
l discussion of example problem cases as a teaching prompt
l highlighting of known improvement strategies to reduce variability as needed
l scanning of volunteer patients for inter- and intraobserver variability studies.
Patients with an AAA who were part of the trial were invited to attend the QA days. Each was informed
that they were to have their AAA measured on at least two occasions by each sonographer who was able
to attend that QA session.
TABLE 7 Numbers and percentages of patients with required AAA measurements collected at
each visit (continued )
Measurement Placebo Perindopril Amlodipine Total
18-month visit (n) 61 52 49 162
External diameter longitudinal 60 (98) 49 (94) 47 (96) 156 (96)
Internal diameter longitudinal 60 (98) 49 (94) 47 (96) 156 (96)
External diameter transverse 60 (98) 49 (94) 47 (96) 156 (96)
Internal diameter transverse 60 (98) 49 (94) 47 (96) 156 (96)
21-month visit (n) 54 44 47 145
External diameter longitudinal 52 (96) 43 (98) 47 (100) 142 (98)
Internal diameter longitudinal 52 (96) 44 (100) 47 (100) 143 (99)
External diameter transverse 52 (96) 43 (98) 47 (100) 142 (98)
Internal diameter transverse 52 (96) 44 (100) 47 (100) 143 (99)
24-month visit (n) 59 53 49 161
External diameter longitudinal 56 (95) 52 (98) 47 (96) 155 (96)
Internal diameter longitudinal 56 (95) 52 (98) 48 (98) 156 (97)
External diameter transverse 56 (95) 52 (98) 47 (96) 155 (96)
Internal diameter transverse 56 (95) 52 (98) 48 (98) 156 (97)
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The scanning protocol was reviewed by all of the clinicians. Teaching on problem cases and strategies for
best practice were presented and the structure for the day outlined in full.
All of the sonographers who had scanned trial patients were observed scanning at least one subject
following the scanning protocol until the trial sonographer was convinced that appropriate protocols were
being followed and adequate images were being obtained consistently. Each of the sonographers from the
sites then scanned each of the AAA patients using the scanning protocol. All sonographers were blinded
to the clinical details, size and anatomical configurations of the aneurysms of patients as far as possible.
Volunteers were not named but were allocated an identifier for anonymity in an attempt to minimise bias.
All four required measurements were recorded and handed to the trial manager. All patients were
measured on at least two occasions by each sonographer. The trial clinical vascular scientist also performed
a set of measurements for each patient.
The mean intraobserver variability is documented in Table 9. The mean intraobserver variability
repeatability coefficient is documented for each of the four measurements obtained by observers in the
study along with the SD and range. The repeatability coefficient is the value below which the absolute
difference between repeated test results is expected to lie with a probability of 95%.
Clearly, measurements in the longitudinal plane were more repeatable than measurements in the
transverse plane. The differences in the mean (range) ITI and OTO intrasonographer repeatability
coefficients for longitudinal measurements were similar at 0.32 (0.24–0.39) cm for ITI measurements and
0.33 (0.21–0.45) cm for OTO measurements. This was compared with 0.48 (0.23–1.07) cm and 0.50
(0.20–1.24) cm for transverse ITI and OTO measurements, respectively.
As most sites used more than one observer to follow up the enrolled trial patients, interobserver variability
was of great importance.
TABLE 8 Attendance at the QA events
Site
QA event date
Number of
sonographers
from the site
Number of
sonographers
attending
8 July
2013
13 September
2013
8 November
2013
Royal Bournemouth Hospital Yes 1 1
Norfolk and Norwich University Hospital Yes 4 1
Colchester General Hospital Yes 1 1
Northern General Hospital, Sheffield Yes 2 2
Freeman Hospital, Newcastle Yes 2 1
University Hospital Coventry Yes 1 1
Sunderland Royal Hospital Yes 1 1
York Hospital Yes 2 1
London sites Yes 3 1
Manchester Royal Infirmary Yes Yes 1 1
Hull Royal Infirmary Yes 1 1
AARDVARK trial vascular scientist Yes Yes Yes NA NA
Total 3 6 3 19 12
NA, not applicable.
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The differences between the AAA measurements taken by the sonographers and those taken by the senior
clinical vascular scientist in the same patients were used to calculate the intersonographer variability by
using Bland–Altman 95% limits of agreement (Table 10). The limits of agreement define the range within
which 95% of the differences between two measurements made by two observers are likely to fall.
Figure 9 shows the variability in the measurements of external longitudinal diameter compared with the
measurements of the senior clinical vascular scientist (expert). Thirteen pairs disagreed by >±4mm for ITI
measurements, whereas seven pairs disagreed by >±4mm for OTO measurements. These data suggest
that the interobserver repeatability is better for longitudinal OTO measurements than for longitudinal
ITI measurements.
TABLE 9 Intraobserver variability at the QA days
Measure of intraobserver
variability
Longitudinal
ITI (cm)
Longitudinal
OTO (cm)
Transverse
ITI (cm)
Transverse
OTO (cm)
Mean 0.32 0.33 0.48 0.50
SD 0.05 0.09 0.27 0.34
Minimum 0.24 0.21 0.23 0.20
Maximum 0.39 0.45 1.07 1.24
TABLE 10 Results of the QA event days
Observera
Intraobserver variability
repeatability coefficient (cm)
Interobserver variabilityb Bland–Altman 95% limits of
agreement (cm)
Long
in
Long
out
Tran
in
Tran
out Long in Long out Tran in Tran out
A1 July 0.39 0.26 0.42 0.34 –0.87 to 0.32 –0.42 to 0.31 –0.54 to 0.19 –0.42 to 0.47
A2 July 0.35 0.44 0.44 0.31 –0.59 to 0.42 –0.59 to 0.48 –0.29 to 0.36 –0.28 to 0.34
A3 July 0.34 0.42 0.33 0.36 –0.32 to 0.25 –0.30 to 0.60 –0.32 to 0.33 –0.25 to 0.54
A1 September 0.36 0.26 1.07 1.24 –0.67 to 0.19 –0.5 to 0.35 –0.57 to 0.04 –0.61 to 0.41
A3 September 0.26 0.24 0.29 0.25 –0.004 to 0.40 –0.34 to 0.26 –0.15 to 0.50 –0.33 to 0.13
A4 September 0.37 0.45 0.41 0.49 –0.06 to 0.71 –0.26 to 0.64 –0.05 to 0.61 –0.34 to 0.68
A5 September 0.34 0.43 0.45 0.48 –0.15 to 0.56 –0.42 to 0.59 –0.13 to 0.38 –0.34 to 0.40
A6 September 0.30 0.34 0.94 1.04 –0.21 to 0.31 –0.65 to 0.62 –0.62 to 1.26 –0.91 to 1.59
A7 September 0.24 0.21 0.68 0.75 –0.44 to 0.22 –0.4 to 0.65 –0.53 to 0.16 –0.4 to 0.63
A1 November 0.27 0.24 0.23 0.25 –0.87 to 0.69 –0.48 to 0.69 –0.87 to 0.66 –0.65 to 0.65
A2 November 0.26 0.28 0.24 0.20 –1.37 to 0.71 –0.87 to 0.74 –1.33 to 0.76 –0.80 to 0.72
A3 November 0.39 0.42 0.28 0.24 –1.10 to 0.69 –0.77 to 0.48 –1.25 to 0.94 –1.01 to 0.76
Long in, longitudinal plane ITI measurement; Long out, longitudinal plane OTO measurement; Tran in, transverse plane ITI
measurement; Tran out, transverse plane OTO measurement.
a A1, A2= attendee 1, attendee 2, etc.
b Each compared with the senior clinical vascular scientist.
Note
The intraobserver variability describes the variation between measurements taken by the same observer in the same patient
over the day in the longitudinal plane and transverse plane. The interobserver variability describes the variability of
measurements taken by different observers in the same patients using the Bland–Altman method.
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FIGURE 9 Interobserver repeatability graphs (longitudinal diameters). (a) Longitudinal internal diameter; and
(b) longitudinal external diameter. Each symbol on the graphs represents a different AARDVARK scanner
(three from the July event, three from the November event and six from the September event). Five or more
patients are shown for each event, so 10 vertical scatters have only three points and five vertical scatters have
six points. Each vertical scatter is a separate patient.
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Quality control of ultrasound scans
The quality of the ultrasound images obtained in trial was assessed centrally to ensure that a reliable
standard of ultrasound scans was obtained across the 11 scanning sites by different sonographers on
different ultrasound scanning systems. The following protocol was used:
l The baseline images for all of the patients in the trial were reviewed as soon as possible after the first
monitoring visit.
l All patients at a site or a minimum of 10 patients at a site (for sites with > 10 patients) had each of
their 3-monthly images reviewed. Review was undertaken by the senior clinical vascular scientist. Up to
10 random patients were selected by the trial statistician for quality control analysis. If one of the
selected patients reached an end point or withdrew from the study or did not attend the visit, the
number of images checked might be less than baseline in certain cases. In addition, we asked for
additional images to be checked if poor image quality was found at sites. Hence, > 10 images were
checked at certain visits. The numbers of recorded images reviewed from each site by the senior clinical
vascular scientist are provided in Table 11.
l All sites were informed of the scans that needed to be forwarded to the trial centre.
l Each site was asked to save images from longitudinal and transverse planes at the point of maximum
dilation to include ITI and OTO calliper placement records.
l The senior clinical vascular scientist reviewed all images sent to the trial centre. All of the images had
patient-identifiable information removed and the senior clinical vascular scientist was blinded to
treatment allocations.
l Each image was assessed on clarity (looking at depth, gain, focus and good wall definition) and calliper
placement (ITI and OTO). The following criteria were used to judge an image as acceptable:
¢ the image was of the highest image quality possible
¢ the callipers were placed correctly for both ITI and OTO measurements in relation to the wall
¢ measurements were taken at right angles to the aneurysm sac wall
¢ the image was labelled correctly
¢ the image was judged to be taken in a true transverse and true longitudinal plane.
Each image that was reviewed was classified as acceptable or unacceptable.
This protocol was based on the standard operating procedures for the NAAASP [see www.gov.uk/
government/collections/aaa-screening-supporting-documents (accessed 3 June 2016)], with the addition of
the following assessment criteria: measurements to be taken at right angles to the aneurysmal sac and
judged to be in the transverse and longitudinal planes.
If an image was deemed unacceptable, the site was contacted and asked to review the image to ensure
that the correct image had been sent, the callipers had been placed correctly and the AARDVARK scanning
protocol had been followed. If required, the senior clinical vascular scientist responsible for quality control
and the relevant sonographer liaised directly until a resolution was reached.
Sites/observers with unacceptable images were contacted. When a single image taken by an observer
was unacceptable, the observer was contacted to review the image. If more than two images were
unacceptable then the site was visited and all observers underwent further dedicated training sessions.
In these training sessions the site was visited by the lead sonographer for the study and (1) the scanning
protocol was reviewed and relevant teaching given and (2) each of the images that was deemed
unacceptable was reviewed. This was required at only one site.
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Quality control of the final ultrasound data
In addition to quality control of the ultrasound images and the QA events, the ultrasound measurement
database as a whole was monitored for any anomalies or spurious results. Sites were requested to
measure the maximum AP diameter of the AAA at each visit. Therefore, the ITI transverse and longitudinal
measurements and the OTO transverse and longitudinal measurements at each visit were expected to be
within ±3mm of each other.
If the longitudinal and transverse measurements varied by >±3mm, sites were contacted and asked to
recheck their scans and measurements to ensure that the maximum AP diameter had been accurately
measured. Cases were accepted or rejected accordingly and remeasured when an obvious error had
been made.
In total, 107 ITI measurements and 35 OTO measurements had differences >±3mm. This, together with
the results of the interobserver variability study and the use of multiple observers for the trial, suggested
that the longitudinal OTO measurement was the most reliable measurement on which to base aneurysm
growth rate. Therefore, longitudinal OTO measurements were used for the evaluation of the trial
end points.
The 35 OTO measurements were reconsidered as this measurement was the primary measurement to be
used in the main trial analyses. Four measurements were amended after obvious measurement errors were
made. Adjusted measurements were used for the analyses in the trial.
Justification for the choice of diameter used for primary
end point
The mean (range) intrasonographer repeatability coefficient for longitudinal measurements was 0.33
(0.21–0.45) cm for OTO measurements and 0.32 (0.24–0.39) cm for ITI measurements compared with 0.48
(0.23–1.07) cm and 0.50 (0.20–1.24) cm for transverse ITI and OTO measurements, respectively.
Longitudinal plane measurements were therefore used for the primary analyses.
However, possibly reflecting the small number of patients included (n= 11), there was no meaningful
difference between the variability of OTO and ITI measurements reported in intraobserver variability studies
that could determine the superiority of OTO or ITI measurements for use as the primary end point in the
study. Considering ITI interobserver variability measurements, 13 pairs of measurements (by an observer
and the senior clinical vascular scientist) differed by >±4mm, whereas for OTO measurements seven pairs
of measurements differed by >±4mm. These data suggest that interobserver repeatability was better for
longitudinal OTO measurements than for longitudinal ITI measurements
When comparing transverse and longitudinal maximum diameters in the same patient at each time point
there was less variation between OTO measurements than between ITI measurements (35 vs. 107
measurements were different by > 0.3 mm, respectively). In addition, there was less variation in the SDs of
AAA measurements for most time points in the study of OTO measurements (see Table 19).
Therefore, OTO diameters measured from longitudinal images were used for evaluation of the primary
outcome measure.
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Chapter 4 Results
Site recruitment
Recruitment was originally to take place at five sites: Imperial College Healthcare NHS Trust (St Mary’s and
Charing Cross Hospitals), Royal Free London NHS Foundation Trust, Guy’s and St Thomas’ NHS Foundation
Trust and University Hospitals Coventry and Warwickshire NHS Trust. We identified a pool of approximately
860 patients potentially eligible for the trial from existing databases from these four hospital trusts (200,
90, 380 and 189, respectively). We also predicted that expansion of the NAAASP was likely to increase this
patient pool before trial recruitment started, with approximately 4% of men screened expected to have an
AAA. Against this, we estimated that 30% of patients would be ineligible for the trial because they were
already receiving ACE-I therapy or because they had an unsuitable BP, that is, SBP could not be controlled
to < 150mmHg before randomisation. Assuming a 15% refusal rate in the remaining 262 patients, the
target of 225 patients seemed achievable given a steady influx of newly screened and eligible patients over
the recruitment period.
The first trial site was opened to recruitment in September 2011, with recruitment due to end after
12 months. However, to meet the recruitment target a further nine sites were added during the trial.
The four sites in London became recruitment and screening sites, with patients having all other study visits
at the ICCH, Imperial College London. The remaining 10 scanning sites were located across the country
and performed all study visits locally.
Participant recruitment
A recruitment extension of 7 months was required before the recruitment target was successfully met.
The reasons for this were as follows:
l The number of patients taking ACE-Is was higher than anticipated and this was the main barrier to
recruitment. At the time of the HTA programme commissioned call in 2009, approximately 32.3% of
the population aged > 60 years received ACE-Is; by 2012 this had increased to 52.9% (Health Survey
for England).94
l The proportion of patients with an AAA picked up through the NAAASP was less than half the
proportion expected: 4% of patients screened were expected to have an AAA, whereas in reality this
proportion was 1.2%.
l Progress was slow in securing NHS research governance approval at some of the participating sites.
The quickest research and development approval was granted in 33 working days (approximately
1.5 months), whereas the longest approval took 147 working days (6 months). After waiting
168 working days (7 months) with approval still not granted in one further site, attempts to gain
approval were abandoned.
To try and overcome some of the barriers to recruitment, the following strategies and actions were
implemented approximately 6 months into the study:
l Review of methods of approaching patients – sites were requested to review their methods of
contacting patients and try different strategies (i.e. speaking to patients at their next visit instead of
cold-calling) in an attempt to increase uptake into the trial.
l Breakdowns of site recruitment were requested monthly and were reviewed at the monthly
management meetings to try and identify and address any specific issues.
l Addition of PICs – some centres had PIC sites set up to widen the pool of potential participants.
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l The age range was expanded to include those aged ≥ 55 years (originally set at ≥ 60 years).
l Patient invitation letter – this was created because some site investigators felt that the PIS was too
lengthy and daunting as a first introduction to the trial.
l Trial poster – this was created and put on the noticeboards in relevant clinical areas (e.g. in the vascular
ultrasound laboratories) at some sites to create awareness of the trial.
l AARDVARK trial web page – this was set up via the ICTU website and was available as a resource for
both patients and site staff. The site contained general information about the trial and was updated
regularly with current recruitment numbers.
l Update/simplify the PIS – some sites felt that the original PIS was written in such a way that the side
effects and risks of the study were unduly worrying to potential participants. Therefore, the PIS was
reworded and a list of side effects tabulated as an appendix.
l Additional research sites – by far the most successful strategy for increasing recruitment was increasing
the number of research sites, specifically targeting those with large populations and time/resources to
conduct the study.
l Chief investigator presence at site initiation visits – the chief investigator visited all sites as part of the
site initiation visits to stress the importance of the trial and answer any clinical queries.
In total, 227 patients were initially randomised to the trial. However, the randomisation of three patients
was subsequently discovered to be a protocol violation because these patients did not meet all of the entry
criteria for the trial. Table 12 shows the final recruitment numbers by site. The Royal Bournemouth Hospital
and Hull Royal Infirmary were the top recruiting sites, with 50 and 40 patients randomised, respectively.
The first patient was randomised to the study on 16 December 2011 and the last patient was randomised
to the study on 19 April 2013 (Figure 10).
Table 13 shows that the number of patients randomised to each treatment arm was well balanced, with
79 patients randomised to placebo, 73 randomised to perindopril and 72 randomised to amlodipine.
TABLE 12 Number of patients randomised at each participating site
Site Randomised, n (%)
Charing Cross Hospital, London 4 (1.8)
Colchester General Hospital 17 (7.6)
Freeman Hospital, Newcastle 5 (2.2)
Hull Royal Infirmary 40 (17.9)
Manchester Royal Infirmary 3 (1.3)
Norfolk and Norwich University Hospital 14 (6.3)
Northern General Hospital, Sheffield 2 (0.9)
Royal Bournemouth Hospital 50 (22.3)
Royal Free Hospital, London 9 (4.0)
St Thomas’ Hospital, London 25 (11.2)
St Mary’s Hospital, London 17 (7.6)
Sunderland Royal Hospital 4 (1.8)
University Hospital Coventry 28 (12.5)
York Hospital 6 (2.7)
Total 224
RESULTS
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FIGURE 10 Participant recruitment by month.
TABLE 13 Numbers of participants randomised to each treatment arm
Site Placebo Perindopril Amlodipine Total
Charing Cross Hospital, London 1 1 2 4
Colchester General Hospital 6 6 5 17
Freeman Hospital, Newcastle 2 2 1 5
Hull Royal Infirmary 14 13 13 40
Manchester Royal Infirmary 2 1 0 3
Norfolk and Norwich University Hospital 5 5 4 14
Northern General Hospital, Sheffield 1 1 0 2
Royal Bournemouth Hospital 17 16 17 50
Royal Free Hospital, London 3 3 3 9
St Thomas’ Hospital, London 8 8 9 25
St Mary’s Hospital, London 7 5 5 17
Sunderland Royal Hospital 1 1 2 4
University Hospital Coventry 10 9 9 28
York Hospital 2 2 2 6
Total 79 73 72 224
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Non-recruited patients
During the trial recruitment period we requested that the sites capture details of reasons why patients with
an AAA were not recruited into the trial. These data were collected by prospective pre-screening by
recruiting staff, mainly by case note and clinical database review. Unfortunately, limited research nurse
availability and clinical service pressures prevented reliable collection of these data at some centres.
However, data were collected from a total of 1912 non-recruited patients. The patients were excluded on
the basis of ineligibility (Figure 11) or because they declined to participate (Figure 12). The main reason
for ineligibility was already taking ACE-Is; this excluded 643 patients from participating in the trial.
Unfortunately, a specific reason for declining to participate was not recorded for 107 patients; however,
56 patients declined because they did not want to participate in a clinical trial.
AAA already repaired
AAA size out of limits
Aged < 55 years
Cancer
Creatinine > 180 µmol
Known allergy/sensitivity to 
study medications
Not recorded
On ACE-I
On ARB
On CCB
Other
Renal artery stenosis
Unable to give consent
Unable to travel
54
(3)
149 (9)
9 (1)
16 (1)
18 (1)
21 (1)
90 (6)
643 (40)
162 (10)
174 (11)
143 (9)
17 (1) 20 (1)
79 (5)
FIGURE 11 Reasons for trial ineligibility, n (%) (N= 1595).
12 (4)
Concerned regarding side effects
Does not want to take more medications
Does not want to take part in a trial
Does not want to travel for the study
Does not want to commit to a 2-year study
Feels too unwell to participate
Other
Declined – no reason given/recorded
13 (4)
54 (17)
56 (18)
40 (13)
19 (6)
16 (5)
107 (34)
FIGURE 12 Reasons for declining the trial, n (%) (N= 317).
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Status of patients in the study
Table 14 shows the numbers of patients who completed each study visit across the three groups. In total,
161 patients (71%) successfully completed all study visits.
As previously described, a 10% attrition rate was included in the power calculations for the trial.
Participants were included in the attrition rate if data from fewer than two study visits were available for
analysis. A total of 13 patients counted towards the attrition rate: three patients who were randomised in
error and 10 patients who withdrew from the study before completing at least two study visits. The
patients randomised in error were not included in the final analyses; however, the remaining 10 patients
were included on an ITT basis. The final attrition rate for the study was therefore 6%. The CONSORT
diagram (Figure 13) shows the status of patients at the end of the trial. Six patients withdrew from the trial
because of AEs attributed to the study medications (n= 2 perindopril, n= 4 amlodipine). Four patients
(n= 3 perindopril, n= 1 amlodipine) switched to losartan because of cough. No patients suffered AAA
rupture and 26 underwent elective surgery (n= 9 placebo, n= 10 perindopril, n= 7 amlodipine) during the
trial period.
TABLE 14 Numbers of patients who completed the study visits
Visit Placebo Perindopril Amlodipine Total
Baseline 79 73 72 224
Month 3 76 68 67 211
Month 6 69 62 62 193
Month 9 64 57 57 178
Month 12 71 61 54 186
Month 15 60 49 47 156
Month 18 61 52 49 162
Month 21 54 44 47 145
Month 24 59 53 49 161
Unscheduled 10 2 2 14
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Baseline comparability of randomised groups
The baseline characteristics for all patients in the study are shown in Table 15. Although groups were
randomised and generally well matched, there were some small imbalances between the groups that may
influence aneurysm growth, for example presence of diabetes [n= 8 (10.1%) placebo, n= 2 (2.7%)
perindopril, n= 6 (8.3%) amlodipine] and use of statins [n= 48 (61%) placebo, n= 53 (73%) perindopril,
n= 45 (63%) amlodipine]. All patients but one were Caucasian.
TABLE 15 Baseline characteristics of randomised patientsa
Characteristic Placebo Perindopril Amlodipine
nb 79 73 72
Age (years) 70.7 (7.5) 71.6 (6.9) 71.5 (6.7)
Male, n (%) 74 (94) 71 (97) 66 (92)
Caucasian, n (%) 79 (100) 73 (100) 71 (99)
SBP (mmHg) 131.7 (12.2) 130.9 (11.5) 131.9 (13)
DBP (mmHg) 77.9 (7.6) 76.7 (8) 78 (7)
Use of statins, n (%) 48 (61) 53 (73) 45 (63)
AAA external diameter longitudinal (cm) 4.06 (0.67) 4.05 (0.65) 4.03 (0.69)
AAA internal diameter longitudinal (cm) 3.67 (0.67) 3.66 (0.68) 3.61 (0.71)
AAA external diameter transverse (cm) 4.05 (0.68) 4.09 (0.65) 4.04 (0.67)
AAA internal diameter transverse (cm) 3.65 (0.69) 3.68 (0.68) 3.61 (0.7)
Current smokers, n (%) 17 (22) 21 (29) 18 (25)
Pack-years current smokers 32.9 (28) 33.1 (24) 29.3 (17.3)
Past smokers, n (%) 56 (72) 41 (57) 44 (63)
Pack-years past smokers 42.2 (45.5) 42 (33.8) 40.5 (36.8)
Height (cm) 174.4 (8.5) 175.9 (8.3) 173.7 (8.7)
Weight (kg) 84.3 (16.1) 84.3 (16.6) 81.2 (13.8)
Diabetes, n (%) 8 (10.1) 2 (2.7) 6 (8.3)
Antiplatelet therapy, n (%) 28 (35.4) 37 (50.6) 33 (45.8)
a Mean (SD) unless otherwise stated.
b Small variation in numbers for some variables.
Source: adapted from Bicknell et al. 2016.95 © Bicknell et al. 2016. Published by Oxford University Press on behalf of the
European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Abdominal aortic aneurysm growth
The changes in AAA diameter over the duration of the trial are shown in Table 16 (summary longitudinal
AAA measurements) and Table 17 (differences in longitudinal AAA measurements). See Appendix 5 for a
summary of the transverse AAA measurement data.
There was a small increase in the mean internal and external AAA diameter across all three treatment
groups. The mean difference between month 24 and baseline for the longitudinal external diameter was
0.27 cm for the three groups combined. Similar results were observed for the mean external transverse
measurements. Comparisons of 2-year changes across the three randomised groups are invalid because of
the variable reduction in numbers in each group over time. The SDs of the diameters recorded in the
longitudinal plane for the ITI measures (see Table 16) were generally systematically higher than those for
the OTO measures at each time point, as were the SDs of the differences between baseline and each time
point (see Table 17).
TABLE 16 Abdominal aortic aneurysm diameter in the longitudinal plane: summary data by randomised group and
combined at each trial visit
Visit
Longitudinal internal diameter (cm) Longitudinal external diameter (cm)
n Mean SD Minimum Maximum n Mean SD Minimum Maximum
Placebo
Baseline 78 3.67 0.67 2.33 5.26 79 4.06 0.67 3.00 5.44
Month 3 74 3.72 0.72 2.46 5.48 74 4.10 0.72 3.01 6.08
Month 6 66 3.74 0.65 2.61 5.55 66 4.13 0.62 3.02 5.83
Month 9 63 3.74 0.70 2.30 5.37 63 4.11 0.68 3.05 5.67
Month 12 69 3.77 0.64 2.48 5.22 68 4.13 0.64 3.00 5.51
Month 15 57 3.78 0.68 2.52 5.41 57 4.15 0.70 3.01 6.01
Month 18 60 3.83 0.65 2.68 5.27 60 4.20 0.68 3.06 5.85
Month 21 52 3.84 0.63 2.71 5.30 52 4.18 0.67 3.04 5.86
Month 24 56 3.79 0.63 2.39 5.37 56 4.12 0.63 3.08 5.58
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TABLE 16 Abdominal aortic aneurysm diameter in the longitudinal plane: summary data by randomised group and
combined at each trial visit (continued )
Visit
Longitudinal internal diameter (cm) Longitudinal external diameter (cm)
n Mean SD Minimum Maximum n Mean SD Minimum Maximum
Perindopril
Baseline 71 3.66 0.68 2.38 5.05 71 4.05 0.65 3.04 5.40
Month 3 65 3.65 0.68 2.27 5.02 65 4.05 0.65 3.04 5.42
Month 6 61 3.72 0.71 2.17 5.18 61 4.11 0.72 3.01 5.93
Month 9 56 3.72 0.72 2.32 5.38 56 4.10 0.69 3.04 5.78
Month 12 60 3.76 0.73 2.51 5.50 60 4.12 0.72 3.03 5.79
Month 15 47 3.75 0.72 2.54 5.49 47 4.09 0.71 3.03 5.74
Month 18 49 3.75 0.62 2.45 5.50 49 4.09 0.64 3.08 5.83
Month 21 44 3.74 0.65 2.57 5.74 43 4.08 0.69 3.08 5.99
Month 24 52 3.71 0.60 2.54 5.28 52 4.03 0.57 3.05 5.42
Amlodipine
Baseline 68 3.61 0.71 2.20 4.99 71 4.03 0.69 3.00 5.50
Month 3 65 3.70 0.70 2.02 5.10 65 4.10 0.67 3.05 5.60
Month 6 60 3.78 0.74 2.27 5.24 60 4.14 0.69 3.04 5.47
Month 9 54 3.87 0.70 2.64 5.52 54 4.22 0.68 3.02 5.75
Month 12 51 3.82 0.70 2.26 5.25 51 4.18 0.69 2.97 5.80
Month 15 44 3.82 0.71 2.15 5.21 44 4.19 0.67 3.00 5.59
Month 18 47 3.87 0.72 2.46 5.51 47 4.17 0.70 3.01 5.78
Month 21 47 3.90 0.74 2.62 5.54 47 4.21 0.72 3.00 5.88
Month 24 48 3.83 0.73 2.44 5.50 47 4.18 0.67 3.02 5.67
Total
Baseline 217 3.65 0.68 2.20 5.26 221 4.05 0.66 3.00 5.50
Month 3 204 3.69 0.70 2.02 5.48 204 4.09 0.68 3.01 6.08
Month 6 187 3.75 0.69 2.17 5.55 187 4.13 0.67 3.01 5.93
Month 9 173 3.77 0.70 2.30 5.52 173 4.14 0.68 3.02 5.78
Month 12 180 3.78 0.69 2.26 5.50 179 4.14 0.68 2.97 5.80
Month 15 148 3.78 0.70 2.15 5.49 148 4.14 0.69 3.00 6.01
Month 18 156 3.82 0.66 2.45 5.51 156 4.16 0.67 3.01 5.85
Month 21 143 3.83 0.67 2.57 5.74 142 4.16 0.69 3.00 5.99
Month 24 156 3.78 0.65 2.39 5.50 155 4.11 0.62 3.02 5.67
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The AAA growth trajectories in each patient by group are shown in Figure 14 (placebo), Figure 15
(perindopril) and Figure 16 (amlodipine). Most of the patients had slow growth rates but there were a
small number of patients with faster growth rates in each randomised group.
Figure 17 shows the observed mean AAA diameter for each treatment group at each visit time point.
The numbers of patients were different across each visit, with lower numbers of patients in the later visits.
There were no significant differences between the groups over time and any apparent differences between
the groups must be considered in the context of the changing numbers of participants. This is especially
relevant when patients with an AAA of ≥ 5.5 cm who are taken for surgery and do not complete any
further measurements are considered.
TABLE 17 Differences in longitudinal AAA diameter compared with baseline by randomised group and combined
Study period
AAA longitudinal internal diameter (cm) AAA longitudinal external diameter (cm)
n Mean SD Minimum Maximum n Mean SD Minimum Maximum
Placebo
Month 3 – baseline 73 0.08 0.23 –0.3 0.87 74 0.06 0.24 –0.73 1.04
Month 6 – baseline 65 0.11 0.27 –0.54 0.84 66 0.08 0.24 –0.61 0.70
Month 12 – baseline 68 0.18 0.31 –0.68 0.91 68 0.14 0.28 –0.57 0.92
Month 18 – baseline 59 0.28 0.29 –0.20 0.94 60 0.26 0.29 –0.19 1.27
Month 24 – baseline 55 0.31 0.35 –0.27 1.20 56 0.27 0.30 –0.22 1.11
Perindopril
Month 3 – baseline 64 0.02 0.26 –0.72 0.86 64 0.05 0.21 –0.65 0.69
Month 6 – baseline 60 0.11 0.24 –0.33 1.06 60 0.12 0.22 –0.42 0.97
Month 12 – baseline 59 0.22 0.30 –0.27 1.35 59 0.19 0.27 –0.40 1.18
Month 18 – baseline 48 0.26 0.26 –0.18 1.04 48 0.23 0.26 –0.35 1.26
Month 24 – baseline 51 0.27 0.21 –0.16 1.00 51 0.23 0.22 –0.35 0.82
Amlodipine
Month 3 – baseline 61 0.08 0.29 –0.7 1.21 64 0.05 0.24 –0.69 0.90
Month 6 – baseline 56 0.18 0.42 –0.84 1.74 59 0.12 0.30 –0.77 1.11
Month 12 – baseline 47 0.29 0.49 –0.69 2.61 50 0.22 0.31 –0.52 1.18
Month 18 – baseline 43 0.35 0.33 –0.3 1.47 46 0.27 0.32 –0.32 1.16
Month 24 – baseline 44 0.37 0.41 –0.73 1.43 46 0.33 0.36 –0.68 1.17
Total
Month 3 – baseline 198 0.06 0.26 –0.72 1.21 202 0.05 0.23 –0.73 1.04
Month 6 – baseline 181 0.13 0.32 –0.84 1.74 185 0.10 0.26 –0.77 1.11
Month 12 – baseline 174 0.22 0.36 –0.69 2.61 177 0.18 0.29 –0.57 1.18
Month 18 – baseline 150 0.29 0.29 –0.3 1.47 154 0.25 0.29 –0.35 1.27
Month 24 – baseline 150 0.31 0.33 –0.73 1.43 153 0.27 0.29 –0.68 1.17
RESULTS
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Histograms of change in longitudinal external AAA diameter from baseline to 3, 12 and 24 months are shown
in Figures 18–20, respectively (for the histograms at 6 and 18 months see Appendix 6). These histograms show
the distribution of the difference in the data between the two specified time points. Overall, no obvious
differences were apparent across groups at any of the three time points, whereas in all three histograms growth
was apparent overall at 12 and 24 months reflected by the shift of bars to the right of the graphs.
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FIGURE 17 Mean longitudinal external diameter over time by randomised group.
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FIGURE 18 Histograms of change in AAA longitudinal external diameter from baseline to month 3. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 20 Histograms of change in AAA longitudinal external diameter from baseline to month 24. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 19 Histograms of change in AAA longitudinal external diameter from baseline to month 12. (a) Placebo;
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Counting those AAAs that exhibit fast growth rates (as defined by growth of > 0.5 cm per year) in these
histograms (n= 14 placebo, n= 8 perindopril, n= 14 amlodipine) suggested possible differential effects
among the three treatment groups. Formal analyses of the number of patients who exhibit fast growth
rates in each of the three groups (taking into account aneurysm size and adjusting for confounders) was
not undertaken as part of the main analyses of this trial but will be considered as part of future
research plans.
Box plots of change in longitudinal external AAA diameter from baseline to 3, 12 and 24 months are
shown in Figures 21–23, respectively (the box plots for change from baseline to 6 and 18 months can be
found in Appendix 7). These figures confirm the findings shown in Figures 18–20 in that there are no
apparent differences in change in diameter at 3, 12 or 24 months across the three groups and growth of a
similar magnitude is apparent in all three groups at 12 and 24 months.
Histograms and box plots of change in diameter for longitudinal internal diameters and transverse external
and internal diameters are provided in Appendices 8–13.
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FIGURE 22 Box plot of change in AAA longitudinal external diameter from baseline to month 12. Circles are
outside values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower
adjacent values.
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FIGURE 21 Box plot of change in AAA longitudinal external diameter from baseline to month 3. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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Primary outcome
Multilevel modelling was used to determine the maximum likelihood estimates for AAA diameter growth.
Table 18 provides these results for the longitudinal external AAA diameter. The estimates for annual
diameter growth were as follows:
l 1.68mm [standard error (SE) 0.02mm] in the placebo group
l 1.77mm (SE 0.02mm) in the perindopril group
l 1.81mm (SE 0.02mm) in the amlodipine group.
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FIGURE 23 Box plot of change in AAA longitudinal external diameter from baseline to month 24. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
TABLE 18 Maximum likelihood estimates for AAA longitudinal external diameter growth
Treatment and visit
Linear model with interaction
Estimate 95% CI
Fixed part
Baseline diameter (cm) for the control group (β1) 4.074 3.931 to 4.218
Change in diameter growth (cm) for a yearly increase in time (β2) 0.168 0.129 to 0.208
Difference in baseline diameter (cm)
β3(perindopril vs. placebo) –0.008 –0.217 to 0.200
β4(amlodipine vs. placebo) –0.021 –0.229 to 0.188
Difference in diameter growth (cm) for a yearly increase in time
β5(perindopril vs. placebo) 0.008 –0.050 to 0.065
β6(amlodipine vs. placebo) 0.012 –0.046 to 0.070
Random part (cm)
SD of individual intercepts (ς1j) 0.646 0.587 to 0.710
SD of individual slopes (ς2j) 0.149 0.128 to 0.173
Correlation between random effects 0.455 0.296 to 0.589
SD of residual errors 0.136 0.130 to 0.141
Source: adapted from Bicknell et al. 2016.95 © Bicknell et al. 2016. Published by Oxford University Press on behalf of the
European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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The differences in the slopes of modelled growth over time were not significant between perindopril and
placebo (p= 0.78) or between perindopril and amlodipine (p= 0.89). The difference in slope between
perindopril and placebo plus amlodipine combined was also not significant (p= 0.92).
Sensitivity analyses
Exclusion of patients with diabetes gave very similar results (Table 19). The estimated difference in annual
growth rate between perindopril and placebo was –0.01mm with a 95% CI of –0.6 to 0.6mm.
Adjustment for baseline age, sex, current smoking status and statin use also gave similar results (Table 20).
TABLE 19 Maximum likelihood estimates for AAA longitudinal external diameter growth excluding patients with
diabetes: sensitivity analysis
Treatment and visit
Linear model with interaction
Estimate 95% CI
Fixed part
Baseline diameter (cm) for the control group (β1) 4.046 3.895 to 4.198
Change in diameter growth (cm) for a yearly increase in time (β2) 0.176 0.135 to 0.217
Difference in baseline diameter (cm)
β3(perindopril vs. placebo) 0.018 –0.198 to 0.232
β4(amlodipine vs. placebo) –0.030 –0.249 to 0.188
Difference in diameter growth (cm) for a yearly increase in time
β5(perindopril vs. placebo) –0.001 –0.059 to 0.057
β6(amlodipine vs. placebo) 0.009 –0.051 to 0.069
Random part (cm)
SD of individual intercepts (ς1j) 0.646 0.585 to 0.712
SD of individual slopes (ς2j) 0.146 0.125 to 0.171
Correlation between random effects 0.495 0.333 to 0.629
SD of residual errors 0.136 0.130 to 0.142
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Blood pressure reduction
Summary BP statistics for the duration of the trial are shown in Table 21 and BP differences from baseline
are shown in Table 22. There was an increase in mean SBP in the placebo group from baseline to month
24 (+2.5mmHg) and a decrease in in mean SBP in both the perindopril (–5.0mmHg) and amlodipine
(–2.8mmHg) groups from baseline to month 24. There was little change in mean DBP between baseline
and month 24 in the placebo group (–0.7mmHg) but reductions were seen in the perindopril and
amlodipine groups (–5.2 mmHg and –3.3mmHg, respectively). Mean SBP and DBP over the duration of the
trial are shown in Figures 24 and 25, respectively.
Figures 26–28 show the histograms of change in SBP from baseline to 3, 12 and 24 months, respectively,
by randomised group and combined. These histograms show the distribution of the difference in the data
between the two specified time points. Negative values indicate a decrease in BP and positive values
indicate an increase in BP. The histograms for the placebo group generally follow a normal distribution
around zero, whereas reductions in SBP in the perindopril and amlodipine groups are shown by the
increased density of bars on the left-hand side of each histogram, particularly at 12 and 24 months.
For histograms of the change in SBP from baseline to 6 and 18 months see Appendix 14.
TABLE 20 Maximum likelihood estimates for AAA longitudinal external diameter growth adjusted for age, sex,
statin use and current smoking status
Treatment and visit
Adjusted for baseline age
and sex (n= 223)
Adjusted for baseline
statin use (n= 223)
Adjusted for baseline
current smoking status
(n= 223)
Estimate 95% CI Estimate 95% CI Estimate 95% CI
Fixed part (cm)
Intercept (β1) 3.681 2.754 to 4.607 4.029 3.851 to 4.207 4.084 3.934 to 4.233
Change in diameter for a
yearly increase in time (β2)
0.168 0.129 to 0.207 0.169 0.129 to 0.208 0.169 0.129 to 0.208
Difference in baseline diameter
β3(perindopril vs.
placebo)
–0.014 –0.222 to 0.195 –0.018 –0.227 to 0.191 –0.005 –0.214 to 0.204
β4(amlodipine vs.
placebo)
–0.025 –0.233 to 0.183 –0.022 –0.230 to 0.186 –0.019 –0.228 to 0.189
Difference in diameter growth for a yearly increase in time
β5(perindopril vs.
placebo)
0.008 –0.049 to 0.066 0.008 –0.049 to 0.066 0.008 –0.049 to 0.066
β6(amlodipine vs.
placebo)
0.012 –0.046 to 0.070 0.012 –0.046 to 0.070 0.012 –0.046 to 0.070
Random part (cm)
SD of individual intercepts (ς1j) 0.644 0.586 to 0.709 0.645 0.587 to 0.710 0.646 0.588 to 0.711
SD of individual slopes (ς2j) 0.149 0.128 to 0.173 0.149 0.128 to 0.173 0.149 0.128 to 0.173
Correlation between
random effects
0.455 0.296 to 0.589 0.459 0.301 to 0.592 0.460 0.300 to 0.595
SD of residual errors 0.136 0.130 to 0.141 0.136 0.130 to 0.141 0.136 0.130 to 0.141
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TABLE 21 Mean SBP and DBP levels by randomised group at each trial visit
Visit n
SBP (mmHg) DBP (mmHg)
Mean SD Minimum Maximum Mean SD Minimum Maximum
Placebo
Baseline 79 131.7 12.2 101 152 77.9 7.6 63 95
Month 3 76 132.5 18.0 89 167 77.4 10.0 54 97
Month 6 69 129.8 14.1 104 164 76.5 8.2 55 96
Month 9 64 131.8 13.8 102 161 77.5 8.1 62 96
Month 12 70 132.8 14.7 102 166 77.9 9.4 61 99
Month 15 59 129.6 14.5 96 167 76.7 9.5 58 98
Month 18 59 129.7 15.3 89 169 75.7 9.0 54 100
Month 21 53 131.3 18.3 98 198 76.0 9.9 52 97
Month 24 59 134.7 18.7 95 197 77.3 10.3 58 102
Perindopril
Baseline 73 130.9 11.5 105 148 76.7 8.0 60 98
Month 3 68 120.4 16.3 85 162 71.0 9.5 47 92
Month 6 62 126.3 17.4 93 182 72.8 9.3 46 93
Month 9 56 122.1 14.8 94 166 72.1 8.7 54 92
Month 12 60 121.4 14.1 85 160 71.0 8.9 44 96
Month 15 49 125.8 18.2 87 172 71.9 8.4 52 88
Month 18 52 120.2 15.2 89 173 69.4 8.2 51 89
Month 21 44 124.0 17.2 93 170 71.8 9.2 51 95
Month 24 53 125.6 17.3 95 169 71.8 10.9 50 102
Amlodipine
Baseline 72 131.9 13.0 104 155 78.0 7.0 63 93
Month 3 67 127.8 13.5 102 176 74.5 8.0 56 98
Month 6 61 127.4 14.2 98 178 74.7 7.8 59 93
Month 9 56 124.7 16.2 98 166 73.7 8.4 54 92
Month 12 54 124.7 13.9 99 159 73.3 8.2 54 89
Month 15 46 127.0 17.1 97 173 74.0 8.3 59 96
Month 18 49 126.3 13.3 101 156 73.8 7.4 59 94
Month 21 47 125.8 14.4 98 165 72.8 6.5 60 89
Month 24 49 127.9 15.2 107 165 74.2 7.3 60 91
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TABLE 22 Differences in SBP and DBP from baseline by randomised group and combined
Visit n
SBP (mmHg) DBP (mmHg)
Mean SD Minimum Maximum Mean SD Minimum Maximum
Placebo
Month 3 – baseline 76 0.8 15.5 –26.5 45.0 –0.6 7.1 –17.5 12.5
Month 6 – baseline 69 –1.9 13.6 –31.5 30.0 –1.7 7.0 –18.5 14.0
Month 12 – baseline 70 0.5 14.3 –33.5 44.5 –0.2 7.3 –22.0 12.5
Month 18 – baseline 59 –1.8 14.2 –34.5 26.0 –2.1 8.4 –21.5 16.5
Month 24 – baseline 59 2.5 16.5 –31.0 69.0 –0.7 7.9 –20.0 19.5
Perindopril
Month 3 – baseline 68 –11.1 14.2 –420 20.0 –5.9 8.9 –26.5 22.5
Month 6 – baseline 62 –5.7 17.4 –34.0 43.5 –4.5 8.0 –20.5 17.0
Month 12 – baseline 60 –9.5 13.1 –35.0 21.5 –5.8 8.1 –300 22.0
Month 18 – baseline 52 –9.6 14.6 –42.5 38.0 –7.9 7.8 –24.5 15.5
Month 24 – baseline 53 –5.0 16.3 –38.5 38.5 –5.2 10.0 –25.0 23.5
Amlodipine
Month 3 – baseline 67 –3.7 13.0 –360 23.0 –3.6 8.3 –26.5 13.5
Month 6 – baseline 61 –4.4 14.3 –51.5 290 –3.5 8.1 –25.5 12.0
Month 12 – baseline 54 –6.7 12.0 –37.0 31.0 –4.7 7.5 –24.5 16.0
Month 18 – baseline 49 –5.4 10.6 –28.5 22.5 –4.5 6.7 –17.5 11.0
Month 24 – baseline 49 –2.8 11.7 –24.5 25.5 –3.3 6.3 –18.5 8.5
Total
Month 3 – baseline 211 –4.5 15.1 –42 45.0 –3.3 8.4 –26.5 22.5
Month 6 – baseline 192 –3.9 15.1 –51.5 43.5 –3.2 7.8 –25.5 170
Month 12 – baseline 184 –4.9 13.9 –37 44.5 –3.4 8.0 –30.0 22.0
Month 18 – baseline 160 –5.4 13.7 –42.5 38.0 –4.7 8.1 –24.5 16.5
Month 24 – baseline 161 –1.6 15.4 –38.5 69.0 –3.0 8.4 –25.0 23.5
TABLE 21 Mean SBP and DBP levels by randomised group at each trial visit (continued )
Visit n
SBP (mmHg) DBP (mmHg)
Mean SD Minimum Maximum Mean SD Minimum Maximum
Total
Baseline 224 131.5 12.2 101 155 77.5 7.5 60 98
Month 3 211 127.1 16.8 85 176 74.4 9.6 47 98
Month 6 192 127.9 15.2 93 182 74.8 8.5 46 96
Month 9 176 126.5 15.4 94 166 74.6 8.6 54 96
Month 12 184 126.7 15.0 85 166 74.3 9.3 44 99
Month 15 154 127.6 16.5 87 173 74.4 9.0 52 98
Month 18 160 125.6 15.1 89 173 73.1 8.6 51 100
Month 21 144 127.3 16.9 93 198 73.7 8.8 51 97
Month 24 161 129.6 17.6 95 197 74.5 10.0 50 102
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FIGURE 24 Mean SBP over the duration of the trial by randomised group. (a) Placebo; (b) perindopril; and
(c) amlodipine. Vertical bars represent the 95% CIs for the means. Reproduced from Bicknell et al. 2016.95
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FIGURE 25 Mean DBP over the duration of the trial by randomised group. (a) Placebo; (b) perindopril; and
(c) amlodipine. Vertical bars represent the 95% CIs for the means. Reproduced from Bicknell et al. 2016.95
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FIGURE 26 Histograms of change in SBP from baseline to month 3. (a) Placebo; (b) perindopril; (c) amlodipine; and
(d) total.
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FIGURE 27 Histograms of change in SBP from baseline to month 12. (a) Placebo; (b) perindopril; (c) amlodipine;
and (d) total.
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Box plots of change in SBP from baseline to 3, 12 and 24 months are shown in Figures 29–31, respectively.
These show that there was little change in SBP in the placebo group but a reduction in SBP in the
perindopril and amlodipine groups. For box plots of change in SBP from baseline to 6 and 18 months see
Appendix 15.
Figures 32–34 show the histograms of change in DBP from baseline to 3, 12 and 24 months, respectively.
In line with the changes seen in SBP, the histograms for the placebo group generally follow a normal
distribution, whereas the reductions in DBP in the perindopril and amlodipine group are shown by the
increased density of bars to the left-hand side of each histogram. For histograms of change in DBP from
baseline to 6 and 18 months see Appendix 16.
Box plots of change in DBP from baseline to 3, 12 and 24 months are shown in Figures 35–37, respectively.
These show that there was little change in DBP in the placebo group but a reduction in DBP in both the
perindopril group and the amlodipine group. For the box plots of change in DBP from baseline to 6 and
18 months see Appendix 17.
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FIGURE 28 Histograms of change in SBP from baseline to month 24. (a) Placebo; (b) perindopril; (c) amlodipine;
and (d) total.
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FIGURE 29 Box plot of change in SBP from baseline to month 3. p-value from regression of SBP at 3 months on
treatment adjusted for SBP at baseline. a, perindopril vs. placebo; b, amlodipine vs. placebo; c, amlodipine vs.
perindopril. Circle is outside value. The box represents the 25th and 75th percentiles and the whiskers are the
upper and lower adjacent values.
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FIGURE 30 Box plot of change in SBP from baseline to month 12. p-value from regression of SBP at 3 months on
treatment adjusted for SBP at baseline. a, perindopril vs. placebo; b, amlodipine vs. placebo; c, amlodipine vs.
perindopril. Circles are outside values. The box represents the 25th and 75th percentiles and the whiskers are the
upper and lower adjacent values.
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FIGURE 31 Box plot of change in SBP from baseline to month 24. p-value from regression of SBP at 3 months on
treatment adjusted for SBP at baseline. a, perindopril vs. placebo; b, amlodipine vs. placebo; c, amlodipine vs.
perindopril. Circles are outside values. The box represents the 25th and 75th percentiles and the whiskers are the
upper and lower adjacent values.
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FIGURE 32 Histograms of change in DBP from baseline to month 3. (a) Placebo; (b) perindopril; (c) amlodipine; and
and (d) total.
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FIGURE 33 Histograms of change in DBP from baseline to month 12. (a) Placebo; (b) perindopril; (c) amlodipine;
(d) total.
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FIGURE 34 Histograms of change in DBP from baseline to month 24. (a) Placebo; (b) perindopril; (c) amlodipine;
and (d) total.
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FIGURE 35 Box plot of change in DBP from baseline to month 3. p-value from regression of DBP at 3 months on
treatment adjusted for DBP at baseline. a, perindopril vs. placebo; b, amlodipine vs. placebo; c, amlodipine vs.
perindopril. Circles are outside values. The box represents the 25th and 75th percentiles and the whiskers are the
upper and lower adjacent values.
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FIGURE 36 Box plot of change in DBP from baseline to month 12. p-value from regression of DBP at 3 months on
treatment adjusted for DBP at baseline. a, perindopril vs. placebo; b, amlodipine vs. placebo; c, amlodipine vs.
perindopril. Circles are outside values. The box represents the 25th and 75th percentiles and the whiskers are the
upper and lower adjacent values.
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Secondary outcomes
Time to reach an AAA diameter of 5.5 cm, being referred to or having AAA surgery,
or AAA rupture
The end points for this analysis were reaching a diameter of 5.5 cm in any of the four measurements
(i.e. the first visit when this happened even if the patient continued in follow-up) or having/being referred
to surgery. A total of 26 patients reached an AAA diameter of 5.5 cm during the course of the trial, with
the same number being referred to/having AAA surgery (Tables 23 and 24). There were no AAA ruptures
reported. For patients who reached both end points, the date of reaching an AAA diameter of 5.5 cm was
used for analysis. Two cases proceeded to surgery before an AAA diameter of 5.5 cm was recorded in-trial
and for these two patients the date of surgery was used. No significant differences were found between
the three treatment groups for this combined secondary end point (Figure 38).
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FIGURE 37 Box plot of change in DBP from baseline to month 24. p-value from regression of DBP at 3 months on
treatment adjusted for DBP at baseline. a, perindopril vs. placebo; b, amlodipine vs. placebo; c, amlodipine vs.
perindopril. Circles are outside values. The box represents the 25th and 75th percentiles and the whiskers are the
upper and lower adjacent values.
TABLE 23 Numbers of patients reaching study end points by randomised group and combined
Study end point Placebo Perindopril Amlodipine Total
Reaching 5.5 cm 11 6 9 26
Being referred to or having AAA surgery 9 10 7 26
Combined end point 11 10 11 32
Surgery only 0 4 2 6
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Quality-of-life outcomes
The overall EQ-5D scores at 12 and 24 months are shown in Table 25 (see Appendix 18 for the scores for
each of the five domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression).
Overall, mean scores were similar across all three treatment groups at 12 months but a reduction in the
mean score from 12 to 24 months was observed in the placebo group (from 71.4 to 64.0), representing
a reduction in quality of life. A similar reduction in score was not observed in the perindopril or
amlodipine group.
TABLE 24 Numbers of patients reaching an AAA diameter of 5.5 cm at each study visit by randomised group
and combined
Visit Placebo Perindopril Amlodipine Total
Baseline 1 0 1 2
Month 3 4 0 1 5
Month 6 0 1 0 1
Month 9 1 1 2 4
Month 12 4 3 2 9
Month 15 0 1 0 1
Month 18 0 0 0 0
Month 21 0 0 1 1
Month 24 1 0 2 3
Total 11 6 9 26
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FIGURE 38 Kaplan–Meier estimates of the proportions of patients reaching secondary end points. a, 11 patients
randomised are not included as they were seen only at baseline; b, apparent disparity in numbers attending their
24-month visit largely because of this visit occurring before 720 days. Reproduced from Bicknell et al. 2016.95
© Bicknell et al. 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. This is
an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Drug compliance
Compliance was evaluated using pill count data (number dispensed minus number returned) for each
time period (Table 26). Mean compliance combining all three groups was > 80% for each 3-month
period evaluated.
Safety
Adverse events
Both active treatments were generally well tolerated, with similar numbers of patients as in the placebo
group discontinuing therapy for AEs (n= 8, 13 and 14 for placebo, perindopril and amlodipine,
respectively). Table 27 provides a summary of AEs and SAEs occurring in the trial. Although there were
more SAEs in the perindopril group, none of these SAEs was deemed to be related to the study IMP by the
PI of the relevant site.
TABLE 25 Overall EQ-5D scores during follow-up by randomised group and combined
Measure Placebo Perindopril Amlodipine Total
Month 12
n 69 59 51 179
Mean 71.4 69.6 72.7 71.2
SD 24.1 27.2 24.4 25.1
Median 80 80 80 80
IQR 25 25 20 30
Month 24
n 56 50 45 151
Mean 64.0 70.2 71.4 68.2
SD 26.9 23.5 26.4 25.7
Median 70.5 75 80 75
IQR 33.5 20 30 25
IQR, interquartile range.
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TABLE 26 Compliance (%) based on pill count for each 3-month study period by randomised group and combined
Study period n Mean SD Median P25 P75 Minimum Maximum
Placebo
Baseline to month 3 60 80 15 82 76 88 14 100
Month 3 to month 6 65 75 25 85 71 90 0 100
Month 6 to month 9 61 80 19 85 73 96 26 100
Month 9 to month 12 60 77 20 84 69 90 10 100
Month 12 to month 15 58 81 21 87 78 92 0 100
Month 15 to month 18 47 82 21 88 80 95 1 100
Month 18 to month 21 45 80 26 87 77 96 0 100
Month 21 to month 24 40 82 20 89 76 94 6 100
Perindopril
Baseline to month 3 56 76 20 80 74 85 0 100
Month 3 to month 6 59 84 16 86 81 96 4 100
Month 6 to month 9 51 82 18 88 73 96 4 100
Month 9 to month 12 45 78 22 85 75 91 20 100
Month 12 to month 15 44 79 25 87 78 94 12 100
Month 15 to month 18 38 76 27 87 75 91 0 99
Month 18 to month 21 37 85 14 89 78 94 26 100
Month 21 to month 24 32 84 20 90 81 94 12 100
Amlodipine
Baseline to month 3 60 75 19 77 71 84 1 100
Month 3 to month 6 59 80 18 81 74 91 0 100
Month 6 to month 9 50 75 22 81 71 89 12 100
Month 9 to month 12 48 72 25 82 70 89 0 96
Month 12 to month 15 43 73 30 84 75 90 3 100
Month 15 to month 18 40 84 11 85 77 93 58 100
Month 18 to month 21 37 82 20 89 84 93 3 100
Month 21 to month 24 31 81 23 89 75 94 0 100
Total
Baseline to month 3 176 77 18 80 74 86 0 100
Month 3 to month 6 183 80 20 85 74 92 0 100
Month 6 to month 9 162 79 20 84 73 93 4 100
Month 9 to month 12 153 75 22 83 71 90 0 100
Month 12 to month 15 145 78 25 86 77 92 0 100
Month 15 to month 18 125 81 21 87 77 92 0 100
Month 18 to month 21 119 82 21 88 78 94 0 100
Month 21 to month 24 103 82 21 89 78 94 0 100
P25, 25th percentile; P75, 75th percentile.
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Serum creatinine
Table 28 and Figure 39 show the distribution of serum creatinine levels at 3, 12 and 24 months for the
three treatment arms and combined. Table 29 shows the serum creatinine differences between each of
the study visits and screening. As expected, there was little difference in mean serum creatinine levels
in the placebo and amlodipine groups across the duration of the trial but a small increase was observed in
the perindopril group (6% at 3 months). However, this increase was not statistically significant and no
patients were withdrawn from the trial because of concerns regarding renal function.
TABLE 28 Serum creatinine levels (µmol/l) at screening and 3, 12 and 24 months by randomised group
and combined
Visit n Mean SD Median P25 P75 Minimum Maximum
Placebo
Screening 73 86.6 20.5 79 73 96 56 154
Month 3 72 87.5 19.7 84 72 100 56 153
Month 12 63 88.2 19.8 85 73 99 55 154
Month 24 52 85.5 16.5 83 74 97 58 126
Perindopril
Screening 69 87.0 18.7 86 75 95 54 156
Month 3 66 92.1 19.1 88 78 101 66 169
Month 12 54 93.0 21.9 89 75 105 64 161
Month 24 49 90.3 20.7 86 75 101 53 137
Amlodipine
Screening 67 90.0 20.0 87 78 96 55 178
Month 3 64 90.0 20.3 88 74 100 61 161
Month 12 50 90.3 18.8 87 78 96 54 136
Month 24 43 89.8 18.7 89 75 95 65 143
Total
Screening 209 87.8 19.7 86 75 96 54 178
Month 3 202 89.8 19.7 87 76 100 56 169
Month 12 167 90.4 20.2 87 77 100 54 161
Month 24 144 88.4 18.7 85 75 98 53 143
P25, 25th percentile; P75, 75th percentile.
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FIGURE 39 Median serum creatinine levels at screening and 3, 12 and 24 months by randomised group. (a) Placebo;
(b) perindopril; and (c) amlopidine. Circles are outside values. The box represents the 25th and 75th percentiles and
the whiskers are the upper and lower adjacent values.
TABLE 29 Differences in mean serum creatinine levels (µmol/l) by randomised group at 3, 12 and 24 months
compared with screening levels
Study period n Mean SD Median P25 P75 Minimum Maximum
Placebo
Month 3 – screening 67 0.6 12.9 0 –4 5 –64 49
Month 12 – screening 61 0.5 14.6 1 –5 6 –61 30
Month 24 – screening 50 –0.4 13.4 –1 –7 8 –51 31
Perindopril
Month 3 – screening 62 5.6 10.4 4 –1 11 –9 54
Month 12 – screening 51 4.8 10.6 4 –2 10 –19 37
Month 24 – screening 47 3.8 11.2 1 –4 11 –17 44
Amlodipine
Month 3 – screening 60 –0.3 10.3 –1 –7 6 –23 35
Month 12 – screening 46 1.7 11.5 1 –4 6 –21 49
Month 24 – screening 41 –0.1 8.2 –2 –5 6 –18 18
P25, 25th percentile; P75, 75th percentile.
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Chapter 5 Discussion
The AARDVARK trial was designed to evaluate whether or not ACE inhibition induces a beneficialeffect on the growth of small AAAs. This trial has shown that 2 years of daily ingestion of the ACE-I
perindopril has no impact on the growth rate of small AAAs (the primary end point of the trial) compared
with that observed among those randomised to the CCB amlodipine or placebo.
In keeping with this lack of any differential effect on AAA growth among the three randomised treatment
arms of the trial, there was also no difference between the groups in the numbers of trial participants
whose AAA reached a diameter of 5.5 cm and/or who were referred for/received surgical intervention for
their AAA (26 patients), which was a secondary end point of the trial. No ruptures were reported in the
study, confirming the safety of a policy of ultrasound surveillance for small AAAs.
Taking into account various sources of data collated during the trial, including three QA events at
which trial sonographers and AAA patient volunteers attended, it was clear that, as expected, AAA
measurements collected in the longitudinal plane were more repeatable than those collected in the
transverse plane and that, overall, OTO measurements were superior to ITI measurements in terms of
interobserver repeatability. Hence, for the primary analyses of this trial, OTO measurements in the
longitudinal plane were used.
Serum creatinine levels as well as other potential AEs were monitored closely in the study. Although
a small and expected increase in creatinine levels was seen in the perindopril group, trial withdrawals
because of study drug-related AEs were similar among the three groups. As expected, no suspected
unexpected serious adverse reactions were reported during the trial, consistent with the established safety
profiles of ACE-Is and CCBs. Compliance with therapy was excellent in all three treatment arms.
The trial was designed to generate equivalent BP reduction in the two actively treated groups, based on
previously published data73–75 and the knowledge that ACE-Is tend to be less effective than CCBs in terms
of BP lowering among the older age group included in the trial.45
Both actively treated groups had lower in-trial BPs than those on placebo; however, somewhat surprisingly,
BP lowering was greater among those randomised to perindopril than among those receiving amlodipine.
Nevertheless, had there been a BP-related benefit in terms of AAA growth rather than a drug class-related
effect, such a BP-related effect could have been detected in this trial. However, no differential effects on
AAA growth were apparent across the three groups, BP related or otherwise.
Although data are inconsistent, ACE-Is have been associated with a reduced incidence of AAA rupture in
analyses of administrative databases.6,70 Evidence for the benefit of other antihypertensive agents has been
lacking,6 suggesting that ACE-Is may act through a BP-independent mechanism; however, it is important
to note that analyses of administrative databases are subject to the caveats and shortcomings of
observational data.
Meanwhile, evidence implicating the RAS in aortic aneurysm formation and growth in animal models has
been reported.67,68,96,97 For example, infusion of angiotensin II induces suprarenal post-dissection aneurysm
formation in animal models and continued infusion has been shown to cause pathological changes in the
aneurysmal tissue including infiltration of macrophages and disruption of elastin in the medial layer.98
The discrepancies between animal and human studies may reflect the challenges of conducting RCTs in
AAA patients, including accurately measuring AAA growth and bias in patient recruitment, but may more
likely reflect differential associations and physiology across species or differences in the pathology of these
aneurysms between humans and artificial animal models.
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Strengths
To our knowledge this study is unique in being the only placebo-controlled RCT to have completed an
evaluation of the impact of ACE-Is on the growth rate of small AAAs. However, two other RCTs of the
ARBs valsartan (NCT01904981) and telmisartan99 are currently in progress. Interestingly, the large
Canadian case–control study6 that reported the protective effects of ACE-Is on the rupture of AAAs did
not show similar benefits for ARBs.
Although a significant proportion of trial participants did not complete 2 years of follow-up in the
AARDVARK trial because of reaching a censoring trial end point (e.g. referral for surgical intervention or
death), the great majority continued regular follow-up and the overall attrition rate was only 6% (which
was less than the target attrition rate of 10% used in power calculations). Hence, 94% of patients did
contribute at least two sequential AAA measurements to facilitate an evaluation of growth.
Drug compliance among attendees was excellent as evaluated by pill counts and data collection was
efficient with only a small number of key measurements or investigations (e.g. BP levels) missing in the
trial overall.
The trial included a system for quality control. The standardised procedures used for AAA measurements
as outlined in the scanning protocol were designed to reduce measurement variability associated with
using 19 sonographers from 11 sites. This protocol was taught at specifically designed QA days.
Image quality was also robustly assessed and sites with poor-quality scans were reassessed. Lastly,
the measurements taken for all time points were audited by the trial senior clinical vascular scientist and,
when obvious differences between measurements in the same subject at the same time point existed,
a review took place.
Limitations
The profile of the trial participants – largely white men aged ≥ 55 years with a heavy smoking history – is
typical of that for UK patients with an AAA but this should be set in the context of those ineligible for the
trial or who did not take part (see Figures 11 and 12). Indeed, the limitations of the AARDVARK trial
include the potentially restricted generalisability of the trial recruits. Trial inclusion and exclusion criteria
predetermined that, although the overall profile of the recruits might at first sight be considered typical
of patients from the UK with an AAA, the age range was limited to ≥ 55 years and SBP had to be
< 150mmHg.
Furthermore, it is clear from Figure 11 that most patients considered for the trial were already taking an
antihypertensive agent that made them ineligible. Allied with the other reasons why patients declined to
join the trial (see Figure 12), it is reasonable to assume that the trial population may not be representative
of the true AAA population in the UK as a whole. This conclusion is supported by the mean SBP and DBP
levels recorded in other AAA studies (see Table 2), with SBP levels ranging from 143 to 157mmHg and
DBP levels ranging from 81 to 91mmHg. These levels appear to be significantly higher than the mean BPs
found at baseline in all three treatment arms in the AARDVARK trial (131.7/77.9mmHg, 130.9/76.7 mmHg
and 131.9/78.0 mmHg for placebo, perindopril and amlodipine, respectively).
At a more global level, the findings of a study predominantly including UK-based white men may clearly
not be generalisable to non-UK populations, women or those of different ethnicities.
The doses of ACE-I and CCB chosen for the trial were expected to cause similar reductions in BP;73–75
however, this was not found to be the case. Although both treatments were effective in lowering BP, the
mean differences in SBP from baseline to 24 months in the perindopril and amlodipine groups were –5.0
(SD 16.3) mmHg and –2.8 (SD 11.7) mmHg, respectively, compared with 2.5 (SD 16.5) mmHg in the
DISCUSSION
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placebo group. With similar withdrawal rates observed among the three treatment groups and no
differences in relation to compliance, the reason for the difference in BP reduction between the perindopril
group and the amlodipine group remains unclear. Although ACE-Is are known to be particularly effective
in treating hypertension in patients with renal artery stenosis, patients with known renal artery stenosis of
> 50% were excluded from the trial. However, no further investigations were undertaken to explore or
exclude lesser degrees of renal artery stenosis in the trial population, making it difficult to draw any further
conclusions about the observed BP differences in relation to the role of renal artery stenosis.
A potentially crucial limitation of the AARDVARK trial relates to the statistical power. To calculate the
sample size of the trial we estimated that the trial would have 90% power at the 5% level to detect a
38% (1-mm) difference in growth rate between those receiving perindopril and those on placebo. This
was based on an estimated annual growth in AAA diameter of 2.6 (SD 1.8) mm, as reported in the UKSAT
trial.22 However, given the actual average annual growth rate observed of 1.7 (SD 3.0) mm, 190 patients
per group would have been required to detect a 1-mm difference in growth with a power of 90%. Based
on the actual sample size (75 per group), we had 51% power to detect a 1-mm difference in growth
(between two groups) and 85% power to detect a difference of 1.5mm (close to the annual growth rate).
However, our estimated difference in the slopes of regression between perindopril and placebo was
0.08mm with a 95% CI of –0.50mm to 0.65mm, which statistically excludes a likely reduction of 1mm.
This implies that an important clinical difference in growth rate of small AAAs is unlikely to occur in this
population in association with the use of perindopril compared with placebo.
Given the very small changes in AAA size that were expected over the 2-year follow-up period, numerous
quality control measures were put in place to obtain accurate AAA measurements. Furthermore, sites were
requested to have the same observer scanning the same patient on the same machine for the duration of
the study. All sites reported that they adhered to this request to the greatest extent possible, bearing in
mind clinical service pressures and staffing changes. Despite this, the mean (range) intrasonographer
repeatability coefficient was 0.33 (0.21–0.45) cm for OTO measurements. Although ultrasonography is a
cost-effective tool for the identification of AAAs and sufficient to direct clinical management of patients,
the accuracy of measurements made in a RCT becomes critical because of its high operator dependence.
During the site initiation visits for the trial it became clear that the routine methods for taking ultrasound
measurements varied among sites. Despite the protocol and training that were provided for the trial,
unfamiliarity with taking some of the AAA measurements required by the trial may explain the greater
than expected range in measurement variability.
The greater than expected intra- and inter-observer variability and measurement error add uncertainty to
the interpretation of the results. For future studies involving observers at multiple sites it would be
pertinent to undertake detailed and practical training sessions prior to the recruitment of patients.
Furthermore, measurement variability might be reduced by using more accurate methods of obtaining
images, such as performing an electrocardiogram simultaneously with recording ultrasound videos,
allowing for electrocardiogram gating in the reading process.100,101
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Chapter 6 Conclusions
We were unable to demonstrate any impact of an ACE-I compared with placebo or a CCB onthe growth rate of small AAAs over a 2-year period. Furthermore, a decrease in BP achieved among
those allocated to active BP-lowering therapy was not associated with a reduction in AAA growth rate
compared with those allocated to placebo. However, because of the small AAA growth rates observed,
as well as the greater than expected AAA measurement variability (including measurement error), the trial
had only 51% power to detect a 1-mm difference in growth (between two groups) and 85% power to
detect a difference of 1.5 mm (close to the annual growth rate). Nevertheless, our estimated difference in
slope between those receiving perindopril and those receiving placebo was 0.08mm, with a 95% CI of
–0.50mm to 0.65mm, which statistically excludes a likely reduction of 1mm. Hence, at least in this type
of population with relatively well-controlled BP, modest BP reduction with a CCB or an ACE-I offers no
obvious benefits in terms of reducing the growth of small AAAs and this trial was unable to show any
indication of any BP-independent beneficial effect on the growth of small AAAs of an ACE-I over placebo
or a CCB or a combination of placebo and a CCB.
Implications for health care
Despite some earlier evidence suggesting that the rupture rates of AAAs may be lower in patients taking
ACE-Is, this trial found no evidence that the growing cohort of patients with a small AAA under
surveillance should be prescribed an ACE-I to slow AAA growth. The QA studies undertaken as well
as the comparison of various aspects of variability of internal and external measurements provide support
for the use of external rather than internal AAA diameter measurements taken in the longitudinal plane as
the routine measurement of choice for the screening and follow-up of AAAs.
Recommendations for future research
The results of this pilot trial do not provide strong support for a larger trial to evaluate the effects of ACE-Is
on small AAA growth rate.
Other than the apparently negative findings of the trial (albeit with some caveats around the issue of
power), the large and increasing numbers of elderly patients with an AAA already receiving some form
of RAS blockade (the most common cause of ineligibility for this trial) would make randomisation to an
ACE-I or an ARB significantly more difficult, with associated concerns about the generalisability of the
findings of any such trial. Nevertheless, patients recruited through the NAAASP were less likely to be
already receiving a RAS blocker than those already in a vascular database and could therefore offset some
of those concerns.
Patients considered unfit for surgery but with an AAA of larger diameter than those included in the
AARDVARK trial may, by virtue of their larger AAA growth rates, provide a further source of eligible
patients for a more powerful evaluation of medical interventions with regard to AAA size and/or rupture.
Importantly, whichever groups of patients are included in future trials of AAA, strict protocols around
ultrasound measurements and training of trial staff are critical if AAA measurements are key outcomes.
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The following research recommendations are made as a consequence of the conduct and findings of the
AARDVARK trial:
l Further work related to the data already collected in the AARDVARK trial:
¢ A multivariate analysis of determinants of AAA growth in the AARDVARK trial.
¢ Potential differences were observed between the three treatment groups in relation to the number
of patients whose AAA grew at a fast rate during the trial (as defined by a growth rate of > 5mm
per year). However formal analyses are still required.
¢ An evaluation of the incremental predictive power of baseline and changing central BPs and BP
variability with regard to AAA growth rates.
l Further work potentially arising from the AARDVARK trial:
¢ An evaluation of currently available data regarding AAA growth rates in those with SBP of
< 150mmHg and ≥ 150mmHg to investigate whether growth rates could be critically affected by
this systolic threshold or other systolic and diastolic thresholds.
¢ An evaluation of whether the BP-lowering effect of perindopril and amlodipine are affected by the
presence or absence of an AAA.
¢ The strong protective effect of type 2 diabetes on the development of AAAs observed in large
observational databases merits further investigation.
¢ A large measurement variability study to optimise training and standardisation.
¢ A trial to evaluate the impact of ACE-Is on the rupture of larger AAAs.
CONCLUSIONS
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Appendix 1 Patient information sheet and
informed consent form
PATIENT INFORMATION SHEET AND CONSENT FORM 
 
An evaluation of the effect of an angiotensin-converting 
enzyme (ACE) inhibitor on the growth rate of small 
abdominal aortic aneurysms 
 
Eudract number : 2010-
020226-17 
Ethics ref : 10/H0711/80 
Sponsors ref : CRO 1644 
 
 
AARDVARK 
Aortic Aneurysm Regression of Dilation: Value of ACE inhibitors on RisK 
 
This patient information sheet is in two parts. Part A is a summary of the AARDVARK 
study. Part B gives more detailed information on the study and administration issues. Please 
read both sections before making your final decision. 
 
PART A 
Invitation  
You are being invited to take part in a research trial. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time to 
read the following information carefully and discuss it if you wish with family, friends or 
your doctor. Do ask the research doctor or nurse if there is anything that is not clear or if you 
would like more information. Take as much time as you need to decide whether or not you 
wish to take part. Thank you for reading this. 
 
If you agree to take part, you will be asked to fill out, sign and date this information sheet and 
consent form and to keep it as a useful reference on trial details and personal contacts 
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WHAT IS THE PURPOSE OF THE TRIAL? 
You have a condition known as an abdominal aortic aneurysm. An abdominal aortic 
aneurysm is a balloon-like swelling of the main blood vessel of the body (the aorta) as it runs 
through the abdomen.  The normal diameter of the abdominal aorta is approximately 1.8cm 
or about three quarters of an inch in diameter. Small aneurysms grow slowly and do not 
appear to cause problems until the diameter exceeds 2-3 times the diameter of the normal 
aorta (about 5.5cm or more than 2 inches in size).  
When the aneurysm is small it is safer to monitor using regular ultrasound scanning - an 
ultrasound scan is a painless test that uses sound waves to create images of organs and 
structures inside your body.  If the aneurysm reaches a large size (usually over 5.5cm), repair 
with an operation is recommended to avoid the serious problem of bursting: Causing 
significant internal bleeding (aneurysm rupture).   
It is important to find treatments that help prevent an aneurysm enlarging. 
One trial has shown that the use of a specific type of drug, angiotensin converting enzyme 
(ACE) inhibitors, which are usually used to treat high blood pressure, may reduce the risk of 
bursting (rupture) of  large aneurysms. Therefore it has been suggested that ACE inhibitors 
also might slow the growth of small aneurysms. It is not clear whether these drugs, ACE 
inhibitors, would have their effect by reducing blood pressure or by acting directly on the 
aneurysm or both.   
This trial will assess whether an ACE inhibitor drug called perindopril will reduce the 
growth rate of small aneurysms.  It will also assess whether a small reduction in blood 
pressure levels with any drug also could reduce the growth rate of these aneurysms. 
 
WHY HAVE I BEEN CHOSEN? 
You have been asked to take part in this trial as you have an aortic aneurysm of a small size 
that is currently being monitored using ultrasound scans.  
 
DO I HAVE TO TAKE PART? 
It is up to you to decide if you want to take part in the research or not.  
If you decide to take part you are still free to stop being in the trial and withdraw your 
consent at any time. In this case, your research doctor may ask you why you want to 
withdraw but you do not have to give a reason. You may also decide at any time that you no 
longer want to take the trial tablet.  In such case, you can stop taking the trial drug but 
continue in the trial and the trial team will collect information on your health until the end of 
the trial. 
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If you agree to take part, your GP will be told that you have agreed to take part in the trial 
and, with your permission, will be told about the trial and the treatments you may be taking. 
He/she will be asked for some additional medical details about you. We may also need to 
contact other doctors or specialists who look after your medical care. 
If you decide not to take part, the care you receive will not be affected in any way. 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? / WHAT DO I HAVE TO DO? 
Each patient in this trial must take part for a 2-year period. There are likely to be 225 patients 
similar to you in this trial. 
You will first undergo a screening visit. At this visit we will check whether you are suitable 
for the study. If your blood pressure is found to be raised, we will suggest some treatment for 
this. We will then invite you back after 6 weeks to check if your blood pressure has lowered.  
If you proceed into the study, you will be asked to take half a tablet for the first two weeks 
(you will be provided with a pill-cutter) and one tablet each day from then onwards. 
This tablet could contain the ACE inhibitor called perindopril (10mg), or another drug used 
to treat blood pressure called amlodipine (5mgs) or a placebo (dummy) pill.  
It will be decided randomly (like the toss of a coin) if you receive the placebo or one of the 
blood pressure medicines so you have a one in three chance or receiving each of the 
medications. 
This is a blinded trial which means you will not know which treatment you are receiving, 
although, if your research doctor needs to find out, he/she can quickly do so. Neither the trial 
doctor nor you may choose which treatment you receive. 
To assess the effects of these drugs we will: 
· Monitor your aneurysm growth by a series of ultrasound scans at either 3 or 6monthly 
intervals. Please speak to your study team in regards to the frequency of your visits.   
· At least once a year your scans will be performed by a specialist scanner  
· Measure your blood pressure at every visit. 
· Collect blood samples at screening, 3 month, 12 month and 24 month visits.  These 
samples are to check that your kidney function is normal. Approximately 1 teaspoon 
of blood will be collected these visits.  
· Ask you to complete questionnaires to assess quality of life and other health care 
resources used (for conditions unrelated to your aneurysm) at the end of each year. 
DOI: 10.3310/hta20590 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 59
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kiru et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
103
Each follow up visit to the hospital (every 3 or 6 months) will take approximately 30 minutes 
although your initial visit could take up to one hour. After this first visit you will be informed 
of the aneurysm size and blood pressure from your visit. There will be no need for you to 
attend your GP for extra visits unless any of our tests show that you may need other treatment 
or tests. 
Reasonable travel expenses for attending a trial visit will be paid to you and you should 
discuss this with the trial team. 
All the costs of the trial (medicines, visits and tests) will be provided for by the trial funder. 
Your research doctor will be compensated for his/her time and resources given to the trial 
however, your research doctor will not be paid for his/her involvement in the trial. 
 
So long as you continue to take part, you will be required to: 
· Attend the scheduled visits organised by your research doctor and nurses. 
· You should take the trial drug as instructed by your trial doctor or research staff.   
· At each visit you should bring all unused medicines and any empty medicine boxes 
with you. 
· Bring a written list of all your medications to each visit. 
· You will not have to limit your normal lifestyle or activities while you are part of the 
trial.  
· Your GP will continue looking after you in the usual way. It is important that you tell 
your research doctor about any other medicine you are taking before starting the trial, 
because some of them may prevent you from joining the trial.  
· Should you start taking a new medicine during the trial, you must tell your research 
doctor or nurse straight away in order to check if it can be taken safely with the trial 
treatment. This includes any medicines prescribed by your GP or specialist or those 
you may have bought yourself even herbal products or food supplements. 
· You should tell your trial doctor or trial staff about any medical problems, doctor 
visits, hospital visits, or medical procedures that you have while you are in the trial. 
· It would be a good idea to mark in your diary card details of any hospital or GP 
appointments with notes of any medication changes. 
· You will be given a contact card with details of the trial. You should carry this card 
with you at all times and should you need to be admitted to hospital make sure that 
the hospital is aware that you are taking part in this trial so that they may contact your 
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trial team. If you experience any serious health problems such as a heart attack or a 
stroke, your trial doctor must be informed immediately. 
· You should not take part in any other research trial whilst you are in this trial 
 
POSSIBLE BENEFITS OF TAKING PART IN THE TRIAL 
Your part in the trial may provide important information and allow doctors to learn more 
about the trial drugs and treating abdominal aortic aneurysms. During this trial you will get 
physical exams and your health  
will be monitored. If this trial demonstrates a decreased growth rate of aneurysms for patients 
taking ACE inhibitor drugs, patients that have the same condition as you may significantly 
benefit from this trial after the resulted have been determined and made public.  
For patients with very small aneurysms less than 4.5 cm (or 1.8 inches) in diameter there will 
be an increased frequency of ultrasound examinations over and above what is normally 
offered in the NHS, but benefits of more regular scans may include earlier detection of 
rapidly growing aneurysms or detection of aneurysms that have reached a size that requires 
treatment.  
ARE THERE ANY SIDE EFFECTS FROM THE DRUGS USED IN THIS TRIAL? 
The active drugs in this trial are small doses, expected to lower the blood pressure by a small 
amount (about 6mm of mercury). They should not cause any untoward effects, but in the case 
of side effects you should contact the trial centre or other medical help as soon as possible for 
advice. 
Common side effects (ie. those that are experienced in 1-10% of patients) specific to each 
drug that may be experienced are noted below. A full list of the side effects is available in the 
appendix of this information sheet. Investigation of any of symptoms you experience may be 
discussed with the study medical team. 
 
Drug  Side Effects  
Perindopri
l (ACE 
inhibitor) 
 
 
 
· Cough - If the cough is intolerable you will be told to stop the drug and you will 
be switched to another blood pressure drug called losartan which has a lower 
incidence of cough. You can continue on the trial receiving this drug.  
· Hypotension (low blood pressure)  
· Gastro-intestinal problems (nausea, vomiting, indigestion, diarrhoea, 
constipation, abdominal pain)  
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· Allergic symptoms – rash, runny nose, nasal congestion, sore throat 
· Headaches   
· Muscle cramps  
· Vision disturbance 
· Tinnitus (ringing in the ears) 
Amlodipi
ne 
(Calcium 
channel 
blocker) 
 
· Headache 
· Ankle swelling 
· Dizziness 
· Abdominal pain 
· Nausea 
· Tiredness   
· Flushing 
Losartan  
· Dizziness  
· Vertigo  
· High potassium levels in the blood  
 
ALTERNATIVE TREATMENTS  
At present there are no treatments used routinely to try to prevent the enlargement of 
aneurysms. However, it is thought however that stopping smoking and treating high blood 
pressure and raised blood fats are all beneficial. We will contact your GP so he may give you 
treatment to lower your cholesterol (blood fats).  This is likely to be with a medication called 
a statin. 
 
ARE THERE ANY SIDE EFFECTS FROM REGULAR ULTRASOUND SCANS? 
The ultrasound examinations do not cause any harm. Ultrasound scans are simple, pain-free, 
non-invasive tests that can image the aneurysm and measure the size and, by comparing to 
previous scans, measure the growth rate. The test is very quick and will take 10-20 minutes. 
We will ask you to eat a small meal only before the scan, as large meals can lead to excess 
gas in the gut and obscure the aneurysm from view. 
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It is likely that you will have had an ultrasound scan previously for the diagnosis or 
monitoring of your aneurysm. This ultrasound examination will not be noticeably different to 
previous scans. 
We will ask you, as part of this trial to undergo ultrasound scans at 3 or 6monthly intervals 
(slightly more frequently than many hospitals ask the majority of patients to undergo scans). 
Following this scan we will give you the results and you will have the chance to ask any 
questions.  
 
BLOOD TESTS may sometimes cause some bruising and discomfort. 
 
WHAT WILL HAPPEN IF MY ANEURYSM GROWS TO A SIZE THAT NEEDS 
INTERVENTION? 
Your GP and vascular surgeon will be informed immediately and options for aneurysm repair 
will be discussed with you. If you proceed to have an aneurysm repair, we will not ask you to 
attend any further appointments as part of this trial and the drug treatment may be stopped. 
 
PART B 
 
WHO IS THE SPONSOR OF THE TRIAL? 
This research is funded by the National Institute of Health Research. There is no funding 
from any industrial or pharmaceutical company.  The research is organised and sponsored by 
the Imperial College. Your local hospital will be compensated for the work performed and 
services used at your local hospital. This trial will be co-ordinated from the Imperial College 
Clinical Trials Unit, London, and take place at hospitals and AAA screening centres in and 
around London and Coventry. 
 
WHAT HAPPENS WHEN THE RESEARCH TRIAL STOPS? 
At the end of the trial you will be informed which of the treatment arms you were assigned 
to. Further drug treatment will not be available from the trial centre but your GP will be 
notified and you may request to continue the medication.  We shall tell you the results of the 
trial as soon as possible. Regular examination of your aneurysm will continue at your local 
aneurysm follow up clinic. 
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WHAT IF NEW RELEVANT INFORMATION BECOMES AVAILABLE? 
Sometimes we get new information about the treatment being studied. If this happens, your 
trial doctor will tell you and discuss whether you should continue in the trial. If you decide 
not to carry on, your trial doctor will make arrangements for your care to continue (aneurysm 
surveillance). If you decide to continue in the trial he may ask you to sign an agreement 
outlining the discussion.  If the trial is stopped for any other reason, we will tell you and 
arrange your continuing care (aneurysm surveillance).  
 
WILL MY GENERAL PRACTITIONER BE INFORMED? 
Your GP (or other health care practitioner) will be notified of your participation. We will 
seek consent for this. We will, in turn, notify your GP (or other health care practitioner) of 
any other problems that occur as a  
 
result of this trial. You will be informed of the measurements of blood pressure and aneurysm 
size after each visit. If the aneurysm grows to a significant size during the trial period, your 
GP (and vascular surgeon) will be notified urgently. 
 
WHO HAS REVIEWED THE TRIAL?  
The trial has been reviewed by the Imperial Clinical Trials Unit at Imperial College and by 
the Health Technology Assessment group of the National Institute of Health Research.  All 
human research is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This trial has been reviewed and received favourable 
opinion by a Research Ethics Committee.  
 
WITHDRAWING CONSENT FROM THE TRIAL 
Your participation in this trial is voluntary. You can choose at any time to withdraw your 
consent for this trial (take yourself out of this trial). Your decision will not affect your ability 
to receive medical care for your disease. You will not lose any rights or benefits to which you 
are otherwise entitled. 
For the purpose of this trial, the sponsor and its agents and representatives (including the trial 
doctor, institution and its representatives) reserves the right to verify your survival status by 
way of your medical records, public records or contacting your physician or the named 
alternate contact person(s) if the law permits. 
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WHAT IF THERE IS A PROBLEM? 
Imperial College London holds insurance policies which apply to this study.  If you 
experience serious and enduring harm or injury as a result of taking part in this study, you 
may be eligible to claim compensation without having to prove that Imperial College is at 
fault.  This does not affect your legal rights to seek compensation. 
  
If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of 
the way you have been treated during the course of this study then you should immediately 
inform the Investigator (Insert name and contact details).  The normal National Health 
Service complaint complaints mechanisms are also available to you.  If you are still not 
satisfied with the response, you may contact the Imperial AHSC Joint Research Office.   
 
WILL MY TAKING PART IN THE TRIAL BE KEPT CONFIDENTIAL? 
If you agree to take part in the research, all personal information collected during the trial 
will be kept strictly confidential. It will be used only for the research and for submission to 
Regulatory Authorities in a way so they will not be able to identify you.  
Your medical records and other personal information created during the trial may be looked 
at by representatives of the sponsor, people working on behalf of the sponsor such as 
monitors of the trial, members of the ethics committee, and from regulatory authorities and 
auditors to check the research is being carried out correctly.  
Any information from your medical records will always be kept strictly confidential. 
All information about you which leaves your research doctor's site will not be able to be 
traced back to you. Any transfer of this information will be done according to the rules and 
regulations protecting personal information.  
With your agreement, your research doctor will inform your general practitioner or other 
medical practitioners who may be treating you of your participation in the trial 
You will be allowed to have a look at your personal information to check it is correct. If you 
wish to do so, you should ask your research doctor.  
You will only be told details of which specific medicine you had been taking once the trial is 
over and when the results are ready. 
If you decide to leave the trial early, any information collected on you up to that point will 
still be used.  
You have the right to check the accuracy of data held about you and correct any errors.  
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Procedures for handling, processing, storage and destruction of information about you are 
compliant with the Data Protection Act 1998. 
Information about you will be kept for 15 years after the end of the trial, and will be disposed 
of securely after this time. 
 
THE RESULTS OF THE TRIAL 
The results from this trial may be published in medical journals or used in scientific reports, 
but your name or any other confidential information will never appear. 
You may have a copy of the results should you wish. You will need to speak to your research 
doctor about this at the time. 
Finally, you will be told which type of medicine you have been taking. 
You should note that you would not be identified in any report/publication unless you have 
given your written consent.  
 
THE ETHICS COMMITTEE BELOW HAS APPROVED THE PROTOCOL 
The Ethics Committee of West London REC 2 has given a favourable opinion to the trial on 
14
th
 February 2011 
 
CONTACTS AT SITE 
Should you have questions about the trial or the trial products, or in the case of an 
emergency please contact: 
 
Research Doctor  
 
Research Nurse  
 
Address and telephone  
 
Emergency contact 
number 
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Full list of side effects  
Drug  Side effects  
Perindopri
l (ACE 
inhibitor) 
 
 
 
Common (affecting 1- 10% of people who take this drug) :  
· Cough - If the cough is intolerable you will be told to stop the drug and you will 
be switched to another blood pressure drug called losartan which has a lower 
incidence of cough. You can continue on the trial receiving this drug.  
· Hypotension (low blood pressure)  
· Gastro-intestinal problems (nausea, vomiting, indigestion, diarrhoea, 
constipation, abdominal pain)  
· Allergic symptoms – rash, runny nose, nasal congestion, sore throat 
· Headaches  and dizziness  
· Muscle cramps 
· Vision disturbance 
· Tinnitus (ringing in the ears)  
 
Less common (affecting less than 1% of people): 
Mood or sleep disturbances. Acute swelling of the throat and face. Inflammation of the 
pancreas which could cause pain in your abdomen. Inflammation of the liver and 
jaundice have been reported.  Altered blood levels of liver tests, other chemicals in the 
blood, lowering of white cells and anaemia have occurred in patients taking this group 
of drugs. 
Amlodipi
ne 
(Calcium 
channel 
blocker) 
 
Common (affecting 1- 10% of people who take this drug):  
· Headache 
· Ankle swelling 
· Dizziness 
· Abdominal pain 
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· Nausea 
· Tiredness   
· Flushing 
 
Less common (affecting less than 1% of people):  
Gastro-intestinal disturbances, dry mouth, taste disturbances, low blood pressure, 
faintness, chest pain, shortness of breath, rhinitis, mood changes, general weakness, 
tremor, pins and needles, disturbances when passing urine, impotence, breast swelling, 
weight changes, muscle pains and cramps, back pain, joint pain, visual disturbances, 
ringing in the ears, skin irritation, rashes, sweating, hair loss and skin discolouration. 
Losartan  Common (affecting 1- 10% of people who take this drug): 
· Dizziness  
· Vertigo  
· High potassium levels in the blood  
 
Less common (affecting less than 1% of people): 
Gastro-intestinal disturbances, chest pain, palpitation, general swelling, shortness of 
breath, headache, sleep disorders, skin rash with irritation and swelling. 
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Study Title An evaluation of the effect of an angiotensin-converting enzyme 
(ACE) inhibitor on the growth rate of small abdominal aortic 
aneurysms 
Subject #  Site #  
Name of Research Doctor  
 
Please initial box if you agree with the following: 
I, (forename and surname)    
freely agree to take part in the study.  
· I have been given the Patient Information Final 8 dated 01/07/2012 to read as well as 
a full explanation by . . . . . . . . . . . . . . . . . . of the aims, the procedures and possible 
risks of the study. I was able to ask him / her questions regarding all areas of the 
study and these questions have been answered to my satisfaction. I have been given 
the name of a person to contact if I have any questions during the study.   
· I have had sufficient time to think about taking part and I agree to cooperate with the 
research team. I will inform them immediately if I have any problems.   
· I understand that I am free to leave the study at any time, if I want to without having 
to give a reason and that my decision will not affect the standard of care I receive.  
· I understand my identity will never be disclosed and any information collected will 
remain confidential. I agree that my medical records and other personal data 
generated during the study may be examined by representatives of the sponsor and by 
people working on behalf of the sponsor, members of the Ethics Committee and by 
representatives of regulatory authorities. I agree that I will not seek to restrict the use 
to which the results of the study may be put.  
· I agree to my GP being informed of my participation in the study  
Participant/Legal Representative Person responsible for collecting the 
informed consent 
Date: 
Signature: 
Date: 
Signature: 
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Name: Name: 
Give one signed original information and consent form to the participant and keep the other 
signed original in the study file. 
Study Title An evaluation of the effect of an angiotensin-converting enzyme 
(ACE) inhibitor on the growth rate of small abdominal aortic 
aneurysms 
Subject #  Site #  
Name of Research Doctor  
 
Please initial box if you agree with the following: 
I, (forename and surname)    
freely agree to take part in the study.  
· I have been given the Patient Information Final 8 dated 01/07/2012 to read as well as 
a full explanation by . . . . . . . . . . . . . . . . . . of the aims, the procedures and possible 
risks of the study. I was able to ask him / her questions regarding all areas of the 
study and these questions have been answered to my satisfaction. I have been given 
the name of a person to contact if I have any questions during the study.   
· I have had sufficient time to think about taking part and I agree to cooperate with the 
research team. I will inform them immediately if I have any problems.   
· I understand that I am free to leave the study at any time, if I want to without having 
to give a reason and that my decision will not affect the standard of care I receive.  
· I understand my identity will never be disclosed and any information collected will 
remain confidential. I agree that my medical records and other personal data 
generated during the study may be examined by representatives of the sponsor and by 
people working on behalf of the sponsor, members of the Ethics Committee and by 
representatives of regulatory authorities. I agree that I will not seek to restrict the use 
to which the results of the study may be put.  
· I agree to my GP being informed of my participation in the study  
Participant/Legal Representative Person responsible for collecting the 
informed consent 
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
Date: 
Signature: 
Name: 
Date: 
Signature: 
Name: 
Give one signed original information and consent form to the participant and keep the other 
signed original in the study file. 
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Appendix 2 The European Quality of Life-5
Dimensions questionnaire
 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
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I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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Appendix 3 Health resource use questionnaire
QUESTIONNAIRE ON USE OF HEALTH SERVICES DURING THE AARDVARK 
TRIAL 
 
 
We would be grateful if you would take a few minutes to answer the following questions 
about services you may have used since you enrolled in the AARDVARK trial on  
Please insert date of enrolment here and where requested on each page. 
Please only provide information since this date. 
  
 
Section A (Questions 1-5) is about services you may have used because of your 
aneurysm.  
 
Section B (Questions 6) is about services you may have used for other health reasons. 
 
 
 
Date of completion: 
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HOW TO FILL IN THE QUESTIONNAIRE 
Most questions can be answered by ticking the box next to the answer that applies to you. 
Please tick one box only for each question. 
 
Example: 
 
Since you enrolled in the AARDVARK trial for have you had further hospital treatment of 
your aneurysm, by either a doctor or nurse? 
  Yes  No 
 
If yes, where was this?  
 
Name of Hospital:  e.g. West Middlesex 
 
If yes, did you an operation?
 
Yes   No  
 
Example: 
How many appointments have you had with the doctor or nurse at an outpatient’s department 
because of your aneurysm? 
 
 Who? 
How 
many 
times? 
OR if you can’t remember the exact number 
of times tick one of the following boxes 
1 A doctor  1 or 2         3 or 4        5 or more  
2 A nurse or similar 1 or 2         3 or 4     5 or more  
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Services used since your enrolment in the AARDVARK trial on       
Section A: Service use for reasons related to your aneurysm 
 
1.1 Have you had further hospital treatment of your aneurysm? 
 
  Yes  No       
(If no, go to question 1.3) 
1.2A If yes, where was this? Name of Hospital: ____________ 
 
1.2B If yes, did you have a different type of scan (not ultrasound) to image your aneurysm? 
 
Yes  No 
 
 
1.2C If yes, did you have an operation? 
 
Yes  No 
 
1.2D How many appointments have you had with the doctor or nurse at an outpatients 
department because of your aneurysm? 
 
 Who? 
How 
many 
times? 
OR if you can’t remember the exact number of times 
tick one of the following boxes 
1 A doctor       0                    1 or 2              3 or more  
2 A nurse or similar       0                    1 or 2              3 or more  
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1.3 Have you seen your GP because of your aneurysm? 
Yes No   (if no go to question 2 about Social Services)
 
1.4 If yes, how many times have you seen the GP? 
 
Exact number of 
times 
OR if you can’t remember the exact number of times tick one of the 
following boxes 
____time(s) 1 or 2                     3 or 4                          5 or more  
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2 Use of social services 
 
2.1 Have you seen a social worker for reasons related to your aneurysm since    
 
(enrolment) 
 
 
Yes  No   
 
2.2 If yes, how many times?  
 
Exact number of 
times 
OR if you can’t remember the exact number of times tick one of the 
following boxes 
____time(s) 1 or 2                            3 or 4                  5 or more  
 
2.3 Has a home carer (someone from social services who comes to assist with cleaning and 
feeding) visited you since    
*<please relevant insert date here >                                  
 
Yes  No   
 
2.4 If yes, how often have has the home carer visited you? 
 
Once a day     1 – 2 times a week 
Once a month    Other (please specify) ____________ 
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2.5 For how many weeks have you had a home carer? 
Exact number of 
weeks 
OR if you can’t remember exactly how many weeks tick one of the 
following boxes 
____weeks 1-3 weeks           4-7 weeks         8-12 weeks     
 
2.6 Did you have a home carer before *<please relevant insert date here >? 
 
Yes  No   
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3 Input from patients and carers 
3.1 Have you had to leave paid employment because of your aneurysm? 
 
Yes  No  
 
 
3.2 Have you had to take time off work because of your aneurysm? 
 
Yes  No   
 
3.3 If yes, how many days?  
 
Exact number of 
days 
OR if you can’t remember the exact number of days tick one of the 
following boxes 
_____days 1-5 days         6-10 days           more than 10 days 
 
3.4 Have any of your friends or relatives had to have time off work for reasons relating to 
your aneurysm? 
 
Yes  No  
 
3.5 If yes, how many days?  
 
Exact number of 
days 
OR if you can’t remember the exact number of days tick one of the 
following boxes 
____days 1-5 days               5-10 days             more than 10 days 
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3.6 Do any of your family or friends help you with feeding, washing or dressing? 
Yes  No  
 
3.7 If yes, on average for how many hours a day? 
 
Exact number of 
hours 
OR if you can’t remember the exact number of hours tick one of the 
following boxes 
____hours       2 hours or less                 3 to 5 hours               More than 5 hours 
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Section B: Service use for reasons not related to your aneurysm 
4.1 Have you had hospital treatment by either a doctor or nurse for anything other 
than your aneurysm (examples might include breathing problems, skin rashes, chest 
pain, constipation etc) since  
date of enrollment                                   ? 
 
Yes  No 
 
4.2 If yes, where was this?  
 
Name of Hospital:_______________________ 
 
4.3 If yes, what was the treatment for? 
 
______________________
 
 
4.4 How many appointments have you had with the doctor or nurse at an outpatients 
department for reasons unrelated to your aneurysm?  
 
Who? 
How many 
times? 
OR if you can’t remember the exact number of times 
tick one of the following boxes 
A doctor  1 or 2     3 or 4         5 or more  
A nurse  1 or 2   3 or 4          5 or more  
 
4.5 Have you seen your GP for reasons unrelated to your aneurysm? 
Yes  No 
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4.6  If yes, how many times have you seen the GP for reasons unrelated to your 
aneurysm? 
 
Exact number of 
times 
OR if you can’t remember the exact number of times tick one of the 
following boxes 
____times 1 or 2                          3 or 4                         5 or more  
 
Many thanks for your help. 
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Appendix 4 Data collection forms
AARDVARK: Screening Visit Worksheet
Screening ID: _________________  
Date of visit: __________________ 
 
Informed consent form completed? Yes               No  
(If No, please ensure that the patient has consented to the trial/completed a consent form 
before continuing with the screening visit) 
Inclusion/Exclusion Checklist 
Inclusion   
Is the patient willing and able to give written informed 
consent?  
Yes               No  
Is the patient aged at least 55 years? Yes               No  
Does the patient have an AAA 3 to 5.4 cm in diameter by 
internal or external measurement according to ultrasound?  
Yes               No  
Does the patient have a systolic BP <150mmHg?  Yes               No  
Exclusion   
Is the patients already required to take either an ACE-
inhibitor or a calcium channel blocker or Angiotensin II 
blocker (ARB) and cannot be converted to diuretic therapy 
and/or a 5mg dose of amlodipine for control (i.e. SBP < 
150mmHg) of their BP? 
 
Yes No 
Does the patient have known renal artery stenosis (>50%), 
or with a serum creatinine of >180µmol/L 
 
Yes               No  
Is the patient unable to give informed consent   
 
Yes               No  
Is the patient too frail to travel for 3-monthly surveillance? 
 
Yes               No  
Does the patient have any clinically significant medical 
condition which, in the opinion of the investigator, may 
interfere with the study results and or reduce life 
expectancy to < 2 years 
 
Yes               No  
Has the patient participated in another trial of an 
investigational product or device within the previous 30 
days? 
Yes               No  
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Does the patient have a known allergy or sensitivity to 
perindopril or amlodipine? 
Yes               No  
Is the patient unable or unwilling to comply with the 
requirements of the study, in the opinion of the 
investigator? 
Yes               No  
 
Completed by:    ____________________                    ___________________________ 
                                              Na me                                                         Signature  
 
Vital Signs & AAA measurement  
 
BP machine used: Omron (please photocopy the printout of the BP results)           
                                         
                                             Pulsecor   (please save the measurements onto a computer) 
 
Time  Pulse  BP measurement 1 
(mmHg) 
BP measurement 2 
(mmHg) 
BP measurement 3 
(mmHg) 
  
 
 
/ 
 
/ 
 
/ 
 
Is the patient receiving statins?  Yes                No  
Has the patient been prescribed indapamide at this 
visit? 
Yes                No  
Does this patient require referral to GP for 
hypertension? 
Yes                No  
Will this patient be attending a 6wk rescreening?  
 
Yes                No 
AAA LONGDITUDINAL internal diameter   
                         cm 
 
AAA LONGDITUDINAL external diameter 
 
                         cm 
 
AAA TRANSVERSE internal diameter  
 
                         cm 
 
AAA TRANSVERSE external diameter 
 
                         cm 
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 Note - Please record the AAA measurements from the previous clinical scan above rather than 
the AAA measurements obtained for the baseline visit. At least one of these measurements 
must be entered.  
 
6 week re-screen  N/A   
 
Date:______________ 
 
 
Time  BP measurement 
1 (mmHg) 
BP measurement 
2 (mmHg) 
BP measurement 
3 (mmHg) 
  
/ 
 
/ 
 
/ 
 
Is the patient suitable to continue in the trial based on 
their BP? (systolic BP < 150mmHg)  
 
 
Yes                No  
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Screening ID: _________________  
 
General Medical History 
Does subject have any clinically relevant past or current medical history conditions?  Yes                  
No  
If yes, please complete table below:  
          Diagnosis  Date of diagnosis 
(dd/mm/yyyy) 
Status  
(if past, please record 
end date) 
End date  
(dd/mm/yyyy) 
 
 
 
  Ongoing 
 
  Past  
 
  Ongoing 
 
  Past
  Ongoing 
 
  Past
  Ongoing 
 
  Past
  Ongoing 
 
  Past
  Ongoing 
 
  Past
  Ongoing 
 
  Past
  Ongoing 
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   Past
  Ongoing 
 
  Past 
 
 
Smoking and Alcohol History 
Current smoker Yes                No  
 
If yes, no. of cigarettes per day:  
________________ 
 
If yes, no. of years smoking: 
___________________ 
 
Past smoker Yes                No  
 
If yes, approx. date of stopping : 
________________ 
 
If yes, no. of cigarettes per day:  
________________ 
 
If yes, no. of years smoking: 
___________________ 
Units of alcohol per week  
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Screening ID: _________________  
 
Height and Weight  
 
Date of measurements: __________________  
Time of measurements: __________________ 
 
Weight (kg) Height (cm) 
 
  
 
Demographics 
Date of birth: _______________ 
 
Age:_________________ 
 
 
Ethnicity: 
 
 
 
 White  
 
 Black or Black British    specify: 
_______________________ 
 
 Asian or Asian British   specify: 
_______________________  
 
 Other, specify: _____________________ 
 
 
Blood Sample 
Date: _____________________
 
Was sample taken for creatinine?  
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Yes   Result: ________umol/L     No  Reason: 
________________________________________ 
 
Was sample taken for electrolytes?    
Yes No Reason: 
________________________________________ 
 
ALL results signed and dated by doctor?      Yes            No  
 
Concomitant Medication 
 
Does the patient currently take any concomitant medication?  Yes            No  
(If Yes, please complete the concomitant medication log) 
 
 
Screening completed by:  
 
 
_____________              ______________________             _________________ 
Name     Signature         Date  
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AARDVARK Worksheet : Randomisation Visit  (Month 0) 
 
 
Patient ID: ____________________ 
Date of visit: __________________ 
 
Inclusion/Exclusion criteria reviewed:  Yes             No  Reason: 
_________________________ 
 
Informed consent reviewed:                  Yes             No  Reason: 
_________________________ 
 
Current medical therapies reviewed:    Yes             No  Reason: 
_________________________ 
 
Screening bloods reviewed:                      Yes             No  Reason: 
_________________________ 
 
Vital Signs & AAA measurement  
 
Time  Pulse  BP measurement 1 
(mmHg) 
BP measurement 2 
(mmHg) 
BP measurement 3 
(mmHg) 
  
 
 
/ 
 
/ 
 
/ 
 
 
AAA LONGDITUDINAL internal diameter  
 
                         cm 
 
AAA LONGDITUDINAL external diameter 
 
                         cm 
AAA TRANSVERSE internal diameter                           cm 
 
AAA TRANSVERSE external diameter 
 
                         cm 
 
 
Patient randomised via InForm to bottle:     ________________ 
(attach print screen to this page) 
 
 
Patient seen by: _________________________ 
 
Signature: ______________________________ 
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AARDVARK Worksheet : Month 3 
 
 
Patient ID: ____________________ 
 
Date of visit: __________________ 
 
Has the patient experienced any adverse events?    Yes           No  
If yes, please complete an adverse event form. 
 
Has there been any change to the patient’s concomitant medications? Yes           No 
 
If yes, please update the concomitant medications form. 
 
Vital Signs & AAA measurement  
 
Time  Pulse  BP measurement 1 
(mmHg) 
BP measurement 2 
(mmHg) 
BP measurement 3 
(mmHg) 
  
 
 
/ 
 
/ 
 
/ 
 
 
AAA LONGDITUDINAL internal diameter  
 
                         cm 
 
AAA LONGDITUDINAL external diameter 
 
                         cm 
 
AAA TRANSVERSE internal diameter  
 
                         cm 
 
AAA TRANSVERSE external diameter 
 
                         cm 
 
Blood Sample 
Was sample taken for creatinine & electrolytes?  
Yes   Time: ____________           No  Reason: _______________________________ 
 
Results reviewed and signed by doctor?      Yes            No  
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Confirmation of bottle dispensed: __________________ 
 
Visit conducted by: _________________________ 
 
Signature: ______________________________ 
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AARDVARK Worksheet : Months 6, 9, 15, 18, 21 
 
 
Patient ID: ____________________ 
Date of visit: __________________ 
 
 
Which month is this? :    6     9   15      18       21   
 
 
Has the patient experienced any adverse events? Yes             No  
If yes, please complete an adverse event form 
 
Has there been any change to the patient’s concomitant medications? Yes             
No  
If yes, please update the concomitant medications form  
 
Vital Signs & AAA measurement  
 
Time  Pulse  BP measurement 1 
(mmHg) 
BP measurement 2 
(mmHg) 
BP measurement 3 
(mmHg) 
  
 
 
/ 
 
/ 
 
/ 
 
 
AAA LONGDITUDINAL internal diameter  
 
                         cm 
 
AAA LONGDITUDINAL external diameter 
 
                         cm 
 
AAA TRANSVERSE internal diameter  
 
                         cm 
 
AAA TRANSVERSE external diameter 
 
                         cm 
 
 
Confirmation of bottle dispensed: __________________ 
 
 
Visit conducted by: _________________________ 
 
Signature: ______________________________ 
DOI: 10.3310/hta20590 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 59
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kiru et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
141
AARDVARK Worksheet : Months 12 & 24 
 
Patient ID: ____________________                               
Date of visit: __________________ 
 
Which month is this? :    12 24 
 
Has the patient experienced any adverse events?   Yes            No  
If yes, please complete an adverse event form 
 
Has there been any change to the patient’s concomitant medications? Yes           No 
 
If yes, please update the concomitant medications form  
 
Vital Signs & AAA measurement 
Time  Pulse  BP measurement 1 
(mmHg) 
BP measurement 2 
(mmHg) 
BP measurement 3 
(mmHg) 
  
 
 
/ 
 
/ 
 
/ 
 
 
AAA LONGDITUDINAL internal diameter  
 
                         cm 
 
AAA LONGDITUDINAL external diameter 
 
                         cm 
 
AAA TRANSVERSE internal diameter  
 
                         cm 
 
AAA TRANSVERSE external diameter 
 
                         cm 
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Blood Sample 
Was sample taken for creatinine & electrolytes?  
Yes   Time: ____________           No  Reason: _____________________________ 
Results reviewed and signed by doctor?      Yes            No  
 
Weight (kg) 
 
Questionnaires 
Was the EuroQoL questionnaire completed by the patient?                Yes            No 
 
If No, reason: __________________________________________________ 
 
Was the Health Resources questionnaire completed by the patient? Yes            No 
 
If No, reason: ______________________________________________ 
 
Confirmation of bottle dispensed: __________________  (12 MONTH VISIT ONLY) 
 
Visit conducted by: _________________________ 
 
Signature: ______________________________ 
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Appendix 5 Transverse abdominal aortic
aneurysm diameter tables
TABLE 30 Abdominal aortic aneurysm diameter in the transverse plane: summary data by randomised group and
combined at each trial visit
Visit
Transverse internal diameter (cm) Transverse external diameter (cm)
n Mean SD Minimum Maximum n Mean SD Minimum Maximum
Placebo
Baseline 78 3.65 0.69 2.29 5.28 79 4.05 0.68 3.00 5.64
Month 3 74 3.74 0.72 2.52 5.40 74 4.12 0.72 3.03 6.07
Month 6 68 3.80 0.66 2.63 5.50 67 4.17 0.64 3.07 5.80
Month 9 62 3.77 0.68 2.59 5.30 62 4.12 0.67 3.08 5.60
Month 12 69 3.78 0.64 2.66 5.46 68 4.15 0.65 3.00 5.55
Month 15 57 3.80 0.68 2.47 5.41 57 4.14 0.68 3.06 5.90
Month 18 60 3.84 0.64 2.56 5.28 60 4.19 0.66 3.07 5.72
Month 21 52 3.85 0.63 2.75 5.28 52 4.18 0.67 3.03 5.95
Month 24 56 3.80 0.63 2.52 5.38 56 4.13 0.62 3.07 5.57
Perindopril
Baseline 71 3.68 0.68 2.39 5.17 73 4.09 0.65 3.08 5.39
Month 3 65 3.67 0.66 2.20 4.99 65 4.09 0.66 3.05 5.41
Month 6 61 3.70 0.70 2.43 5.23 61 4.12 0.73 3.05 5.90
Month 9 56 3.72 0.69 2.29 5.29 56 4.10 0.67 3.07 5.64
Month 12 60 3.80 0.70 2.50 5.47 60 4.14 0.72 3.03 6.07
Month 15 47 3.73 0.69 2.46 5.42 47 4.09 0.67 3.06 5.74
Month 18 49 3.77 0.61 2.59 5.50 49 4.10 0.64 3.03 5.83
Month 21 44 3.78 0.65 2.42 5.73 43 4.09 0.70 3.09 6.03
Month 24 52 3.73 0.58 2.42 5.13 52 4.04 0.58 3.03 5.42
Amlodipine
Baseline 69 3.61 0.70 2.20 4.92 72 4.04 0.67 3.00 5.35
Month 3 65 3.71 0.68 2.18 5.12 65 4.08 0.66 3.02 5.52
Month 6 60 3.79 0.75 2.14 5.30 60 4.13 0.72 3.00 5.60
Month 9 54 3.87 0.72 2.08 5.26 54 4.22 0.66 3.05 5.66
Month 12 52 3.85 0.70 2.39 5.21 52 4.20 0.69 3.01 5.76
Month 15 44 3.85 0.69 2.33 5.22 44 4.20 0.66 3.04 5.63
Month 18 47 3.90 0.71 2.78 5.50 47 4.18 0.70 3.03 5.88
Month 21 47 3.89 0.76 2.58 5.46 47 4.22 0.70 3.02 5.80
Month 24 48 3.85 0.72 2.59 5.45 47 4.18 0.67 3.03 5.67
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TABLE 30 Abdominal aortic aneurysm diameter in the transverse plane: summary data by randomised group and
combined at each trial visit (continued )
Visit
Transverse internal diameter (cm) Transverse external diameter (cm)
n Mean SD Minimum Maximum n Mean SD Minimum Maximum
Total
Baseline 218 3.65 0.69 2.20 5.28 224 4.06 0.67 3.00 5.64
Month 3 204 3.71 0.69 2.18 5.40 204 4.10 0.68 3.02 6.07
Month 6 189 3.77 0.70 2.14 5.50 188 4.14 0.69 3.00 5.90
Month 9 172 3.78 0.69 2.08 5.30 172 4.14 0.67 3.05 5.66
Month 12 181 3.81 0.67 2.39 5.47 180 4.16 0.68 3.00 6.07
Month 15 148 3.80 0.68 2.33 5.42 148 4.14 0.67 3.04 5.90
Month 18 156 3.84 0.65 2.56 5.50 156 4.16 0.66 3.03 5.88
Month 21 143 3.84 0.68 2.42 5.73 142 4.16 0.69 3.02 6.03
Month 24 156 3.79 0.64 2.42 5.45 155 4.12 0.62 3.03 5.67
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TABLE 31 Differences in transverse AAA diameter compared with baseline by randomised group and combined
Study period n
Transverse internal diameter (cm)
n
Transverse external diameter (cm)
Mean SD Minimum Maximum Mean SD Minimum Maximum
Placebo
Month 3 – baseline 73 0.12 0.31 –0.5 1.48 74 0.09 0.24 –0.64 0.83
Month 6 – baseline 67 0.19 0.29 –0.32 1.44 67 0.12 0.27 –0.47 0.89
Month 12 – baseline 68 0.24 0.34 –0.67 1.49 68 0.18 0.29 –0.51 0.91
Month 18 – baseline 59 0.33 0.38 –0.41 1.67 60 0.26 0.27 –0.28 1.36
Month 24 – baseline 55 0.37 0.37 –0.28 1.62 56 0.30 0.31 –0.34 1.12
Perindopril
Month 3 – baseline 64 0.02 0.28 –0.68 0.70 65 0.06 0.22 –0.69 0.78
Month 6 – baseline 60 0.07 0.21 –0.37 0.77 61 0.10 0.22 –0.47 0.73
Month 12 – baseline 59 0.24 0.28 –0.29 1.27 60 0.19 0.27 –0.52 1.14
Month 18 – baseline 48 0.26 0.22 –0.13 0.83 49 0.21 0.27 –0.53 1.15
Month 24 – baseline 51 0.28 0.22 –0.15 0.89 52 0.21 0.26 –0.53 0.76
Amlodipine
Month 3 – baseline 62 0.08 0.29 –0.68 1.19 65 0.04 0.21 –0.57 0.74
Month 6 – baseline 57 0.19 0.43 –0.65 2.38 60 0.10 0.26 –0.75 0.76
Month 12 – baseline 49 0.31 0.49 –0.65 2.68 52 0.23 0.27 –0.44 0.86
Month 18 – baseline 44 0.37 0.37 –0.3 1.57 47 0.27 0.28 –0.25 0.85
Month 24 – baseline 45 0.37 0.42 –0.66 1.42 47 0.32 0.33 –0.63 0.95
Total
Month 3 – baseline 199 0.07 0.30 –0.68 1.48 204 0.06 0.23 –0.69 0.83
Month 6 – baseline 184 0.15 0.32 –0.65 2.38 188 0.11 0.25 –0.75 0.89
Month 12 – baseline 176 0.26 0.37 –0.67 2.68 180 0.20 0.28 –0.52 1.14
Month 18 – baseline 151 0.32 0.34 –0.41 1.67 156 0.25 0.27 –0.53 1.36
Month 24 – baseline 151 0.34 0.34 –0.66 1.62 155 0.27 0.30 –0.63 1.12
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Appendix 6 Histograms of change in abdominal
aortic aneurysm longitudinal external measurements
(6 and 18 months)
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FIGURE 40 Histograms of change in AAA longitudinal external diameter from baseline to month 6. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 41 Histograms of change in AAA longitudinal external diameter from baseline to month 18. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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Appendix 7 Box plots of change in abdominal
aortic aneurysm longitudinal external measurements
(6 and 18 months)
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FIGURE 42 Box plot of change in AAA longitudinal external diameter from baseline to month 6. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower
adjacent values.
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FIGURE 43 Box plot of change in AAA longitudinal external diameter from baseline to month 18. Circles are
outside values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower
adjacent values.
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Appendix 8 Histograms of change in abdominal
aortic aneurysm longitudinal internal measurements
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FIGURE 44 Histograms of change in AAA longitudinal internal diameter from baseline to month 3. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 45 Histograms of change in AAA longitudinal internal diameter from baseline to month 6. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 46 Histograms of change in AAA longitudinal internal diameter from baseline to month 12. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 47 Histograms of change in AAA longitudinal internal diameter from baseline to month 18. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 48 Histograms of change in AAA longitudinal internal diameter from baseline to month 24. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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Appendix 9 Box plots of change in abdominal
aortic aneurysm longitudinal internal measurements
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FIGURE 49 Box plot of change in AAA longitudinal internal diameter from baseline to month 3. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 50 Box plot of change in AAA longitudinal internal diameter from baseline to month 6. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 51 Box plot of change in AAA longitudinal internal diameter from baseline to month 12. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 52 Box plot of change in AAA longitudinal internal diameter from baseline to month 18. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 53 Box plot of change in AAA longitudinal internal diameter from baseline to month 24. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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Appendix 10 Histograms of change in abdominal
aortic aneurysm transverse external measurements
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FIGURE 54 Histograms of change in AAA transverse external diameter from baseline to month 3. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 55 Histograms of change in AAA transverse external diameter from baseline to month 6. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 56 Histograms of change in AAA transverse external diameter from baseline to month 12. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 57 Histograms of change in AAA transverse external diameter from baseline to month 18. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 58 Histograms of change in AAA transverse external diameter from baseline to month 24. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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Appendix 11 Box plots of change in abdominal
aortic aneurysm transverse external measurements
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FIGURE 59 Box plot of change in AAA transverse external diameter from baseline to month 3. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 60 Box plot of change in AAA transverse external diameter from baseline to month 6. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
DOI: 10.3310/hta20590 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 59
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Kiru et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
163
– 1.0
– 0.5
0.0
0.5
1.0
1.5
C
h
an
g
e 
in
 t
ra
n
sv
er
se
 e
xt
er
n
al
 d
ia
m
et
er
 (
cm
)
Placebo Perindopril Amlodipine
FIGURE 61 Box plot of change in AAA transverse external diameter from baseline to month 12. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 62 Box plot of change in AAA transverse external diameter from baseline to month 18. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 63 Box plot of change in AAA transverse external diameter from baseline to month 24. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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Appendix 12 Histograms of change in abdominal
aortic aneurysm transverse internal measurements
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FIGURE 64 Histograms of change in AAA transverse internal diameter from baseline to month 3. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 65 Histograms of change in AAA transverse internal diameter from baseline to month 6. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 66 Histograms of change in AAA transverse internal diameter from baseline to month 12. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 67 Histograms of change in AAA transverse internal diameter from baseline to month 18. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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FIGURE 68 Histograms of change in AAA transverse internal diameter from baseline to month 24. (a) Placebo;
(b) perindopril; (c) amlodipine; and (d) total.
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Appendix 13 Box plots of change in abdominal
aortic aneurysm transverse internal measurements
– 1.0
– 0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
C
h
an
g
e 
in
 t
ra
n
sv
er
se
 in
te
rn
al
 d
ia
m
et
er
 (
cm
)
Placebo Perindopril Amlodipine
FIGURE 69 Box plot of change in AAA transverse internal diameter from baseline to month 3. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 70 Box plot of change in AAA transverse internal diameter from baseline to month 6. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 71 Box plot of change in AAA transverse internal diameter from baseline to month 12. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 72 Box plot of change in AAA transverse internal diameter from baseline to month 18. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 73 Box plot of change in AAA transverse internal diameter from baseline to month 24. Circles are outside
values. The box represents the 25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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Appendix 14 Histograms of change in systolic
blood pressure (6 and 18 months)
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FIGURE 74 Histograms of change in SBP from baseline to month 6. (a) Placebo; (b) perindopril; (c) amlodipine;
and (d) total.
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FIGURE 75 Histograms of change in SBP from baseline to month 18. (a) Placebo; (b) perindopril; (c) amlodipine;
and (d) total.
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Appendix 15 Box plots of change in systolic
blood pressure (6 and 18 months)
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FIGURE 76 Box plot of change in SBP from baseline to month 6. Circles are outside values. The box represents the
25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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FIGURE 77 Box plot of change in SBP from baseline to month 18. Circles are outside values. The box represents the
25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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Appendix 16 Histograms of change in diastolic
blood pressure (6 and 18 months)
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FIGURE 78 Histograms of change in DBP from baseline to month 6. (a) Placebo; (b) perindopril; (c) amlodipine; and
(d) total.
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FIGURE 79 Histograms of change in DBP from baseline to month 18. (a) Placebo; (b) perindopril; (c) amlodipine;
and (d) total.
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Appendix 17 Box plots of change in diastolic
blood pressure (6 and 18 months)
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FIGURE 80 Box plot of change in DBP from baseline to month 6. The box represents the 25th and 75th percentiles
and the whiskers are the upper and lower adjacent values.
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FIGURE 81 Box plot of change in DBP from baseline to month 18. Circle is an outside value. The box represents the
25th and 75th percentiles and the whiskers are the upper and lower adjacent values.
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Appendix 18 Breakdown of European Quality of
Life-5 Dimensions scores by domain
Domain
Placebo Perindopril Amlodipine Total
n % n % n % n %
Mobility
Month 12
I have no problems in walking about 34 48.6 37 61.7 33 63.5 104 57.1
I have some problems in walking about 35 50 23 38.3 19 36.5 77 42.3
Missing 1 1.4 0 0 0 0 1 0.5
Month 24
I have no problems in walking about 31 55.4 32 61.5 32 69.6 95 61.7
I have some problems in walking about 25 44.6 20 38.5 14 30.4 59 38.3
I am confined to bed 0 0 0 0 0 0 0 0
Self-care
Month 12
I am unable to wash or dress myself 0 0 1 1.7 0 0 1 0.5
I have no problems with self-care 63 90.0 53 88.3 48 92.3 164 90.1
I have some problems washing or dressing myself 6 8.6 6 10 4 7.7 16 8.8
Missing 1 1.4 0 0 0 0 1 0.5
Month 24
I am unable to wash or dress myself 0 0 0 0 0 0 0 0
I have no problems with self-care 50 89.3 46 88.5 42 91.3 138 89.6
I have some problems washing or dressing myself 6 10.7 6 11.5 4 8.7 16 10.4
Usual activities
Month 12
I am unable to perform my usual activities 2 2.9 0 0 2 3.8 4 2.2
I have no problems performing my usual activities 44 62.9 44 73.3 43 82.7 131 72.0
I have some problems with performing my usual activities 23 32.9 16 26.7 7 13.5 46 25.3
Missing 1 1.4 0 0 0 0 1 0.5
Month 24
I am unable to perform my usual activities 1 1.8 0 0 1 2.2 2 1.3
I have no problems performing my usual activities 38 67.9 37 71.2 34 73.9 109 70.8
I have some problems with performing my usual activities 17 30.4 15 28.8 11 23.9 43 27.9
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Domain
Placebo Perindopril Amlodipine Total
n % n % n % n %
Pain/discomfort
Month 12
I have extreme pain or discomfort 5 7.1 4 6.7 2 3.8 11 6.0
I have moderate pain or discomfort 36 51.4 27 45.0 18 34.6 81 44.5
I have no pain or discomfort 28 40.0 29 48.3 32 61.5 89 48.9
Missing 1 1.4 0 0 0 0 1 0.5
Month 24
I have extreme pain or discomfort 4 7.1 4 7.7 1 2.2 9 5.8
I have moderate pain or discomfort 25 44.6 29 55.8 16 34.8 70 45.5
I have no pain or discomfort 27 48.2 19 36.5 29 63.0 75 48.7
Anxiety/depression
Month 12
I am extremely anxious or depressed 1 1.4 0 0 0 0 1 0.5
I am moderately anxious or depressed 20 28.6 9 15.0 7 13.5 36 19.8
I am not anxious or depressed 48 68.6 51 85.0 45 86.5 144 79.1
Missing 1 1.4 0 0 0 0 1 0.5
Month 24
I am extremely anxious or depressed 2 3.6 1 1.9 0 0 3 1.9
I am moderately anxious or depressed 13 23.2 10 19.2 4 8.7 27 17.5
I am not anxious or depressed 41 73.2 41 78.8 42 91.3 124 80.5
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